**Title:** CHEMICALLY INDUCED INTRACELLULAR HYPERTERMIA

**Abstract**

An invention relating to therapeutic pharmacological agents and methods to chemically induce intracellular hyperthermia and/or free radicals for the diagnosis and treatment of infections, malignancy and other medical conditions. The invention relates to a process and composition for the diagnosis or killing of cancer cells and inactivation of susceptible bacterial, parasitic, fungal, and viral pathogens by chemically generating heat, and/or free radicals and/or hyperthermia-inducible immunogenic determinants by using mitochondrial uncoupling agents, especially 2,4 dinitrophenol and, their conjugates, either alone or in combination with other drugs, hormones, cytokines and radiation.
FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL Albania
AM Armenia
AT Austria
AU Australia
AZ Azerbaijan
BA Bosnia and Herzegovina
BB Barbados
BE Belgium
BF Burkina Faso
BG Bulgaria
BJ Benin
BR Brazil
BY Belarus
CA Canada
CF Central African Republic
CG Congo
CH Switzerland
CI Côte d'Ivoire
CM Cameroon
CN China
CU Cuba
CZ Czech Republic
DE Germany
DK Denmark
EE Estonia
ES Spain
FI Finland
FR France
GA Gabon
GB United Kingdom
GE Georgia
GH Ghana
GN Guinea
GR Greece
HU Hungary
IE Ireland
IL Israel
IS Iceland
IT Italy
JP Japan
KE Kenya
KG Kyrgyzstan
KP Democratic People's Republic of Korea
KR Republic of Korea
KZ Kazakhstan
LC Saint Lucia
LI Liechtenstein
LK Sri Lanka
LR Liberia
LS Lesotho
LT Lithuania
LU Luxembourg
LV Latvia
MC Monaco
MD Republic of Moldova
MG Madagascar
MK The former Yugoslav Republic of Macedonia
ML Mali
MN Mongolia
MR Mauritania
MW Malawi
MX Mexico
NE Niger
NL Netherlands
NO Norway
NZ New Zealand
PL Poland
PT Portugal
RO Romania
RU Russian Federation
SD Sudan
SE Sweden
SG Singapore
SI Slovenia
SK Slovakia
SN Senegal
SZ Swaziland
TD Chad
TG Togo
TJ Tajikistan
TM Turkmenistan
TR Turkey
TT Trinidad and Tobago
UA Ukraine
UG Uganda
US United States of America
UZ Uzbekistan
VN Viet Nam
YU Yugoslavia
ZW Zimbabwe
CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA

CROSS-REFERENCE TO RELATED APPLICATIONS:

This application claims benefit of priority to United States provisional patent application serial number 60/094,286, filed July 27, 1998, which is hereby incorporated by reference in its entirety.

FIELD OF INVENTION:

This invention relates to therapeutic pharmacological agents and methods to chemically induce intracellular hyperthermia and/or free radicals for the diagnosis and treatment of infections, malignancy and other medical conditions. This invention further relates to a process and composition for the diagnosis or killing of cancer cells and inactivation of susceptible bacterial, parasitic, fungal, and viral pathogens by chemically generating heat, free radicals and hyperthermia-inducible immunogenic determinants. Such pathogens, infected or transformed cells are inactivated or killed without irreparable injury to non-transformed, uninfected, normal cells. More specifically, this invention relates to the diagnosis and treatment of cancer; treatment of AIDS; and, other diseases and conditions using mitochondrial uncoupling agents, especially 2,4 dinitrophenol and, their conjugates, either alone or in combination with other drugs, hormones, cytokines and radiation.

GENERAL BACKGROUND:

Local heat, systemic hyperthermia and fever therapy have been empirically used as effective treatments for malignant, infectious and other diseases since antiquity. Therapeutic hyperthermia was first documented in the Edwin Smith surgical papyrus in the 17th century B.C. Coley's toxin extracts of Streptococcus erysipelas (group A streptococcus) and Bacillus prodigiosus (Serratia marcescens) were used to induce fever for the treatment of patients with advanced cancer. The Nobel Prize was awarded for using fever therapy in the treatment of neurosyphilis with the injection of malarial blood. As late as 1955, the Mayo Clinic advocated using malarial therapy or heat therapy for cases of tertiary syphilis "resistant to penicillin". Long
term remissions in patients with inoperable carcinomas that were treated with hot baths and local
heat applications have also been reported. Published observations on the disappearance of
malignancies such as a soft tissue sarcoma in a patient experiencing high fever due to erysipelas
and tumor lysis of Burkitt's lymphomas following malignant hyperthermia during surgical
anesthesia are known. A comprehensive historical review on anecdotal observations and
intuitive rational for the empirical use of therapeutic hyperthermia has been published by Myer,
J.L.

The temperature of a body can be intentionally increased either by pyrogens to produce fever
(fever therapy) or, by the induction of hyperthermia (therapeutic hyperthermia). Fever raises
body temperature by elevating the thermoregulatory “set point” located in the preoptic region of
the anterior hypothalamus. In so doing, the body physiologically works to maintain the higher
temperature setting. The elevated core body temperature increased by fever may or may not be
raised above the higher set point value. In contrast, induced hyperthermia always raises the body
temperature above the hypothalamic thermoregulatory set point and the physiologically intact
body attempts to lower it's core temperature back to the set point baseline.

Renewed clinical interest in hyperthermia has occurred over the past 35 years due to continued
failure of standard therapies to treat various forms of cancer and emerging infections. Except for
a few exceedingly rare forms of cancer like childhood leukemias and testicular cancer or
immune responsive infections, chemotherapy, radiation or drug therapy often do very little
except briefly extend survival. One of the major obstacles to “cure” disseminated cancer and
infections has been the innate or acquired resistance of tumor cells and emerging microbes to
antibiotics, drugs and treatments given in tolerable doses. Escalation of treatments, or use of
multiple drugs to overcome resistance is invariably prevented by concomitant toxicities or
development of multi-drug resistance. Further, in contrast to drugs, which represent a single
molecular species that biochemically interact with specific enzymes or receptors of viruses,
prokaryotes and eukaryotes, the action of hyperthermia is biophysical and global. Hyperthermia
has no specific heat receptors. Therefore, the possibility of a point mutation causing a functional
change in a receptor and conferring resistance to hyperthermia is unlikely, and would be
equivalent to the development of resistance to the in vitro process of Pasteurization. Among
pathogenic bacteria, it has been reported that only one variant in 1 x 10^6 cells of an original
population is resistant to hyperthermia.
Hyperthermia has been used alone or in conjunction with radiation and chemotherapy in the treatment of a variety of malignancies. Overgaard et al., reported that a combination of heat and radiation results in complete control of twice as many melanoma lesions compared to radiation alone. Maeda, M., Watanabe, N. et al., published in Gastroenterologia Japonica, that hyperthermia with tumor necrosis factor resulted in successful treatment of hepatocellular carcinoma. Prospective randomized studies of hyperthermia combined with chemoradiotherapy for esophageal carcinoma demonstrated the cumulative three year survival rates to be more than doubled with the addition of hyperthermia to chemoradiotherapy. Combination chemotherapy with hyperthermia in metastatic breast cancer refractory to common therapies, i.e., failed prior hormonal therapy and chemotherapy, resulted in 39% complete remissions and 23% partial remissions: relief of bone pain was striking. Fujimoto, S., Takahashi, M. et al., demonstrated that the 5 year survival rate of patients with peritoneal carcinomatosis from gastric carcinoma treated with intraperitoneal hyperthermic chemoperfusion was 41.6%, whereas the 50% survival duration of the group that did not receive intraperitoneal hyperthermia was 110 days. 

Preoperative hyperthermia with chemotherapy and radiation is also known to improve long-term results in patients with carcinoma of the rectum, especially those with advanced disease. It is clinically known that regional, i.e., limb, hyperthermic perfusions with chemotherapy is useful for the treatment of melanoma. Combination therapy with hyperthermia and radiation has been successful in the treatment of non-Hodgkins lymphomas. More recently, a survival benefit of hyperthermia was shown in a prospective randomized trial for patients with glioblastoma multiforme undergoing radiotherapy. However, rigorous clinical prospective randomized trials with hyperthermia alone or, in combination with agents outside its use with radiation therapy have not been performed.

The scientific rationale for therapeutic hyperthermia in cancer therapy rests on known data from pre-clinical, in vitro and animal studies. Tumor cells in tissue culture have been demonstrated to be directly more sensitive to heat as compared to their non-malignant counterparts. Cells undergoing mitosis, synthesizing DNA in the ‘S-phase’, are especially more sensitive to hyperthermia. Human leukemic progenitor cells have been shown to be selectively killed by hyperthermia and, such in vitro use has been shown to purge bone marrow of residual tumor cells before autologous bone marrow transplantation. Microcalorimetric measurements confirm that tumorous tissues produce more heat and are “hotter” than their non-tumorous counterparts. As a consequence, they are less able to tolerate additional heat loads.
Tumor cells are also killed by heat indirectly. Tumor angiogenesis is inhibited by heat. Hyperthermia causes tumors to have increased heat retention with increased cytotoxicity due to tumor neovasculature lacking smooth muscle and vessel wall precursors needed for cooling by vasodilation. Increased hypoxia, acidity, Fos gene death signaling, decreased nutrient supply and enhanced immunologic cytotoxicity have also been reported to be caused by hyperthermia and contribute to enhanced tumor cell death. Further, the combination of hyperthermia with chemotherapy and/or radiation has been shown to be supraadditive or synergistic on killing of tumors. Human gastric carcinoma cells have been shown to be selectively killed by a combination of cisplatin, tumor necrosis factor and hyperthermia: a 40% increase in cisplatin DNA damage was noted in the presence of the three agent combination over cisplatin alone or either dual combination. Numerous animal studies, including the initial publication by Crile, show that neoplasms transplanted into mice regress when treated with hyperthermia without irreparable damage to adjacent tissues.

Body temperature is a critical factor in determining host susceptibility, location of lesions, and the natural history of many infectious diseases. Temperature has direct effects on the growth of all microorganisms, including those that are pathogenic. Almost all of the bacteria that cause disease in humans grow optimally within the range of 33-41°C and, their temperature growth characteristics are not easily altered in vitro. By example, the lesions of Hansen’s disease (leprosy) caused by Mycobacterium leprae, characteristically grow and destroy the most acral, coolest parts of the body such as fingers, toes, external ear, the air-stream cooled nasal alae and larynx. Leprosy organisms proliferate and follow the coolest temperature gradients in the body, 25-33°C. In animals, the lepra e organisms can only be grown in the armadillo or foot pads of mice were the in situ lesion temperatures are 27-30°C. Spontaneous improvement in leprosy lesions have been reported in patients following febrile illness. Fever therapy, hot baths and local heat therapy were formerly utilized in treating this disease. Hyperthermia is also known to destroy Treponema pallidum, the causative agent of syphilis, by heating five hours at 39°C, three hours at 40°C, two hours at 41°C or one hour at 41.5°C. The spirochetes responsible for yaws, bejel, pinta and Lyme disease show similar temperature sensitivity.

Other bacteria that predominate ly cause lesions at cool sites and are susceptible to heat inactivation include, Neisseria gonorrhoea, Hemophilus ducrei (chancreoid), Mycobacterium ulcerans, Mycobacterium marinum (“swimming pool” granuloma), Diphtheria, etc. Further, hyperthermia has been reported to be synergistic with antibiotic and chemotherapy in the
treatment of various bacterial diseases. Elevated body temperature potentiates the effect of penicillin on staphylococci and syphilis. Hyperthermia makes sulfadiazene bactericidal for streptococci. Moreover, recent controlled studies show that when antipyretics are used in animals with severe experimentally induced infections, there is increased mortality. Nonetheless, systemic hyperthermia has generally been abandoned as a treatment for bacterial infections with the advent of antibiotics.

Hyperthermia has remained an effective treatment for many fungal infections. Superficial dermatophytosis flourish in cooler regions of the body and heat treatment is oftentimes the only viable therapy for their chronic granulomatous lesions. By example, Sporothrix schenckii, the causative agent of sporotrichosis, has a temperature growth optimum well below 37°C and is successfully eliminated by local hyperthermia. Similarly, patients with pseudallescheriosis unresponsive to antifungal antibiotics are healed with hyperthermic treatments. In Japan, pocket warmers, hot water and infrared heating remain current and effective treatments for various fungal infections. Systemic hyperthermia, utilizing a Liebel-Flarsheim (Kettering) Hypertherm Fever Cabinet, dramatically treated a case of disseminated sporotrichosis with recurrent iridocyclitis, repeated post-treatment cultures from the patient remained negative.

The role of hyperthermia in modulating the clinical course of other fungal infections, including histoplasmosis, North American blastomycosis, chromomycosis, cryptococcosis, paracoccidioidomycosis, Lobos’ disease and candidiasis has been described. Fungi, such as Nocardia, Actinomycetes and Aspergillus also proliferate in cooler regions of the body causing mandible (lumpy jaw) and foot lesions (Madura foot) respectively. In vitro heat sensitivity data for many of the above and other pathogenic fungi have been reported by Mackinnon et al., Silva and others.

The effect of temperature and hyperthermia on the pathogenesis of parasitic disease is also well known. Leishmaniasis, a wide spread parasitic disease transmitted by the bite of a sandfly, clinically infects 12 million people worldwide. The cutaneous and mucocutaneous lesions, i.e., Oriental sore, Baghdad boil, Delhi boil, Chiclero’s ulcer and espundia, are often very destructive and permanently disfiguring. Hyperthermia with moist heat of 39°C to 41°C applied for 20 hours over several days has proven to be an effective treatment. In vitro, human macrophages infected with Leishmania mexicana are completely destroyed by heating at 39°C for 3 days. All mucocutaneous Leishmania strains, regardless of subspecies, demonstrate a growth optimum of 35°C.
with only the L. tropica and L. donovani strains surviving temperatures of 39\(^0\) C. Clinical observations have shown that hyperthermic treatment of one Leishmania lesion often invokes an immune response and results in the healing of other lesions over a 5-6 week period. The effect of hyperthermia on other parasites, including Trypanosoma cruzi, malaria, microfilaria, acanthamoeba, trematodes and cestodes has been published.

Increased body temperature is also recognized as a major factor in recovery from viral infections. Many viruses multiply better at temperatures below 37\(^0\) C and their multiplication is inhibited or stopped if the body temperatures exceeds 39\(^0\) C. In vitro Rhinovirus replication, for example, falls off by 10\(^6\) log units with an upward temperature shift of 20\(^0\) C (37\(^0\) to 39\(^0\) C). Herpes virus replication, as well as the intracellular and extracellular herpes virus concentration, markedly decrease when the incubation temperature is elevated to 40\(^0\) C. Varicella virus production in human fibroblastic cell culture is optimal at 37\(^0\) C and ceases at 39\(^0\) C.

Beneficial effects of hyperthermia on the outcome of viral disease in laboratory animals infected with myxomatosis, encephalomyocarditis, herpes, gastroenteritis, rabies and the common cold in man have been documented. Influenza and viruses causing upper respiratory infections, such as the common cold, thrive in a cool body milieu of 30\(^0\) - 35\(^0\) C. Temperature gradients in this range exist in the fall and winter within the oral, nasal, tracheal and laryngeal mucosa and lead to flu and influenza epidemics. Live respiratory-virus vaccines for influenza have been developed by use of heat-sensitive mutants that cannot reduplicate or cause clinical disease at 36\(^0\) - 37\(^0\) C. It is known that even as little as a 0.5\(^0\) C difference in the ceiling replication temperature of a virus can have a dramatic effect on virulence and pathogenicity.

Other animal viruses such as Newcastle disease in chickens, rabbit papilloma, feline leukemia, rabbitpox, hoof-and-mouth disease in cattle, hand, foot, and mouth disease, human plantar warts, and the "grease" of horses, due to horsepox involvement of the colder aeral extremities above the fetlocks, are known to be very sensitive to inhibition by heat. Heat treatment of cells infected with human immunodeficiency virus (HIV-1) at 39\(^0\) C for 2 days has been documented to significantly decrease viral production and reduce reverse transcriptase enzyme marker activity 30 fold. In vitro hyperthermia of 42.0\(^0\) C for 1 hour, 4 days apart selectively lowers HIV RNA loads in chronic (latent) infected T lymphocytes. Hyperthermia of 42\(^0\) C for 3 hours combined with tumor necrosis factor has been published to selectively kill all acute and chronically infected HIV cells in tissue culture.
Use of whole body hyperthermia has been reported to cause regression of Kaposi's sarcoma, clear oral candidiasis, eliminate hepatitis C, cause remission of Varicella-zoster, increase weight gain and improve CD4 lymphocytes counts in patients with acquired immunodeficiency syndrome (AIDS). Dramatic improvement with hyperthermia therapy has been documented in a patient infected with a debilitating Verruca vulgaris and HIV. The FDA has approved clinical trials involving hyperthermia for the treatment of AIDS with a patented extracorporeal blood heating machine to induce whole body hyperthermia. The FDA has recently expanded the extracorporeal heating machine trials to permit treatment of 40 HIV infected patients.

Hyperthermia can augment cytotoxicity and reverse drug resistance to many chemotherapeutic agents. Moreover, hyperthermia has also been shown to enhance the delivery of many novel cancer therapeutic agents, i.e., monoclonal antibodies to neoplasms with resultant improvement in antitumor effect; enhance the delivery of gene therapy with use of viral vectors; and, augment drug delivery and antitumor effects when using drug containing liposomes. In addition to increasing the rate of extravasation of liposomes from the vascular compartment by a factor of 40-50, hyperthermia can also be used to selectively release chemotherapeutic agents from liposomes designed to be thermosensitive. Thermosensitive liposomes are small vesicles composed of lipid phosphatidylcholine moieties constructed to contain and transport a variety of drugs. The liposomes are designed to remain stable in the blood and tissues at physiologic temperatures. When passing through an area of heated tissue however, they dissolve and effectively release their encapsulated contents. Thermosensitive liposomes are used to entrap and carry drugs whose systemic toxicity is desired to be limited to a particular heated tumor, organ or tissue. Examples of drugs that have been encapsulated into liposomes include methotrexate, doxorubicin, amphotericin B, cisplatin and others. Liposomes can be designed so as to release their contents at pre-determined temperatures.

Hyperthermia has also been an effective solution for the treatment of a variety of heat labile toxin or poisonous envenomations. For example, an easy treatment for Scorpaenidae and Siganidae envenomation is the local application of heat. The major poisonous component of this and many other venoms from lionfish, weever fish, bullrout, sculpin, surgeon fish, scorpion fish, stonefish, butterfly cod, etc., is a very heat labile, non-dialyzable protein. As opposed to the nuances of using specific anti-venom, emmersing the envenomated area or patient in hot water, or applying other forms of hyperthermia, is a simple and prompt treatment.
Standard clinical methods of inducing hyperthermia are dependent on the deposition of exogenous heat to that normally produced by the metabolism. All current deliberate and controlled methods of heating require an external source of energy. Non-surgical methods of heating include: hot air, ultrasound, microwaves, paraffin wax baths, hot water blankets, radiant heat devices, high temperature hydrotherapy and combinations thereof. Invasive means of inducing hyperthermia include surgical insertion of various heating devices, infusion of heated solutions into the peritoneal cavity through catheters or heating the blood extracorporeally through a heat exchanger. The later method, developed by Parks et al., involves the surgical placement of a femoral arterio-venous shunt for the removal, heating and replacement of blood to induce whole body hyperthermia. A more recent experimental improvement on this method has been the induction of whole body hyperthermia with veno-venous shunt perfusions. Several machines have been patented for extracorporeal heating of blood to induce hyperthermia (see US Patent Nos. 5, 391, 142 and 5, 674,190).

Endogenous heating by creating fevers induced with toxins, pyrogens and microorganisms have been used in the past and have recently been re-attempted. Heimlich has been reported to use Malaria therapy for the treatment of Lyme disease, AIDS and malignancy. Pontiggia et al, treated AIDS patients by combining fever, induced by parenteral injections of a streptococcal lysate preparations, with hyperthermia generated by an infrared heating bed.

Another way that the prior art has dealt with inducing hyperthermia has been by introducing micron size magnetic particles and subjecting them to either magnetic fields or hyperbaric oxygen (see US Patent No. 4,569,836). This method was designed for the treatment of cancer based on the belief that cancer cells would engulf the particles and concentrate them intracellularly. A magnetic field would then be applied to heat the particles and generate lethal hyperthermia within the cancer cells. A modification of this technology is the use of magnetic cationic liposomes to induce intracellular hyperthermia. This technology was based on the observation that glioma cells have a greater affinity for positively charged rather than ‘neutral’ magnetic liposomes. A more recent variation on this science has been developed in Germany using ‘targeted’ magnetoliposomes. This methodology has been developed in an attempt to treat AIDS by using magnetic nanoparticles coupled to either CD4 lymphocyte or anti-gp120 HIV antibodies. The magnetic nanoparticles are intended to selectively bind to either the HIV protein
envelope or the HIV infected cells and then be heated by external high-frequency alternating magnetic fields.

Whether invasive or non-invasive, all current methods of inducing hyperthermia depend on an external energy source and cannot safely deliver adequate power to result in therapeutic heating. Delivery of heat to obtain the actual desired temperature to deep target tissues has not been possible because of the actual physics involved in the thermodynamic, conductive transfer of heat from the outside into the cell. Heating tissues deeper than five centimeters below the skin with microwave, radio frequency or ultrasound devices is difficult because energy absorption is not uniform or focused. Radiant heat, hot water, molten wax and other methods cause excessive heating of subcutaneous fat which acts as a barrier to body heat gain. Common adverse effects of such external heating methods include surface skin burns, blistering, ulcerations, secondary opportunistic infections and pain. Additionally, many tumors have high blood flow cooling which nullifies any potential therapeutic gain achievable through the use of such extracellular, systemic hyperthermia devices. Also, insufficient heating power prolongs the induction time required to reach the actual therapeutic temperature. This promotes resistance to heat treatment through the development of the heat shock response and thermotolerance.

High frequency electromagnetic devices used to heat intracellular magnetic particles invariably induce eddy currents within the body making it difficult to provide uniform, controlled and safe heating without toxic effects to normal cells. Further, not all tumors possess characteristics that cause them to selectively take up magnetic particles or have an affinity for positively charged magnetic liposomes. Also, magnetic cationic liposome particles are subject to various neutralizing interactions with anions, giving them a short charged half-life. Moreover, the complexity of using specific anti-HIV antibodies bound to electromagnetic particles also assumes a non-mutating HIV genome with stable antigenic determinants. To the contrary, a high mutation rate in the HIV genome and its protein antigenic determinants is known to exist and is the main obstacle to the development of an effective vaccine. Such treatments therefore, do not selectively heat transformed cells without heating and injuring normal cells.

Extracorporeal blood heating methods require surgery and anesthesia. Further, as with all external heating methods, temperature variances and toxic conductive thermogrades from the point of initial heating to the target tissue cannot be avoided. By example, bone marrow temperatures are consistently known to be 10° - 20° C below the average body core temperature.
achieved by extracorporeal blood hyperthermia. This is a major problem in systemic hyperthermic therapy since the marrow is a common repository of metastatic cancer cells and infectious microorganisms. Therapeutic bone marrow temperatures are not achievable due to the fact that the intermediate tissues between the blood and the marrow create a temperature gradient cooling the blood before it reaches the bone marrow. Since efficacy and toxicity of hyperthermia depend on both the actual temperature and duration of heating, delivering the desired temperature-and-duration of heating (thermal dose) to the bone marrow would require the blood and intermediate tissues to be heated beyond that which is safe for normal, healthy cells. A multicentre European trial documented that only 14% of all protocols achieve required target temperatures. Further, current extracorporeal heating methodology and equipment is labor intensive, time-consuming and expensive.

Use of fever inducing agents such as live microorganisms, pyrogens and toxin lysates is clinically uncontrollable, unpredictable or insufficient as to both the degree and duration of temperature increase.

Further reasons why hyperthermia has not yet become more widely accepted as a mode of therapy is because current heating machines are not compatible with noninvasive temperature measurement technology. Measurement of the actual temperatures reached in target tissues is critical for heating efficacy, i.e., determining the thermal dose. Recently, noninvasive thermometry with Magnetic Resonance Imaging (MRI), ultrasound backscatter, electrical impedance, electromagnetic adaptive feedback and advanced, high-precision pixel infrared temperature imaging have been developed. To use MRI or other equipment to monitor real time hyperthermia however, it is necessary to combine a hyperthermia device with an MRI unit. This has proven to be difficult and costly since each device is functionally disturbed, if not damaged, by the presence of the other.

The exact molecular and cellular mechanism by which heat kills or inactivates tumor cells and microorganisms is unknown. Heat is an entropic agent and acts globally on every molecule constituting the cell. Heating is known to cause conformational changes in proteins, denature enzymes and affect cell membrane fluidity. By example, herpes simplex virus (type 1) thymidine kinase has a shortened half-life at 40°C of only 30 minutes. The transforming gene product-enzyme of Rous sarcoma virus (protein phosphatase), a critical protein for cellular regulation, is totally inactivated in 30 minutes at 41°C. Hyperthermia is known to increase the formation of
oxygen free radicals, including superoxide, hydroxyl, hydroperoxyl, hydrogen peroxide and lipid peroxides. These reactive oxygen species react indiscriminately and oxidize many organic molecules causing DNA damage, protein denaturation, lipid peroxidation and other destructive chain reactions. Acid microenvironments, known to exist in tumors and microorganisms with high rates of glycolysis (Embden-Meyerhof Pathway) and lactic acid production, favor protonation of the superoxide radical to form the highly reactive and toxic hydroperoxyl radical. Thus, thermal sensitivity of many tumors increases with decreasing intracellular pH. As compared to normal cells, many malignant and virally transformed cells have a reduced total functional capacity to withstand the increase flux of oxygen free radicals produced by hyperthermia.

On the intracellular level, moderate heating is known to activate phospholipase A2, which increases the formation of pro-inflammatory mediators such as the leukotrienes, prostaglandins and eicosanoids. Heat also increases release of intracellular calcium through the stimulation of phospholipase C. Calcium cycling across the mitochondrial membrane appears critical to the increased production of oxygen free radicals. Increased intracellular calcium also inhibits the mitochondrial, anti-apoptotic Bcl-2 protein and induces the production of heat shock proteins, mediating thermotolerance. Heat injury to the intracellular tubulin network, lysosomes, Golgi bodies, mitochondria, and control of RNA splicing are some of the many known subcellular systems affected by heat. While the initial primary event leading to cell death by hyperthermia is unknown, a decrease in mitochondrial membrane potential followed by uncoupling of oxidative phosphorylation and generation of reactive oxygen species on the uncoupled respiratory chain are the first biochemical alterations detectable in cells irreversibly committed to apoptosis. The cytotoxic effect of hyperthermia is thus believed to be caused by numerous changes and complex damage to multiple vital cell functions. Those biochemistries altered by heat and essential to the function or viability of the cell are the pivotal targets of therapeutic heating.

The mode of hyperthermic cell injury is dependent on the severity of the heat stress, temperature and duration of heating. Moderate heating of 39⁰ - 42⁰ C is used therapeutically and is known to promote programmed cell death through apoptosis, an active process of selectively eliminating heat sensitive cells without inflammation, bystander-cell death or subsequent tissue fibrosis. Malignant and other transformed cells undergo apoptosis by suppression or activation of one or more genes such as bcl-2, c-myc, p53, TRPM-2, RP-2, RP-8, raf, abl, APO-11FAS, ced-3, ced-4, ced-9, etc. Drugs (methotrexate, cisplatin, colchicine, etc.), hormones (glucocorticoids),
cytokines (tumor necrosis factor-alpha), radiation (free radicals) and hyperthermia can all initiate apoptosis. Increasing the temperature or duration of heating, or both, leads to cell death via necrosis. This physical process of indiscriminate cell killing is associated with inflammation and causes significant injury to normal, healthy cells.

For purposes of systemic hyperthermia, apoptosis of target cells is the therapy of choice. In the clinical setting it must be controlled under conditions of moderate heating so as to selectively differentiate and eliminate target cells with minimum toxicity to normal cells. Such controlled conductive heating by external technologies is inherently not possible. The thermal physical and thermophysiologic properties of cells vary and are dependent on their thermal conductivity, specific heat, density and blood perfusion among the various organs and tissues. Based on these properties, the actual temperatures at some of these sites are often 'partitioned', independent of one another and do not represent the monitored, mean "core" temperature achieved during therapy. Additionally, it is well recognized that it is the actual intracellular temperature increase, with it's associated internal physical and chemical changes, that is critical to the successful use of hyperthermia in exploiting the fundamental biochemical differences between normal and heat susceptible cells. Unfortunately, the initial cellular targets of all extracorporeal heating methods are the cell membrane and it's integrated proteins. The cell's internal contents, including mitochondria, compartmentalized enzymes, other organelles and any intracellular pathogens, etc., are progressively heated in sequence by thermal conduction from the outside-in. Thus, to sufficiently heat the interior of the cell, the external temperature must overcome the cellular and mitochondrial membranes, each composed of a lipid bilayer that acts as an effective thermal barrier.

By necessity, therefore, prior art heating methods require high external temperatures to establish a sufficient gradient to overcome the nonisotropic and non-homogeneous conductive heat loss between internal tissues and the insulating barrier of the cellular and mitochondrial membranes. For example, the Organetics PSI® (now First Circle Medical Inc.) device has to heat blood externally to 480 C (118.40 F) before returning it directly into the vascular system of the patient. Other extracorporeal circuit perfusion devices need to achieve ex vivo temperatures of 490 C (120.20 F). Animal studies require temperatures of 540 C (129.10 F) during the induction phase to achieve adequate target tissue temperatures. Safety in such prior art is therefore limited by the incipient destruction of surrounding tissues at the sites of the high temperature phases of heating. When lesser temperatures are attempted, effectiveness is compromised by either inadequate
temperatures or duration of heating or development of thermotolerance. As a result, only
regional hyperthermia has been widely used clinically and only in combination with more
traditional techniques such as radiation and chemotherapy. Presently, none of the known heating
technologies provide clinically safe and effective hyperthermia to treat systemic or disseminated
disease. In order for systemic hyperthermia to become more widely used clinically, current
heating methods must also overcome the use of labor intensive, complex equipment, including
invasive extracorporeal infusion and it's related toxicity problems to interposed tissues. Further,
new hyperthermic technology must be compatible with noninvasive, real time thermometry.

The present invention avoids the problems of heat toxicity, inadequate target tissue heating,
excessive cost, surgery, anesthesia and incompatibility with noninvasive temperature measuring
devices: problems that are inherent to all therapeutic methods that deliver heat extracellularly,
from the outside-in. This invention is an intracellular, therefore, an intracorporeal heating
system which has additional distinct advantages. First, the human body is biochemically and
physiologically designed to tolerate higher temperatures when heated from the inside-out as
opposed from the outside-in. By example, in comparison to extracorporeal heating, which can
safely generate a maximum body core temperature of 42°C (107.6°F), intracorporeal
hyperthermia caused by strenuous exercise induces physiologic temperatures of up to 45°C
(113.0°F) in muscle and liver with body core temperatures of up to 44°C (111.2°F).

Exertional heat stroke patients have survived rectal body temperatures as high as 46.5°C
(115.2°F) without any permanent clinical sequela. While the critical maximum temperature
humans can tolerate is unknown, physiologic hyperthermic temperature induced under controlled
conditions with adequate hydration have not shown any permanent untoward effects. Liver
biopsies from subjects with such temperatures have not shown any significant microscopic
abnormalities. Second, since heating with the present invention is chemically induced from
within the cell, the actual intracellular therapeutic temperature will be higher than the measured
core temperatures. As a result, intracellular organelles, including mitochondria, are heated at
higher temperatures, undergo greater uncoupling and generate an increased flux of reactive
oxygen species. Since oxygen free radicals, including superoxide, enhance and probably
mediate the effects of hyperthermia, an improved therapeutic gain will be obtained at lower body
core temperatures. Further, it is known that for each 0.5 degree Celsius increase in body
temperature the metabolic rate and oxygen consumption increase 7%. Such an increase will
assist heating the body in itself. Third, safety and control of temperatures with the present
invention is far superior to that of exogenous methods. The body is naturally designed to
dissipate heat from the inside-out. This is evident from the fact that a temperature gradient of 3.5° - 4.5° C exists between the visceral core and the skin. This gradient represents the transfer of heat from regions of high temperature to regions of low temperature, with ultimate heat loss from the skin to the environment through conduction, convection, radiation and sweat induced evaporation. The margin of safety and control represented by the ‘feedback gain’ of this intact physiologic heat dissipating system is extremely high, approximating 27-33. This rate of cooling can balance an influx of heat in a naked human body in a dry room at about 120°C (248.0°F). Thus, the human heat flow system permits the body to rid itself of excess endogenous heat very quickly and effectively. As a result, there is a wide margin of safety in case the target temperature is exceeded. In contrast, exogenous heating contravenes the natural physiologic flow of heat and its dissipating mechanisms. The natural heat dissipating mechanisms are overwhelmed and compromised. Control and safety over hyperthermia induced by extracellular means is thus fragile, with little room for error.

SUMMARY OF THE INVENTION:

The present invention encompasses a composition and method using mitochondrial uncoupling agents, especially DNP, DNP with free radical producing drugs, DNP with liposomes, DNP conjugated to free radical formers, and DNP with other therapeutic pharmaceutical agents which are activated intracellularly by heat or reaction with mitochondrial electrons or free radicals to cause release of active medications for the treatment of cancer, HIV, other viruses, parasites, bacteria, fungi and other diseases. While not being bound by theory, it is submitted that the use of mitochondrial uncoupling agents, to increase intracellular heat and free radicals, as treatment for non-related cancers, viruses and other pathogens presupposes that the mechanism of action is non-specific for enzymes and receptors but is specific for interference with cellular and pathogen viability and induction of programmed cell death. The degree of intracellular heating, free radical formation, whole body hyperthermia and release of active drug molecules is controlled by the dose of DNP. Based on the quantity of oxygen consumed, the dose of DNP is adjusted to achieve the desired degree of hyperthermia. Safety and effectiveness is further controlled by manipulating metabolic rates of target tissues, duration of treatment and permissiveness of body cooling. In accordance with the present invention, intracellular, mitochondrial heat is generated by the use of DNP, other uncouplers, their conjugates, either alone or in combination with other drugs for the treatment of thermosensitive cancers such as non-Hodgkins lymphoma, prostate carcinoma, glioblastoma multiforme, Kaposi’s sarcoma, etc; bacteria such as Borrelia
burgdorferi, Mycobacterium leprae, Treponema pallidum, etc.; viruses such as HIV, hepatitis C, herpes viruses, papillomavirus, etc.; fungi such as Candida, Sporothrix schenckii, Histoplasma, Paracoccidiodes, Aspergillus, etc.; and, parasites such as Leishmania, malaria, acanthomoeba, cestodes, etc. 2,4-dinitrophenol was selected as the uncoupler of choice because it can be used at relatively high concentrations, permitting uniform distribution in organs and tissues. This invention also encompasses the use of DNP to selectively augment energy metabolism and heat production in inchoate malignant tumors for the purpose of increasing sensitivity of diagnostic positron emission tomography, temperature-sensitive magnetic resonance, and high-precision pixel temperature infrared imaging in differentiating normal from aberrant cell metabolisms. An additional object of the invention is the use of DNP to increase transcription of heat shock proteins, especially HSP 72, as a form of cellular pre-conditioning to decrease post-angioplasty restenosis, increase successful outcome of other surgeries, and facilitate antigen processing and presentation of immunogenic determinants on infectious agents, virally transformed cells and tumors so as to increase the natural or biologically activated immunological response.

In accordance with another aspect of the present invention, controlled thermogenesis with DNP is combined with other agents used to treat infectious, malignancy and other diseases. Examples of other agents include antifungal, antiviral, antibacterial, antiparasitic and antineoplastic drugs. Such drugs, including angiogenesis inhibitors and radiation have increased synergistic or additive activity when combined with hyperthermia in the treatment of cancer.

The method can be used for enhancing the sensitivity of positron emission tomography, nuclear magnetic resonance spectroscopy and infrared thermography in the diagnosis and monitoring of treatment of various diseases, including cancer. Similarly, the method can be used for enhancing the identification of unstable “hot” coronary and carotid artery plaques predisposed to rupture or undergo thrombosis. Such diagnostic and treatment monitoring methodology is based on the fact that most tumors have higher metabolic rates and generate more heat than normal tissues. Likewise, unstable atherosclerotic plaques are presumed to rupture because they have a dense infiltration of macrophages which have high metabolic rates and generate excessive enzymes and heat, causing the plaque to degrade and loosen. In both instances, controlled doses of DNP or other uncouplers can further increase metabolic rates and heat production to increase diagnostic sensitivity. Controlled heating with DNP and fibrinolytic recombinant tissue-type plasminogen activators can also be used therapeutically to accelerate fibrinolysis of clotted arteries.
In another aspect of the invention, DNP is administered in controlled and timed dosages to provide physiologic stress, "chemical exercise", so as to induce synthesis of autologous heat shock proteins (HSPs). Intracellular heat exposure associated with autologous HSP induction has a significant cytoprotective effect against ischemia and cellular trauma and acts as a form of cellular thermal preconditioning in patients about to undergo surgery. Induction of HSPs by DNP in patients some 8 to 24 hours prior to angioplasty, coronary bypass surgery, organ transplantation and other forms of high risk surgery, would provide for improved clinical outcome with decreased post-angioplasty intimal thickening or restenosis, increased myocardial protection from infarction, improved musculocutaneous flap survival in plastic reconstruction and reduced ischemia/reperfusion injury in organ transplantation cases.

Another aspect of the invention provides for controlled dosages of DNP to induce long duration (6 to 8 hour), mild whole body hyperthermia (39.0 to 40.0°C) to afford maximum expression of immunogenic HSPs or peptides associated with HSPs. The antigenic properties of HSPs and HSP-peptide complexes, induced by DNP in infectious agents, especially those located intracellularly, or on tumors can be exploited to enhance the immune response. This aspect of the present invention provides a process for modulating the immune system of a patient with other therapies, comprising the steps of: (1) increasing the expression of HSPs by the process described above, and (2) administering humanized monoclonal or polyclonal antibodies, or (3) administering recombinant cytokines, lymphokines, interferons, etc., or (4) administering standard anti-infectious or anti-neoplastic therapy.

Additional objects and advantages of the invention will be set forth in part in the description of drawings that follows, and in part, will be obvious from the description, or may be learned by practice of the invention. The objects and advantages can be realized and obtained by means of the uses and compositions particularly pointed out in the detailed description of the preferred embodiments and in the appended claims.

BRIEF DESCRIPTION OF DRAWINGS:

Figure 1 shows features of glycolysis with formation of pyruvic acid and release of energy as heat.
Figure 2 depicts the conversion of pyruvic acid into acetyl CoA and the 2 carbon fragments entering the TCA cycle.

Figure 3 shows the transfer of electrons down the electron transport chain during the process of oxidative phosphorylation.

Figure 4 shows oxidative phosphorylation as a coupling of two distinct processes, oxidation of reducing equivalents and formation of ATP. Both processes are “coupled” by an electrochemical membrane potential created by electrons passing down the electron transport chain. Figure 5 shows the process of chemiosmosis. Electrons passing down the electron transport chain create energy to pump H⁺ outside the inner mitochondrial membrane. This process creates a protonmotive force that causes formation of ATP by protons re-entering the membrane through ATP-synthase.

Figure 6 depicts the uncoupling of oxidative phosphorylation through injury of the inner mitochondrial membrane. Figures 6(a) shows how oxidative phosphorylation is uncoupled by DNP in intact and uninjured mitochondrial membranes.

Figure 7 shows the initial formation of superoxide radicals by the univalent reduction of oxygen in the electron transport chain. Figure 7(a) depicts the formation of hydrogen peroxide and hydroxyl radicals through the Haber-Weiss Reaction. Figure 7(b) shows an overview of mitochondrial oxygen utilization and free radical formation.

Figure 8 depicts the effects of heating on mitochondrial uncoupling and correlation of uncoupling to superoxide free radical formation.

Figure 9 depicts the increased formation of oxygen free radicals after cessation of DNP uncoupling and normalization of oxygen consumption.

Figure 10 shows the global intracellular effects of DNP, including the dominant foci of increased heat generation.

Figure 11 shows the relative potencies of various uncouplers.

Figure 11(a) shows the effect of body temperature on metabolic rate.

Figure 12 shows six of the Hottest organs in the human body and their relative blood flow.

Figure 13 shows the effect of successive doses of 2,4-DNP on oxygen consumption.

Figure 14 shows a typical DNP induced hyperthermia patient monitored flow chart.

Figure 15 shows a monitored patient flow chart after successive infusions of DNP and glucagon for treatment of parasitic disease of the liver.

Figure 16 shows killing of chronically HIV infected HUT-78 cells with varying concentrations of DNP.
Figure 17 shows a patient flow chart after infusion of norepinephrine and successive intravenous doses of DNP for treatment of HIV disease. Figure 17(a) depicts surrogate parameters relating to HIV disease before and after DNP treatment.

Figure 18 shows a monitored patient flow chart after successive infusion of DNP for treatment of Lyme disease.

Figure 19 shows a monitored patient flow chart using an alpha-1 adrenergic agonist with DNP to induce hyperthermia in a patient with disseminated cancer.

Figure 20 shows survival studies of tumor growth-regressed animals treated with DNP and a thermosensitive liposome encapsulated drug.

Figure 21 shows the protective effects of DNP pretreatment on arterial catheter balloon induced injury.

Figure 22 shows the protective effects of DNP pretreatment on survival after prolonged hepatic ischemia induced by Pringle's maneuver.

Figure 23 shows the improved effect of musculocutaneous flap skin survival after DNP pretreatment.

Figure 24 shows the effects of oral DNP on oxygen consumption prior to a patient undergoing a PET scan.

Figure 25 shows a monitored DNP flow chart with incremental increases in oxygen consumption prior to a patient undergoing diagnostic thermography.

Figure 26 shows a monitored patient flow chart using dinitrophenol and methylene blue for the treatment of prostate carcinoma.

Figure 27 shows biochemical and clinical response of androgen-independent prostatic carcinoma to dinitrophenol and methylene blue treatment.

Figure 28 shows a monitored patient flow chart using interferon-alpha and dinitrophenol for the treatment of chronic hepatitis C infection.

Figure 29 shows the effects of dinitrophenol and interferon-alpha treatment on liver enzymes and hepatitis C viral loads.

Figure 30 shows an exemplary method of synthesis of novel 2,4-dinitrophenol conjugates and derivatives.

Figure 31 shows synthesis of an expanded combinatorial library of uncoupling agents.

DETAILED DESCRIPTION OF THE INVENTION

SUBSTITUTE SHEET (RULE 26)
Electron transferring, transporting and energy converting elements are ubiquitous and are necessary for life. All eukaryotic and prokaryotic organisms depend on electron transferring and transporting elements such as metal containing hemes and nonmetal moieties such as flavins and adenine nucleotides. These biochemical entities convert the energy stored in chemical bonds of foodstuffs into cellular and organelle membrane potentials, high energy containing molecules such as adenosine triphosphate (ATP), creatinine phosphate, and other forms of chemical energy needed to maintain the highly negative entropic state of life.

The most common form of biologic energy is adenosine triphosphate (ATP). ATP is produced either anaerobically through the Embden-Myerhoff Pathway (glycolysis) or through oxidative phosphorylation. The latter, an oxygen dependent chemical energy conversion process, is generally associated with the Tricarboxylic Acid Cycle [(TCA), Krebs Cycle or Citric Acid Cycle]. The TCA cycle links the products of glycolysis to a multi-enzyme coupled series of electron carriers called an electron transport chain (ETS). The electron transport chain is coupled to production of ATP. The entire TCA cycle and oxidative phosphorylation process is located in intracellular organelles known as mitochondria.

While release of energy from foodstuffs can come about through a variety of biochemical means, the most important means by which energy release is initiated is by splitting glucose into two molecules of pyruvic acid. This occurs through the non-oxygen dependent process of glycolysis in a series of ten chemical steps depicted in Figure 1. The overall efficiency of trapping energy in the form of ATP through this anaerobic process is 43%. The remaining released energy (57%) is discharged in the form of heat.

Pyruvic acid molecules derived from glucose, as well as end products of fat and protein breakdown, are transported into the mitochondrial matrix were they are converted into 2 carbon fragments of acetylcoenzyme A, Figure 2. As depicted, these acetyl fragments enter the TCA cycle were their hydrogen atoms are removed and released as either hydrogen ions (H⁺) or combined with nicotinamide and flavin adenine dinucleotides (NAD⁺ and FADH) to produce large quantities of usable reducing equivalents (NADH and FADH₂). The carbon skeleton is converted to carbon dioxide (CO₂) which becomes dissolved in body fluids. Ultimately the dissolved CO₂ is transported to the lungs and expired from the body. As noted in Figure 2, the flux of reactants in the TCA cycle is always in the same direction because NADH and FADH₂ is constantly removed as hydrogen is oxidized by the mitochondrial electron transport chain.
It is the electron transport chain that provides approximately 90% of the total ATP formed by glucose catabolism. During this process, known as oxidative phosphorylation, hydrogen atoms that were released during glycolysis, the TCA cycle, and converted to NADH and FADH$_2$, are oxidized by a series of enzymatic redox complexes (electron transport chain) located in the inner mitochondrial membrane, Figure 3. Energy released in these steps is captured by a chemiosmotic mechanism that is dependent on the ultimate reduction of O$_2$ to form H$_2$O. As depicted in Figure 4, oxidative phosphorylation is two distinct processes: (1) oxidation of NADH and FADH$_2$; and, (2) formation of ATP. Both processes are interdependent or “coupled” by a high energy linked proton (H$^+$, pH) gradient and membrane potential across the inner mitochondrial membrane provided by electrons as they pass through the electron transport chain. Energy released by the electrons pumps hydrogen ions (H$^+$) from the inner matrix of the mitochondrion into the outer inter-membrane space, Figure 5. This process is known as chemiosmosis and creates a high concentration of H$^+$ outside the inner mitochondrial membrane and a powerful negative electrical potential in the inner matrix. This transmembrane proton gradient (protonmotive force) causes hydrogen ions to flow back into the mitochondrial matrix through an integral membrane protein (ATP synthase) to form ATP from ADP and free ionic phosphate. The efficiency of oxidative phosphorylation in capturing energy as ATP is about 69%. The remaining (31%) liberated energy is dissipated as heat. The overall efficiency of energy transfer to ATP from glucose via glycolysis, the TCA cycle and oxidative phosphorylation is 66% with about 34% of the energy being released as heat.

Heat is continually produced by the body as a byproduct of metabolism and eventually all energy expended by the body is converted to heat. On a thermodynamic basis, total body heat production is the algebraic sum of the enthalpy changes of all biologic processes in the body. The pathways are irrelevant, even though in the body oxidation involves numerous enzyme catalyzed reactions taking place at 37°C. Biochemically, approximately 95% of all the oxygen (O$_2$) consumed is used by mitochondria to stochiometrically couple oxygen reduction to ATP and heat production via oxidative phosphorylation. The rate of O$_2$ consumption (VO$_2$) can be measured by indirect calorimetry and thus related to body heat production. Although this method does not include anaerobic processes such as glycolysis, indirect calorimetry is in close agreement with direct body heat measurements and it is generally accepted that 1 liter of VO$_2$ generates 4.825Kcal (kilocalorie of energy), 5/6ths of which can be detected as heat.
In human adults, increased VO$_2$ and endogenous heat production can occur via muscular (work or shivering) and/or chemical ([catecholamines, thyroid, etc.] non-shivering) thermogenesis. Whereas muscular activity can increase heat production 4-10 fold, non-shivering thermogenesis can only increase heat production by a maximum of 15%. However, oxygen consumption and non-shivering thermogenesis can dramatically increase when even mild injury to the inner mitochondrial membrane occurs so that it is no longer intact and protons leak or reenter the mitochondrion, uncoupled to ATP synthesis. Heating, endotoxin, osmotic imbalance, etc., can cause such injury, i.e., loss of coupling, with resulting respiration and ATP metabolism proceeding independently and maximally - respiration forward, phosphorylation in reverse. Figure 6 compares normal coupled respiration and ATP formation to that which occurs when there has been injury to the inner mitochondrial membrane. The increased reduction of oxygen results in increased heat production.

Additionally, certain chemicals, including biologicals, can selectively increase the transport of protons across uninjured, intact inner mitochondrial membranes and dramatically increase VO$_2$ and heat production. These compounds dissipate the electrochemical-protonmotive transmembrane potential of mitochondria and uncouple the electron transport chain from ATP synthesis. Figure 6(a) depicts one such uncoupling agent, DNP, cycling protons across an intact mitochondrial membrane. DNP and other uncouplers permit each of the two distinct processes involved in oxidative phosphorylation to "unlink" and increase their rates according to their own separate kinetic and thermodynamic signals, Figure 6(b). Uncouplers increase respiratory rates, electron transport, VO$_2$, heat production and increased utilization of foodstuff substrates through glycolysis and the TCA cycle. Controlled doses of an uncoupler will increase O$_2$ consumption and heat production with minimal or no decrease in ATP levels because of intracellular equilibrium shifts in creatinine phosphate, oxidative phosphorylation reactants and increased production of ATP through the anaerobic, glycolytic pathway. Excess or toxic doses of virtually all uncouplers however, will produce secondary untoward effects, including decreased respiration, decreased heat production and eventual cellular death.

In addition to heat being a byproduct of oxidative phosphorylation, reactive oxygen species are also continuously produced by the mitochondrial electron transport chain. Free radicals of oxygen are produced during aerobic oxidation as electrons are transported by the electron carriers to ultimately reduce O$_2$ to H$_2$O. As depicted in Figure 7, superoxide (O$_2^-$) radicals are generated by leaked electrons through the univalent reduction of oxygen. Figure 7(a) shows that

SUBSTITUTE SHEET (RULE 26)
superoxide dismutase then converts the superoxide radical to hydrogen peroxide. Additional hydrogen peroxide (H₂O₂) and hydroxyl (OH-) radicals are formed through the Haber-Weiss Reaction, the hydroxyl radical being the most reactive species, reacting with any biologic moiety instantly. Figure 7(b) depicts the overall scheme of oxygen metabolism and free radical formation at the level of the mitochondrion.

As mitochondria become progressively heated, uncoupling occurs with increased flux of oxygen free radicals. The effects of heat on mitochondrial uncoupling and superoxide radical generation are depicted in Figure 8. A linear correlation of 0.98 (P<0.01) is obtained for the relationship between percent uncoupling and percent superoxide generation. Similar to exercise increased body temperature and VO₂, hyperthermia induced by uncoupling agents appears to inhibit electron transport at the level of cytochrome c in the redox chain. Normal rat liver, infused with DNP, increases formation of reactive oxygen species threefold upon cessation of uncoupling, Figure 9.

Generally, uncouplers are agents that are hydrophobic ionophores which bind protons and traverse biologic membranes to dissipate transmembrane proton (pH) and membrane potential gradients(ΔΨ, Delta Psim). In so doing, uncouplers increase the rate of metabolism (substrate utilization) in intact animals and isolated tissues by increasing the rate of oxygen reduction through increased availability of protons. 0₂ consumption is increased and remains rapid as long as the mitochondrial respiratory (electron transport) chain attempts to overcome the effects of the uncoupler to maintain a pH gradient. Energy is still used to pump protons across the mitochondrial membrane, but the protons are carried back across the membrane by the uncoupler as depicted in Figure 6(a). This creates a futile cycle and energy is released as heat. This chemical heat releasing process is comparable to heating that occurs when an electrical wire is “short circuited”. Depending on the degree of external body heat dissipation, body temperature rises some 30 to 60 minutes after the increase in 0₂ consumption. Onset of action is rapid after an intravenous injection of an uncoupler. Depending on the intravenous dosage, human oxygen consumption is increased in about 15-20 minutes and the intracellular heat production is increased proportionately. Metabolic rates as high as 10 times normal have been reported. Persistent increases in the metabolic rate can continue as long as 12 to 36 hours because of the long hydrophobic half-life of uncouplers in tissues. Temperature increases can be seen within 10 to 15 minutes in subjects whose heat dissipation mechanisms have been compromised.
Heretofore, hyperthermia induced by uncoupling compounds has not been reported to have any therapeutic application.

While there are three general classes of uncoupling agents, each containing specific uncouplers of oxidative phosphorylation, the present invention utilizes 2,4-dinitrophenol (DNP) as the preferred embodiment. This is because DNP has been extensively studied. DNP was commonly used in food dyes in the late 1800's and in the munitions industry of World War I. Rapid increased respiration and hyperthermia, up to 49°C, was noted in man and animals that were accidentally intoxicated. Such dramatic physiologic effects by the dinitro-aromatic dyes, especially DNP, caused them to be inextricably tied to early and later modern studies of metabolism and bioenergetics. In the 1930's DNP was introduced into clinical medicine for the purpose weight loss. It was, however, sold as an over the counter secret nostrum and seriously misused. Had its long half-life in tissues been recognized and physician supervision implemented, it might have become an accepted drug. DNP has been reported in countless, different enzyme, cellular and metabolic studies. Review of such vast published studies have documented DNP's very specific mechanism of action as a proton ionophore, with all other effects a direct pharmacologic extension thereof. DNP is not mutagenic by the Ames and modified Ames tests; it has not been found to be carcinogenic or teratogenic; and, DNP blood plasma levels can easily be determined. DNP can be used at pharmacologic doses that achieve therapeutic concentrations in tissues. Further, DNP is stable, inexpensive and commercially available in reagent grade purity. It is understood however, that other uncouplers and combinations of other uncouplers with other drugs, hormones, cytokines and radiation can potentially be used under appropriate clinical settings and dosages to induce intracellular hyperthermia and promote additive or synergistic effects.

Figure 10 shows the overall intracellular mechanism of action of DNP (and other uncouplers). Intracellular foci of increased heat and oxygen free radical flux are highlighted. Circled numbers in the figure indicate both direct and indirect effects of DNP: circled 1 and 2 effects shows that upon its intercalation into the inner mitochondrial membrane, DNP shuttles H⁺ (hydrogen ions) across the membrane [see Figure 6(a)] - this short circuits (de-energizes) the proton gradient established by the H⁺ pumping action of the mitochondrial electron transport system (see Figure 5). As a consequence, the inner mitochondrial membrane potential is lowered from −180 to −145 mV. Circled 3, 4, 5 and 6 effects shows that normal oxygen consumption and flux of NADH and FADH₂ (reducing equivalents) through the electron transport system is coupled to H⁺ re-entry.
via mitochondrial availability of ADP for re-synthesis of ATP (see Figure 4). By freely returning protons into the mitochondrial matrix without concomitant dependency on ADP to ATP reformation, DNP increases oxygen consumption proportionately to the degree of uncoupling. The rate of oxygen consumption remains linked however, to the flux of electrons provided by NADH and FADH$_2$ through the electron transport chain [see Figure 6(a)]. NADH and FADH$_2$ utilization (re-oxidation) is concomitantly increased. Circled 7, 8, 9, and 10 effects show that oxygen use and electron transfer proceed at increasing rates to accelerate proton pumping against the added hydrogen ion load introduced by DNP. As a result, NADH and FADH$_2$ is continually depleted by re-oxidation to NAD$^+$ and FAD$^{++}$. The high "oxidation pressure" of NAD$^+$ and FAD$^{++}$ increases substrate oxidation and flux of 2 carbon segments through the tricarboxylic acid cycle (TCA). Augmented acetyl-CoA consumption in turn is maintained by an increased rate of glycolysis by depletion of pyruvate. If oxygen delivery is inadequate, or the dose of DNP excessive, the concentration of reduced NADH increases, pyruvate oxidation through acetyl-CoA and the TCA cycle is inhibited and lactic acid will accumulate. Lactate is also overproduced when cellular hypoxia is not present per se but glycolysis exceeds pyruvate oxidation. Such intracellular lactic acidosis exists in neoplastic cells, when there is lack of insulin, when fructose is infused and in other conditions or use of drugs which augment glycolysis and/or inhibit the mitochondrial electron transport system. While it is understood that the intracellular heat generated by DNP is the algebraic sum of the enthalpy changes from all the metabolic processes within the cell, effects circled as 11, 12 and 13 depict the most significant intracellular foci of heat generated by DNP. Intracellular and total body hyperthermia results when DNP releases energy at a rate faster than it can be dissipated. Heat is generated mainly at the inner mitochondrial membrane (electron transport system), the TCA cycle and sites of cytoplasmic glycolysis. Initially DNP generates heat at the inner mitochondrial membrane by discharging a portion of the energy stored in its electrochemical gradient. Operationally, such heat is from the "chemical short circuit" created by DNP shuttling protons to the negative (matrix) side of the polarized inner mitochondrial membrane [see Figure 6(a)]. By usurping controlled proton re-entry and energy capture as ATP from availability of ADP through ATP-synthase, DNP causes NADH and FADH$_2$ (higher concentrations of NAD$^+$ and FAD$^{++}$) reoxidation to occur at rates much higher than necessary for oxidative phosphorylation. This causes an increased fall of electrons through the electron transport chain with rapid reduction of oxygen to water (see Figure 3). The resultant energy is released as heat within the mitochondrial membrane. The rate of heat production from the TCA cycle is increased as it operates at a higher flux to maintain depleting amounts of reduced NADH and FADH$_2$ used to reduce
molecular oxygen. Flux of acetyl-CoA and all metabolites through the TCA cycle (see Figure 2) is increased by activation of enzymes which sequentially degrade the hydrogen containing two carbon fragments to CO₂, NADH, FADH₂ and heat.

Glycolysis and its associated heat production in the cytoplasm is also increased by DNP. Glycolytic activity is increased by reduced concentration ratios of ATP to ADP, activating pyruvate dehydrogenase and phosphofructokinase respectively (see Figure 1). These enzymes increase the rate of glucose catabolism to pyruvate and its conversion to acetyl-CoA for entry into the TCA cycle. Glycolysis is very “energy inefficient” in making up the energy equilibrium shortfall created by DNP. Uncaptured energy from the glycolytic exergonic reactions accelerated by DNP is released as heat in the cytoplasm. DNP stimulated anaerobic heat production through glycolysis can oftentimes be greater than that produced by the mitochondria. By example, many tumors and normal fibroblasts treated with DNP increase heat production by 83%, with only a 36% increase in oxygen consumption. Glycolysis is known to contribute greater than 62% of the total heat produced by human lymphocytes. Circled effect 14 shows that the mitochondrial electron transport chain normally produces reactive oxygen species through the univalent reduction of oxygen [see Figure 7, 7(a) & 7(b)]. Under physiologic conditions, 2 to 4% of mitochondrial oxygen is converted to superoxide. DNP induced partial uncoupling and mitochondrial heating increases reactive oxygen species production manifold. Cytochrome oxidase and reductase is known to be inhibited by heating of the electron transport system. As a result, heated mitochondrial membranes produce increased amount of oxygen free radicals when DNP induced uncoupling is stopped and oxygen consumption is normalized (see Figure 9). Reactive oxygen species act in synergy with heat to alter proteins, induce membrane changes and initiate apoptosis in susceptible cells. Circled effects 15 and 16 shows the effects of DNP on intracellular calcium homeostasis. Normally calcium is stored in the mitochondrial matrix, being pumped by the energized mitochondrial membrane. By DNP directly de-energizing mitochondria, and indirectly inducing membrane heating and prooxidant stress, inner mitochondrial membrane permeability is non-specifically increased with calcium efflux and cycling. This activates intramitochondrial dehydrogenases to produce more reducing equivalents in the form of NADH and FADH₂ to match increased energy demands. Heat production is increased as a byproduct from the augmented TCA cycle.

Other known uncouplers that are considered to be “classic”, in the same category and act as DNP include clofazimine, albendazole, cambendazole, oxibendazole, triclabendazole (TCZ), 6-chloro-
5-[2,3-dichlorophenoxy]-2-methylthio-benzimidazole and their sulfoxide and sulfone metabolites, thiobendazol, rafoxanide, bithionol, niclosamide, eutypine, various lichen acids (hydroxybenzoic acids) such as (+)usnic acid, vulpinic acid and atranorin, 2', 5-dichloro-3-t-butyl-4'-nitrosalicylanilide (S-13), 3, 4', 5-trichlorosalicylanilide (DCC), platanetin, 2-trifluoromethyl-4, 5, 6, 7- tetrachlorobenzimidazole (TTFB), 1799, AU-1421, 3,4,5,6,9,10-hexahydro-14,16-dihydroxy-3-methyl-1H-2-benzoxacyclotetradecin-1,7(8H)-dione (zearalenone), N,N'-bis-(4-trifluoromethylphenyl)-urea, resorcylic acid lactones and their derivatives, 3,5-di-t-butyl-hydroxybenzylidenemalononitrile(SF6847), 2,2'-bis (hexafluoroacetonyl) acetone, triphenyl boron, carbonylcyanide 4-trifluoromethoxyphenylhydrazone (FCCP), tributylamine (TBA), carbonyl cyanide 3-chlorophenylhydrazone (CICCP), 1, 3, 6, 8-tetranitocarbazole, tetrachlorobenzotriazole, 4-isooctyl-2,6-dinitrophenol(Octyl-DNP), 4-hydroxy-3,5-didobenzonitrile, mitoguazone (methylglyoxal bisguanylhydrazone), pentachlorophenol (PCP), 5-chloro-2-mercaptobenzothiazole (BZT-SH), tribromomidazole (TBI), N-(3-trifluoromethylphenyl)-anthranilic acid (Flufenamic acid), 4-nitrophenol, 4, 6-dinitroresol, 4-isobutyl-2,6-dinitrophenol, 2-azido-4-nitrophenol, 5-nitrobenzotriazole, 5-chloro-4-nitrobenzotriazole, tetrachlorobenzotriazole, methyl-o-phenylhydrazone, N-phenylantranilic acid, N-(3-nitrophenyl)anthranilic acid, N-(2,3-dimethylphenyl) anthranilic acid, mfenamic acid, diflunisal, flufenamix acid, N-(3-chlorophenyl) anthranilic acid, carbonyl cyanide 4-trifluoromethoxyphenylhydrazone (FCCP), SR-4233 (Tirapazamine), atovaquone, carbonyl cyanide 4-(6'-methyl-2'-benzothiazyl)-phenylhydrazone(BT-CCP), ellipticine, olivacine, ellipticium, isoepliticine and related isomers, methyl-0-phenylhydrazonocyanaceticacid,methyl-0-(3-chlorophenylhydrazono) cyanoacetic acid, 2-(3'-chlorophenylhydrazono)-3-oxobutyronitrile, thiosalicylic acid, 2-(2',4-dinitrophenylhydrazono)-3-oxo-4,4-demethylvaleronitrile, relanium, melipramine, and other diverse chemical entities including unsaturated fatty acids (up to C14 optimum), sulfluramid and its metabolite perfluorooctane sulfonamide (DESA), perfluorooctanoate, clofibrate, Wy-14, 643, ciprofibrate, and fluoroalcohols. Additional unnamed classic uncouplers can include any analog which generally has a weakly acidic, removable proton and an electron withdrawing, lipophilic molecular body that is capable of charge delocalization. Hydrophobicity and capacity to exchange proton equivalents are integral features of classic DNP types of uncouplers.

A second class of uncouplers are ionophorous antibiotics. These molecules uncouple oxidative phosphorylation by inducing cation or anion influx across the mitochondrial membranes and
diffusing back in a protonated form. As a result, chemical futile cycling ensues to reestablish the initial membrane potential. Liberated energy is dissipated as heat. Examples of ionophores that shuttle potassium ions ($\text{K}^+$) across membranes includes the antibiotics gramicidin, nigericin, tyrothricin, tyrocidin, and valinomycin. Nystatin shuttle sodium ions. The calcium ionophore, compound A23187, is a lipid soluble ionophore which mediates the electroneutral exchange of divalent cations for protons. Alamethicins, harzianin HA V, saturnisporin SA IV, zervamicins, magainin, cecropins, melittin, hypelcins, suzukacillins, monensins, trichotoxins, antiamoebins, crystal violet, cyanine dyes, cadmium ion, trichosporin-B and their derivatives are examples of uncoupling ionophores that depend on shuttling inorganic phosphate (P$\text{O}_4^{3-}$) across the mitochondrial membrane.

A third class of uncouplers is a group of heterogeneous compounds that dissipate the proton gradient by attaching or interacting with specific proteins in the inner mitochondrial membrane. Examples of such compounds include desaspidin, ionized calcium (Ca$^{++}$), uncoupling proteins such as UCPI-1, UCP-2, UCP-3, PUMP (Plant Uncoupling Mitochondrial Protein) histones, polylysines, and A206668-a protein antibiotic that ties up phosphoryl-transfer proteins. Examples and a potency comparison of a few uncouplers are depicted in figure 11.

Various conjugates, adducts, analogs and derivatives of the above mentioned agents can be formulated and synthesized to enhance intracellular uncoupling and heat production. Further, various covalent compounds of uncouplers may be synthesized as prodrugs, which upon, redox or reaction with free radicals within the cell will become activated to induce uncoupling, heat production and free radical cycling. Such derivatives and formulations may be desirable in the treatment of many tumors with higher mitochondrial membrane potentials and increased total bioreducte capacity. Uncoupling-free radical prodrug compounds may thus exert greater selective killing of transformed cells by undergoing a higher flux of reduction or electron acceptance in tumor cells. In this regard, the contents of U.S. Patent NO. 5,428,163 and the published methods of C-Alkylation of phenols and their derivatives by Hudgens, T.L. and Turnbull, K.D. are hereby incorporated by reference.

From a physico-chemical and thermodynamic standpoint, the amount of heat produced by uncoupling is proportional to the density and rate of flux of electrons through the mitochondrial electron transport chains. Such electron flux is initially reflected by the magnitude of the electrochemical proton gradient across the inner mitochondrial membrane. Those cells, tissues,
organs and organisms that are metabolically more active will generally have an increased membrane potential and will respond with a greater amount of heat production for a given dose and type of uncoupler. Figure 12 lists the six most “hottest” organs in the human body along with their rates of blood flow and rates of heat production. The actual amount of intracellular hyperthermia produced by an uncoupler is dependent on the uncoupler dose, its relative potency and availability of substrate such as glucose, glutamine, fatty acids or other substances that produce NADH or FADH₂. Oxygen and magnitude of the mitochondrial proton electrochemical gradient (ΔμH⁺) are additional factors that determine the amount of heat that can potentially be released by an uncoupler. Among all the constituents, ΔμH⁺ is the most clinically important. ΔμH⁺ is composed of the transmembrane potential [ΔΨ (charge difference)] and pH gradient [Δ pH (H⁺ concentration difference)], ΔμH⁺ = FΔΨ - 2.3RTΔpH, where, F=Faraday Constant, R= Gas Constant, and T= degrees Kelvin. Thus, ΔμH⁺ represents the potential amount of heat that can be liberated by an uncoupler when 1 mole of H⁺ is dissipated through the inner mitochondrial membrane. This potential heat energy is normally expressed in units of millivolts (mV) and is called the protonmotive force, Δp = ΔμH⁺/F = ΔΨ-2.3(RT/F)ΔpH. In vivo, ΔpH is generally 1 unit or less so that 75% or more of the total Δp is comprised of ΔΨ. Consequently, the intracellular heat produced by an uncoupler can be estimated by the mitochondrial membrane potential (ΔΨ) alone.

Knowing the ΔΨ is of practical importance because biopsy specimens may be incubated with cationic organic probes to estimate the ΔΨ and the degree of differential heating that will occur between normal and transformed tissues. Dyes such as rhodamine 123, mitotracker green, calcinein plus Co²⁺, 3,3'-dihexyloxacarbocyanine, triphenylmethylphosphonium, J1,5,1,6,61-tetracloro-1,1',3,3'-tetraethylbenzimidazolocarbocyanine, etc., all have an affinity for a negative mitochondrial ΔΨ. Based on the amount of cationic dye uptake, the membrane potential of specific tissue, tumors, and cells may be determined through the Nernst equation: ΔΨ = -(RT/F) ln(Cₘᵢᵣ/Cₖₒᵤₜ). Which at physiologic conditions and 37⁰C is = -61 log (Cₘᵢᵣ/Cₖₒᵤₜ), where Cₘᵢᵣ/ₖₒᵤₜ is the concentration of the probe inside or outside the mitochondria and plasma membrane. By example, a 10 to 1 gradient = -60mV, 100 to 1 = -120mV. Uncouplers dissipate the ΔΨ, generate heat and release or prevent uptake of cationic dyes. Six years of systematic measurement of mitochondrial membrane potentials have been performed on human and mammalian cells, including some 200 cell types derived from human malignant tumors of kidney, ovary, pancreas, lung, adrenal cortex, skin, breast, prostate, cervix, vulva, colon, liver, testis, esophagus, trachea and tongue. Based on this exhaustive study, a ΔΨ difference of at
least 60 mV is known to exist between normal epithelial cells and carcinoma cells. This is significant for the present invention in that uncoupling or “short circuiting” a 60 mV potential across a 5-nm mitochondrial membrane would be equivalent to the amount of heat generated by short circuiting 120,000 V across 1 centimeter. By exploiting or increasing the membrane potential between normal and transformed cells the rate of intracellular heat production by an uncoupler can be selectively increased in target tissues.

In order for uncoupler induced intracellular hyperthermia to be of therapeutic benefit, the development of thermotolerance is also taken into account in practicing this invention. Mammalian cells and prokaryotes acclimate and acquire transient resistance or thermotolerance to gradual or non-lethal hyperthermia. Such adaptation is believed to occur through increased synthesis of highly conserved groups of proteins known as heat shock proteins (HSP). The amount of HSP present in tissues, cells and organisms subjected to non-lethal heat, or other forms of prolonged metabolic stress, is proportional to their survival at higher temperatures. In general, thermotolerance develops after 3 to 4 hours of continuous hyperthermia, peaks in 1 to 2 days and decays back to normal thermosensitivity within 3 to 4 days. Thermotolerance is known to alter lethality of hyperthermia by as much as 20°C increase or double the heating time required to achieve the same temperature-cytotoxic effect. Such adaptive thermo-resistance by human tumors is problematic for continuous or fractionated cytotoxic treatment with hyperthermia. Induction heating times with the present invention are therefore kept to a minimum of 1 to 2 hours. Further, the uncoupler induced cytotoxic hyperthermia in the present invention induces relative tissue hypoxia, lowers intracellular pH and limits the production of ATP, all of which repress the development of thermotolerance. Low doses of uncoupler, which produce gradual heating can be used to induce HSP synthesis and promote thermotolerance.

Determining the amount of DNP in mg/kg of body weight required to produce the desired level of cytotoxic hyperthermia in a safe and efficacious manner is established from the thermal equivalents (Kcal) of oxygen consumed (VO₂), and the known average specific heat capacity of the human body. It is known that at standard temperature and barometric pressure, 1 liter of oxygen consumed per minute (VO₂) generates approximately 4.862 Kcal. It is also known that the average specific heat capacity of humans is about 0.83 of that required to raise 1 gm of H₂O 10 K = 4.184 J, a heat capacity of 3.47 J g K⁻¹. An initial estimate of the total energy required to be generated by DNP to induce 41.00°C hyperthermia in 1 hour may be very simply determined from the above and customized for a specific patient as outlined below:

SUBSTITUTE SHEET (RULE 26)
Patient Characteristics

Body weight 70 kg
Resting VO₂ 0.25L/min

Basal energy expenditure 73.1 Kcal/hr (1754.4Kcal/24 hrs.)
Basal core temperature 37.0°C
Target temperature 41.0°C

Required energy to raise temperature to target level in 1 hour

(Weight in grams=70 x 10³) (human specific heat=3.47 J g K⁻¹) (Temperature increase=41.0°C-37.0°C) ~ 0.97 x 10⁶ J. Since 1 J = 4.184 x 10⁻⁴ Kcal, a total power input of about 232 Kcal would be required to raise the temperature of the patient to the objective level in 1 hour less that amount of heat generated by a heated metabolism outlined below.

Increase in metabolic rate/heat production with increase in body temperature

The basal metabolic rate (BMR) is known to increase in patients with endogenous fevers by approximately 7% for each 0.5°C rise in temperature. This is graphically depicted in Figure 11a. As a result, the increase in BMR relative to the temperature will in itself assist in achieving the objective level during the induction phase by the following equation:

\[ \text{BMR}_{\text{Tcore}} = 73.1 \times 1.07(\text{Tcore}-37)/0.5 \]

Thus, at 41.0°C the metabolic rate will be 134.4 Kcal/hr, 61.3 Kcal/hr above the basal energy expenditure level. This increase in metabolic rate will therefore reduce the initial energy required to heat the patient by approximately 61 Kcal over the 1 hour timeframe.

Initial net energy input required to reach target temperature in 1 hour

232 Kcal – 61 Kcal (by increased BMR) = 171 Kcal

Required increase in initial VO₂ to obtain 171 Kcal heat input

Since the Kcal equivalent for 1 liter of oxygen consumed per minute is 4.862, then the initial increase in VO₂ required to generate 171 Kcal can be calculated as follows: Heat in Kcal/min = VO₂ x 4.862. Since the individual patient has a resting VO₂ of 0.25 l/min which = 73.1 Kcal/hour BMR, then

\[ X (\text{VO₂}) = 171 \text{Kcal}, \text{ or} \]

SUBSTITUTE SHEET (RULE 26)
An initial minimal increase in \( V_02 \) to approximately 0.60 l/min is required.

**DNP dosage required to increase \( V_02 \) to 0.60 l/min**

The individual DNP dosage (mg/kg) required to produce an increase in oxygen consumption to 0.60 l/min so as to achieve a 171 K/cal heat output is accomplished in the following fashion: (1) DNP is prepared in a 200mg/100ml sterile aqueous solution. If not fully dissolved, it can be brought into solution by buffering with 1% NaHCO₃, the pH must be kept below 8 to avoid hydrolysis; (2) the dose of DNP for each intravenous infusion can vary from 0.5 to 4mg/kg and will depend on the clinical situation, as well as the initial and subsequent increases in the metabolic rate (\( V_02 \)). In an especially preferred embodiment, the patient is given an initial dose of DNP no greater than 1mg/kg intravenously, infused over no less than a 2 minute period. Within approximately 10-15 minutes, a minimum of a 15% increase in \( V_02 \) will occur. The \( V_02 \) will continue to increase until a plateau is reached within an additional 5 to 10 minutes.

After a 5 minute plateau in \( V_02 \), a subsequent dose of either 0.5, 1, 2, 2.5, or 3.0 mg/kg DNP is administered and \( V_02 \) is again increased until a desired plateau is reached. Additional infusions of DNP or other medications are administered under clinical parameters of \( V_02 \), respiratory rate, pulse rate, blood pressure, urine output, cardiac output, core temperature, and clinical status of the patient so as to maintain safe and effective control of heating. If heat dissipating mechanisms are neutralized, measurable increases in core temperature will occur approximately 20 to 30 minutes after an increase in the \( V_02 \). Figure 13 illustrates the increases in \( V_02 \) associated with repeated infusions of DNP.

Medications which increase the overall metabolic rate, or that of specific target tissues, and have short half-lives can be utilized to increase the relative activity of DNP or other uncouplers to further adjust \( V_02 \) and heat production. Examples of such medications are almost limitless because any drug, hormone or biologic response modifier that causes changes in enthalpy (heat content) during the course of its intracellular chemical and biophysical activity and interaction in the life cycle of biological cells can be utilized. A few illustrative examples include glucagon (half-life of 9 minutes in plasma), arbutamine (half-life 10 minutes), dobutamine (half-life 2 minutes), and vasopressin (half-life 5 minutes). Various amino acids and fatty acids, e.g., glutamine, proline, octanoate, etc., increase \( V_02 \) by translocating reducing equivalents into the mitochondrial matrix via the malate-aspartate shuttle, B-oxidation or proline metabolism. Agents such as methylene blue (tetramethylthionine), ubiquinone, menadione, hematoporphyrin,
phenazine methosulfate, 2,6-dichlorophenolindophenol, coenzyme Q1, CoQ2, or their analogs duroquinone and decylubiquinone, etc., can increase heat and/or free radical production by acting as artificial electron acceptors. Such agents, and numerous others, can be co-administered with DNP or other uncouplers to effectively increase the enthalpy changes in the entire organism or specific targeted tissues.

Minimizing heat loss and temperature control

Increased radiative and evaporative heat loss from man are the two most dominant thermoregulatory mechanisms for cooling the body. The body’s methods of adjusting heat loss are vasoconstriction and vasodilation in the skins blood vessels. Radiation can account for 60% of the heat loss generated by the body, while evaporation by sweating at 1.0 liter/hour can represent a potential heat loss of about 1,000 Kcal/hour. By far, sweating and evaporation is the principal mechanism that dissipates heat under conditions that induce large heat gains. Depending on the clinical circumstances, heat loss due to evaporation, as well as radiation, can be managed and controlled by a variety of methods including, but not limited to, using vasoconstricting agents, placing the patient in a scuba diving wet suit, humidified survival suit, or enveloping the patient in a water soaked blanket covered or containing a polyethylene lining to prevent evaporative heat losses. Use of room ultrasonic nebulizers to induce continuous mist and high humidity is also known to prevent evaporative heat losses. Evaporative and radiant heat loss from the cranium is controlled by appropriate head gear, shower caps and/or wet towels. Control of local air velocities and management of surroundings as to temperature, emissivity, drafts, and convection currents are important to avoid large heat losses. In those clinical circumstances where total body hyperthermia is required, failure to adequately control body heat loss will necessitate using higher doses of DNP and induce a greater metabolic stress upon the patient.

If the core target temperature is exceeded or continues to rise after the target temperature is achieved, exposure of an extremity or body surface for a brief interval will permit sufficient heat loss to lower the core temperature to the target range. At target temperatures of 39-41°C, residual uncoupling by DNP will continue for approximately 3 hours. Heat production as a byproduct of glycolysis, and heated metabolism further maintains body heat content and compensates for any heat loss. Therefore, target plateau temperatures can be regulated with a large margin of safety and with little to no additional use of uncoupler. Therapy is terminated by
removing the vapor barrier from the patient. Evaporative and radiant heat loss from the patient generally produces a fall in core temperature of about 2-2.5°C in about 20-30 minutes. Obese patients and those with compromised thermoregulatory systems experience a slower falloff in temperatures.

Patient monitoring, fluid support and evaluation during treatment

Placement of physiologic monitoring sensors, intravenous fluids, supplemental oxygen (4l/min) and optional oral diazepam sedation (5-10mg) is initiated prior to treatment. Patients receive 0.85 to 1.0 liter of intravenous (IV) 5% dextrose in 0.25 normal saline per hour alternated with 5% dextrose in 0.5 normal saline plus 7.5 to 10 meq of KCl per liter to insure a urinary output of no less than 1ml/kg/hr. Oxygen consumption, caloric expenditure, rectal core temperature, cardiac rhythm, blood pressure, heart rate and respiratory rate are continuously displayed, monitored by a trained member of the treatment staff. The data is automatically downloaded into a computer every 20 seconds to 3 minutes for the entire procedure and immediately re-displayed on computerized graphs and charts. Two hours after treatment and 48 hours post-treatment, serum chemistries and hematologic profiles are repeated. A typical patient flow chart is depicted in Figure 14.

Treatment of excessive heating and antidotes

In those rare instances when too much uncoupler is administered or the metabolic rate of the patient unexpectedly increases and VO₂, hyperthermia, pulse rate and patient fatigue ensue, appropriate supportive measures of cooling, intravenous hydration and administration of specific medication should be instituted. Cooling should be instituted by uncovering the patient, spraying with tepid water and fanning with an industrial grade fan. If cooling is inadequate, surface, axillary and groin ice packs and intravenous cold glucose solutions should immediately be considered. Bicarbonate, 1-2 mEq/kg should be administered in the absence of blood gas analysis. Urine output of >1 ml/kg/hour should always be maintained to avoid pre-renal azotemia and oliguria secondary to possible rhabdomyolysis and myoglobinuria. Mannitol should be administered if urine output is inadequate. Hypoglycemia should immediately be corrected with 50% saturated intravenous glucose. If severe or persistent hypermetabolism ensues, rectal propylthiouracil- 1,000 mg, hydrocortisone (100 mg q 6 h) or dexamethasone 2 mg q 6 h intravenously and/or sodium iodide as 1 g sodium ipodate (contrast agent) should be administered intravenously to induce iatrogenic hypothyroidism. The decreased metabolic rate
will dramatically reduce the physiologic response to DNP. Patient agitation and restlessness can be avoided by appropriate IV or IM dose of diazepam. Salicylates are of no value and may contribute to further uncoupling. Medications that reduce sweating, e.g., tricyclic antidepressants, antihistamines, anticholinergics, phenothiazines, or decrease vasodilation, e.g., sympathomimetics, α-agonists, or decrease cardiac output, e.g., diuretics, beta-blockers or induce hypothalamic depression, e.g., neuroleptics, α-blockers, opioids, etc., should be avoided prior, during and immediately after treatment with uncoupplers.

The hypermetabolic and hyperthermic activity of DNP can further specifically be reduced by using calcium channel blockers such as nifedipine, verapamil and others, in intravenous doses that do not cause a drop in blood pressure or induce cardiac arrhythmias. Dihydrobenzperidol (a neuroleptic drug with α1-adrenergic properties) can also be used to cause similar, significant reductions in DNP induced hypermetabolism and hyperthermia. Dosages of these anti-DNP agents are titrated in 5 mg to 30 mg increments and can be given either by mouth or intravenously. In those cases where DNP appears to decrease electrical conduction or cause EKG conduction abnormalities, Coenzyme Q10, in doses of 50mg/kg, can be used to restore normal electrical activity.

**Patient selection and pretreatment evaluation**

It is imperative that in the practice of this invention, patients be selected and evaluated prior to treatment. Recommended patient inclusion and exclusion criteria includes: (1) patients have a definitive histopathologic or other laboratory confirmed diagnosis of their disease; (2) the disease or condition should be responsive to intracellular hyperthermia treatment; (3) patients should have a Karnofsky score of 70% or greater; (4) not be pregnant; (5) weight should be within 45% (+/-) of ideal body weight and patients must weigh at least 35 kg; (6) there should be no history or findings of anhidrosis, scleroderma, ectodermal dysplasia, Riley-Day Syndrome, arthrogryposis multiplex, extensive psoriasis, serious dysrhythmias, malignant hyperthermia or neuroleptic malignant syndrome, pheochromocytoma, hypocalcemia, repeated episodes of hypoglycemia, chronic or recurrent venous thrombosis, alcoholism, renal failure, cirrhosis, untreated hyperthyroidism, anaphylaxis associated with heat or exercise-induced cholinergic type urticaria, exercise or heat induced angioedema, schizophrenia, catatonia, seizure disorders, emotional instability, Parkinson’s disease, brain irradiation, cystic fibrosis, unstable angina pectoris, congestive heart failure, patients with cardiac pacemakers, severe cerebrovascular disease, spinal cord injury, severe pulmonary impairment, hereditary muscle disease such as
Duchenne type muscular disease, central core disease of muscle, myotonia congenita, King-Denborough syndrome, Sewnary-Jampol syndrome, or osteogenesis imperfecta; (6) no immediate use of drugs that impair the body's heat dissipation mechanisms such as phenothiazines, anticholinergics, antihistamines, antiparkinsonians, glutethimide, hallucinogens, lithium, cocaine or other illicit drug use, monamine oxidase inhibitors, sympathomimetics, phencyclidine, opioids, phenylephrine, INH, tricyclic antidepressants, withdrawal from dopamine agonists, or cardiovascular drugs that clinically impair cardiac output or thermoregulatory vasodilation such as high doses of β-blockers, vasodilators, or calcium channel blockers; and, (7) the patient should not be anemic or otherwise have a reduced oxygen absorbing, carrying or utilizing capacity.

Pretreatment evaluation should include a complete medical history and physical examination focused on the selection criteria listed above. Laboratory evaluation should include pulmonary function tests-if indicated, full hematological survey with hemastatic profile, EKG, liver function tests, serum biochemical profile, thyroid panel, serum creatinine, calcium, phosphate, and stress-EKG or exercise-multigated radionuclide ejection scan on patients whose cardiac ejection fraction is suspect not to be greater than 45% with probable deterioration on exercise. While clinical exceptions to entry laboratory values may exist, the following laboratory data should be a benchmark guide for initiation of treatment: hemoglobin \( \geq 11.0 \text{ g/dl} \) for men and \( \geq 10.0 \text{ g/dl} \) for women, platelet count \( \geq 75,000 \text{ platelets/mm}^3 \), bilirubin \( \leq 2 \times \text{ULN} \) (ULN = upper limit of normal), ALT (SGPT) \( \leq 2 \times \text{ULN} \), AST (SGOT) \( \leq 2 \times \text{ULN} \), pancreatic amylase < 1.5 × ULN, neutrophil count \( \geq 1,000 \text{ cells/mm}^3 \). Serum electrolytes and \( K^+ \) should be well within normal limits, as hypokalemia decreases muscle blood flow, cardiovascular performance, and sweat gland function.

More generally, the method outlined above is to be tailored to an individual patient. As set forth above, the DNP may be administered by intravenous infusion. Alternatively, the route of administration may also be orally, rectally or topically. The frequency and optimal time interval between administrations is individualized and determined by measuring \( V_{O2} \), as well as other parameters. For example, various laboratory, x-ray, CAT scan, MRI, PET scan, HIV load, CD4+ lymphocyte counts, HSP expression, prostatic specific antigen (PSA) and other surrogate markers of clinical outcome can establish the \( V_{O2} \), frequency and duration of therapy. One treatment, or treatments as frequent as every day, or every other day, as far apart as 1 year or longer may be required for sustained beneficial results.
The optimal VO₂, temperature, duration, and frequency between treatments will probably vary from patient to patient and the specific disease or condition being treated. One skilled in the art would be able to modify a protocol within the present invention, in accordance with standard clinical practice, to obtain optimal results. For example, the HIV relationships between viral load, CD4⁺ lymphocyte counts, presence of opportunistic infections and clinical status of the patient can be used to develop more optimal regimes of DNP administration. Applicants’ studies have revealed that the methods of the present invention can be effective in the diagnosis and treatment of a wide range of disease states and conditions in which uncoupler induced hypermetabolism, hyperthermia, oxidative stress and their sequela, play a beneficial role. To those skilled in the art, it is also encompassed that a variety of different veterinary, as well as medical, applications for treatment and diagnosis can be practiced with the present invention.

It is envisioned that DNP, or other uncouplers, may also be administered with other compounds used to treat infectious, malignant or other diseases. Examples of other agents include antifungal, antibacterial, antiviral or anti-neoplastic drugs, cell differentiating agents, and, various biologic response modifiers. Examples of anti-fungal agents include Amphotericin B, Griseofulvin, Fluconazole (Diflucan), Intraconazole, 5-fluoro-cytosine (Flucytosine, 5-FC), Ketatoconazole and Miconazole. Examples of anti-bacterial agents include antibiotics, such as those represented from the following classifications: beta lactam rings (penicillins), macrocyclic lactone rings (macrolides), polycyclic derivatives of naphthacenecarboxamide (tetracyclines), amino sugars in glycosidic linkages (aminoglycosides), peptides (bacitracin, gramicidin, polymixins, etc.), nitrobenzene derivatives of dichloroacetic acid, large ring compounds with conjugated double bond systems (polyenes), various sulfa drugs including those derived from sulfanilamide (sulfonamides, 5-nitro-2-furianyl compounds (nitrofurans), quinolone carboxylic acids (nalidixic acid), fluorinated quinilones (ciprofloxan, enoxacin, ofloxacin, etc.), nitroimidazoles (metroindazole) and numerous others. These antibiotic groups are examples of preferred antibiotics, and examples within such groups include: peptide antibiotics, such as bacitracin, bleomycin, cacinomycin, capreomycin, colistin, dactinomycin, gramicidin A, enduracitin, amphotomycin, gramicidin J, mikamycins, polymyxins, stendomycin, actinomycin; aminoglycosides represented by streptomycin, neomycin, paromycin, gentamycin ribostamycin, tobramycin, amikacin; lvidomycin beta lactams represented by benzylpenicillin, methicillin, oxacillin, hetacillin, pipercillin, amoxicillin and carbenacillin; lincoaminides represented by clindamycin, lincomycin, celestocetin, desalicetin; chloramphenicol; macrolides represented by

**SUBSTITUTE SHEET (RULE 26)**
erythromycins, lankamycin, leucomycin, picromycin; nucleosides such as 5-azacytidine, puromycin, septacidin and amicetin; phenazines represented by myxin, lomofungin, iodin; oligosaccharides represented by curamycin and evenominycin; sulfonamides represented by sulfathiazole, sulfadiazine, sulfanilimide, sulfapyrazine; polyenes represented by amphotericins, candidin and nystatin; polyethers; tetracyclines represented by doxycyclines, minocyclines, methacyclines, chlorotetracyclines, oxytetracyclines, demeclocyclines; nitrofurans represented by nitrofurazone, furazolidone, nitrofurantoin, furium, nitrovin and nifuroxime; quinolone carboxylic acids represented by nalidixic acid, piromidic acid, pipemidic acid and oxolinic acid. The Encyclopedia of Chemical Technology, 3rd Edition, Kirk-Othmer, editors, Volume 2 (1978), which is hereby incorporated by reference in its entirety.

Antiviral agents that can be used with DNP include: interferons α, β and γ, amantadine, rimantadine, arildone, ribaviran, acyclovir, abacavir, vidarabine (ARA-A) 9,1,3-dihydroxy-2-propoxymethylguanine (DHPG), ganciclovir, enviroxime, foscarnet, amipligen, podophyllotoxin, 2,3-dideoxythidine (ddC), iododeoxyuridine (IDU), trifluorothymidine (TFT), dideoxyinosine (ddi), d4T, 3TC, zidovudine, efavirenz, protease inhibitors such as indinavir, saquinavir, ritonavir, nelfinavir, amprenavir, etc., and specific antiviral antibodies.

Anti-cancer drugs that can be used with DNP include, but are not limited to, various cell cycle-specific agents represented by structural analogs or antimetabolites of methotrexate, mercaptopurine, fluorouracil, cytarabine, thioguanine, azacitidine; bleomycin peptide antibiotics, such as podophyllin alkaloids including etoposide (VP-16) and teniposide (VM-26); and various plant alkaloids such as vincristine, vinblastine, and paclitaxel. Anti-neoplastic cell cycle-nonspecific agents such as various alkylating compounds such as busulfan, cyclophosphamide, mechlorethamine, melphalan, altretamine, ifosfamide, cisplatin, dacarbazine, procarbazine, lomustine, carmustine, lonusmiste, semustine, chlorambucil, thiopeta and carboplatin. Anticancer antibiotics and various natural products and miscellaneous agents that can be used with DNP include: daunorubicin, doxorubicin, plicamycin, mitomycin, idarubicin, amnoscarine, asparaginase, quinacrine, retinoic acid derivatives (etretinate), phenylacetate, suramin, taxotere, tenizolamide, gencytabine, amonafide, streptozocin, mitoxanthrone, mitotane, fludarabine, cytarabine, cladribine, paclitaxel (taxol), tamoxifen, and hydroxyurea, etc.
DNP can also be administered with various hormones, hormone agonists and biologic response modifying agents which include, but are not limited to: flutamide, prednisone, ethinyl estradiol, diethylstilbestrol, hydroxyprogesterone caproate, medroxyprogesterone, megestrol acetate, testosterone, fluoxymesterone and thyroid hormones such as di-,tri- and tetraiodothyroidine. The aromatase inhibitor, amino glutethimide, the peptide hormone inhibitor octreotide and gonadotropin-releasing hormone agonists such as goserilin acetate and leuprolide can also be used with DNP. Biologic response modifiers such as various cytokines, interferon alpha-2a, interferon-alpha-2b, interferon-gamma, interferon-beta, interleukin-1, interleukin-2, interleukin-4, interleukin-10, monoclonal antibodies (anti-HER-2/neu humanized antibody), tumor necrosis factor, granulocyte-macrophage colony-stimulating factor, macrophage-colony-stimulating factor, various prostaglandins, phenylacetates, retinoic acids, leukotrienes, thromboxanes and other fatty acid derivatives can also be used with DNP.

The use of this invention should be under the strict direction of a qualified and specialized treatment team to insure safety and effectiveness. The treatment team remains with the patient throughout the procedure to insure that safe and controlled dosages of an uncoupler are administered by monitoring real time changes in VO2, metabolic rate, temperature, respiratory rate, heart rate, urine output and clinical status of the patient. This invention is practiced in controlled steps so as to attain a predetermined VO2 and plateau of heating time for a particular disease or condition. For example, in cases were heat dissipation mechanisms do not have to be blocked, the specialized team will periodically recheck VO2, heart rate, blood pressure, CAT scan, MRI, etc., and other laboratory and clinical parameters to insure continued safety and efficacy of DNP therapy. It is preferred that the specialized team undergo a training period in the use of this invention prior its administration to human patients.

The present invention is further illustrated by reference to the following examples, which illustrate specific elements of the invention but should not be construed as limiting the scope of the invention.

Example 1

METHOD OF USING DNP WITH GLUCAGON TO TREAT PARASITIC INFECTIONS, HYDATID DISEASE OF THE LIVER

SUBSTITUTE SHEET (RULE 26)
History: A 52 year old white Swiss male, European fox hunting dog trainer, presented with right upper quadrant pain and vomiting. Past history revealed he had hepatic "cyst" surgery 2 years ago. Preoperatively, he was treated with albendazole. Only one dose of albendazole was given because of a "near death" anaphylactic reaction. He denied history of weight loss, pulmonary, cardiac, neurologic or thermoregulatory problems. There was no history of alcohol abuse or medication use. The patient was adamantly opposed to any further surgery or treatment with albendazole or mebendazole.

Physical Examination: Weight=90 Kg; height=177.8 cm; BP=140/80; HR=76 & reg; Resp.=18min; T=37.0

An old well healed scar consistent with prior hepatic surgery was present. Physical exam otherwise was unremarkable.

Laboratory studies: EKG, chest X-ray, blood panel, including serum electrolytes, thyroid studies and liver function tests were within normal limits (WNL). A complete blood count was unremarkable except for 20% eosinophilia. Ultrasound and nuclear magnetic resonance revealed 4, 2 to 3 cm in diameter, cysts in the right middle lobe of the liver and a solitary 2 cm semi-solid medullary cyst in the neck of the right humerus. ELISA serology showed a diagnostic titer for hydatid disease. Review of previous surgical liver pathology reports revealed a cestode compatible with Echinococcus multilocularis.

Clinical assessment and treatment evaluation: The patient had no historical or physical contraindications to DNP induced hyperthermia. Conventional therapy of hydatid disease is either surgical resection or medical therapy with albendazole for 4 weeks. Hydatid bone cysts are not amenable to surgery and respond poorly to standard medical therapy. Echinococcus multilocularis protoscoleces and the germinal membranes of hydatid cysts are known to be irreversibly destroyed by heating at 41°C for 15 minutes. Human liver and hepatocytes can withstand artificial temperatures of 42°C for as long as 20 hours without irreversible damage. Acute glucagon treatment is known to preferentially stimulate hepatocyte mitochondrial V02.

Rates of hepatocyte uncoupled V02 are also known to be stimulated up to 100% in less than 6 minutes after the hormonal action of glucagon. Acute glucagon treatment has been shown to selectively increase the pH gradient across hepatocyte mitochondrial membranes. Thus, it can be empirically presumed that any increase in V02 from glucagon administration causes increased thermogenesis, predominantly in the liver.
Pretreatment protocol: the patient was given 10 mg diazepam by mouth and dressed into a modified wet suit. The wet suit was cut lengthwise at the arms and legs. Velcro strappings were attached at the cuttings for closure, rapid removal or exposure of the limb(s). After placement of monitoring sensors, he was started on IV fluids of 5% dextrose, 0.5 normal saline with 7 meq K⁺, infused at an initial rate of 12cc/kg/hr. Evaporative heat loss from the head was minimized by a plastic shower cap and towels. A 401AC temperature probe (YSI Incorporated, Yellow Springs, Ohio) was inserted 11 cm. into the rectum. The probe was connected to a Model 4600 telethermometer (YSI 4600 Precision Thermometer) and readings within 0.1°C were continuously displayed and recorded at baseline and during treatment on Hewlett-Packard (HP) computer systems with customized software developed by MR&S (Manalapan, New Jersey). A TEEM 100 Metabolic Analysis System (AeroSport Inc., Ann Arbor, Michigan), with a modified face mask and oxygen delivery system (38-40% O₂ saturation) for patient comfort and increased accuracy, was attached to the patient. Oxygen consumption (V̇O₂), carbon dioxide production (V̇CO₂), expired air volume (V̇E), heart rate (HR), and Kcal of heat produced were measured in 20 second intervals and extrapolated to minute or hourly rates. All patient data was monitored in real time, continuously displayed at baseline and during treatment and recorded on HP computer systems with customized software from MR&S (Manalapan, New Jersey).

Treatment procedure: After baseline recordings of 10 minutes, the required amount of DNP to raise the initial V̇O₂ to achieve a temperature in the patient of 40°C was calculated as described under “DNP dosage required to increase V̇O₂”. The patient was given an initial dose of 1 mg/kg of DNP, infused intravenously over a 3 minute period. After the V̇O₂ stabilized at 40% above baseline, an additional DNP infusion of 3 mg/kg was given. Upon attaining a stable V̇O₂, 0.5 mg of glucagon was administered intravenously. After this stabilization of V̇O₂, a glucagon drip was variably infused from 0.5 to 5mg/kg/hour to additionally control V̇O₂ and selectively augment heat production in the liver. The treatment procedure was discontinued after the patient was maintained at a rectal body temperature of 40°C for about 1 hour. The wet suit was opened and head covering removed. After the patient's body temperature reached 38°C, the Foley catheter was removed and intravenous fluids were discontinued. Evaporative and radiant heat loss lowered the body temperature to a normothermic level within 30 minutes. No immediate or delayed post-treatment toxicity was encountered. Monitored patient parameters are shown in Figure 15.
Treatment outcome: Serial imaging studies revealed hepatic and bone cyst shrinkage with increased density at 2 and 4 weeks post treatment. Repeat magnetic resonance imaging at 4 months showed complete cyst disappearance in the liver and bone.

Example 2

METHOD OF USING DNP TO TREAT VIRAL INFECTIONS, HIV DISEASE

History: A 38 year old white male, past intravenous heroin addict, was diagnosed approximately 8 years ago with HIV by ELISA and positive Western blot for HIV p24 and gp41 antigens after presenting with weight loss and thrush. His history included repeated treatment for candidiasis, pneumocystis carinii, and various subcutaneous abscesses. Past medications included sulfamethoxazole, ketoconazole, fluconazole, zidovudine, didanosine and various other antibiotics. For the past year and a half he has been on highly active antiretroviral therapy (HAART) with various HIV protease inhibitors combined with thymidine, purine or cytosine nucleoside and nonnucleoside inhibitors. He was unable to tolerate nelfinavir because of diarrhea. Ritonavir caused intractable vomiting and abdominal pain. Current medications include indinavir, zidovudine and lamivudine. Review of the most recent viral load (VL) and CD4+ lymphocyte counts showed an initial drop in plasma HIV RNA (copies/ml) from 200,000 to 2,000 over a 12 week period with the VL rebounding back to 200,000 at week 16. CD4+ lymphocyte counts have remained between 100 to 200 cells/mm³. Approximately 5 months ago he was treated for oral and endobronchial Kaposi’s sarcoma (KS) with liposomal daunorubicin followed by liposomal doxorubicin. He denied treatment with vincristine or bleomycin. There is no history of recent diarrhea, recent weight loss, hemoptysis, shortness of breath on moderate exertion, or cardiac problems. There has been no illicit drug use over the past 2 years. The patient stated no combination of HAART has been able to lower his viral load and multiple side effects from the drugs are limiting his compliance to take the medications. There was no history of thermoregulatory problems.

Physical examination: weight = 60 Kg; height = 155 cm; BP = 128/72; Resp = 20; T = 38.2°C; and, the pulse was 92 & reg. Exam revealed asthenia and generalized enlargement of lymph nodes, some 2 to 3 cm in diameter in the axillary and inguinal regions. There was diffuse oropharyngeal thrush. Beneath the thrush, the oral cavity also contained several dark red plaque to nodular like lesions on the hard palate and gingiva. The lesions did not blanch on
compression with the tongue blade. A crusted strawberry like mass, 1 by 2 cm, was present at the anus. There were no neurologic deficits or ocular lesions.

Laboratory studies: EKG, serum electrolytes, renal and liver function tests were normal. Hematocrit was 35.5%, WBC was 9,900 with 81% neutrophils, 4 bands, 11 lymphocytes and 4 monocytes. Platelets were 314,000/mm³. Viral load was 400,000 copies/ml (AmpliCor HIV Monitor test, Roche). A CD4⁺ T cell count was quantified by flow cytometry at 250/mm³. He was antibody positive for hepatitis C. Chest radiograph showed some bilateral apical patchy opacities. Pulmonary function tests showed all parameters, including forced expired volume, greater than 80% of predicted. Karnofsky score was greater than 70. Normal and tumor tissue biopsies, 3 to 6 mm in diameter, from the oral cavity and anus were obtained. The tissues were equally divided, weighed and placed in 4°C Ringers lactate solution. Histologically confirmed normal and KS tissues were then subjected to microcalorimetric measurements in a thermal activity monitor (ThermoMetric, Jarfalla, Sweden). Recorded heat output (μW/min) was 8.2-8.5 times greater for the KS sarcoma lesions than nontumorous oral mucosa. tissues. Repeat measurements with biopsies specimens in 30 μM DNP increased heat production in tumorous tissues 20.5 times more than nontumorous specimens.

Clinical assessment and treatment evaluation: HIV and HIV-infected T cells are known to be more sensitive to killing by heat than uninfected lymphocytes. Susceptibility to heat killing is enhanced with increased oxygen free radical production. Acute and chronically infected cells have decreased levels of manganous superoxide dismutase (MnSOD) activity. MnSOD is located exclusively in mitochondria. Mathematical modeling of human HIV production and CD4⁺ T cell turnover predicts that reducing both free virus and actively infected cells by a minimum of 40% with 1 hour of 42°C therapeutic hyperthermia every third day will promote recovery of the uninfected T-cell population. Human HIV studies with extracorporeal hyperthermia of 41-42°C have reported isolated cases of extended patient survival, elimination of detectable virus, and improvement of Kaposi's sarcoma lesions. DNP is known to generate intracellular hyperthermia and oxygen free radicals from the level of the inner mitochondrial membrane. Studies on in vitro inactivation of chronically HIV infected HUT-78 cells by various concentrations of DNP are graphically represented in Figure 16.

The patient has been and remains resistant to treatment with HAART. Opportunistic infections with candida and Kaposi's sarcoma herpes virus (KSHV, human herpesvirus type 8) causing his
thrush and Kaposi's sarcoma are comorbid conditions indicative of a worsening prognosis. In spite of having AIDS with candidiasis and Kaposi's sarcoma, the patient maintains good cardiac and pulmonary function. There was no history of thermoregulatory problems. It was discussed and agreed that hyperthermia treatments with core body temperatures of 41°C would be administered on a daily or every other day basis, as tolerated, for a minimum of 3 hours, not to exceed 5 hours.

Pretreatment protocol: all medications were stopped 2 weeks prior to treatment. The patient refused taking diazepam, placement of a Foley catheter and oxygen face mask. He dressed himself into a dry cold water immersion suit (Sears, ISS-590L, Universal Adult) designed to prevent heat loss and modified for easy placement of physiologic monitors. Equipment for measurement of heart rate, temperature, carbon dioxide production and Kcal of heat produced were conducted as outlined in Example 1. An oral breathing tube was used to measure V0₂ from room air. Urine output was measured when the patient voluntarily urinated through a "Texas" catheter (superficial condom tightly fitted around the head of the penis with tubing connected to urine collection bag). The patient was informed that hyperthermia would be administered as tolerated by his stamina and monitored clinical parameters, not to exceed 5 hours, on a daily or every other day basis, for a total of 5 sessions.

Treatment procedure: Baseline reading for 5 minutes established an average V0₂ of 300 cc/min. An initial dose of 2mg/kg of DNP was administered over a 2 minute period. V0₂ increased and stabilized at 15 minutes at 340-380cc/min. An additional 2mg/kg DNP infusion was given, the V0₂ increased and stabilized at 610-630 cc/min. Body core temperature increased to 39.4°C within 60 minutes. A gradual fall in blood pressure was noted at 90 minutes to 100/60 mm/Hg.

Norepinephrine bitartrate (Levophed) was given IV drip at a dose of 1 microgram/min. and adjusted to maintain blood pressure at 130/80. Approximately 1 minute after initiating the vasopressor, heart rate increased from 90 to 100 and V0₂ to 0.85 liters/min. Core body temperature increased within 20 minutes to 41.5°C. V0₂ was maintained at 1.0 liters/min. by lowering or increasing the dose of norepinephrine. An additional infusion of 1mg/kg DNP was given at hour 4 to correct a dropping V0₂. On occasions when the core temperature increased above 41.6°C, a lower extremity was exposed for evaporative heat loss. The patient withstood the procedure without any untoward effects for a period of 7 hours. The protocol was repeated consecutively for 5 days without the additional use of vasopressors.
Treatment outcome: Immediately after the first treatment oral candidiasis improved by 50%. The oral and anal Kaposi's lesions exhibited marked erythema with circumferential areas of blanching. On the second day of treatment the KS erythema diminished. There was no evidence of oral candidiasis on the 3rd day of therapy. The anal tumor was crusted and approximately 60% diminished in size on the 5th and last day of therapy. Lymphadenopathy progressively decreased and was resolved at 2 weeks post-treatment. At 30 days post-treatment, there was complete regression of both oral and anal KS lesions. Repeat blood work on days of treatment showed no significant hematologic, electrolyte, liver or kidney changes from baseline. Viral load immediately after treatment day 5 showed 50,000 HIV-RNA copies/ml. HIV RNA was non-detectable at 4, 6 and 12 weeks post-treatment. CD4+ T cell lymphocyte counts increased to 380–420 cells/mm³ by week 4 and remained stable at week 6 and 12. Figure 17 shows monitored patient parameters on treatment day 1. Figure 17a) shows changes in surrogate markers immediately after treatment, weeks 4, 6 and 12.

Example 3

USE OF DNP TO TREAT BACTERIAL INFECTIONS, LYME DISEASE

History: A 33 year old white female with a textbook case of Lyme borreliosis related being bitten by a tick and developing a pathognomonic erythema migrans on her right anterior thigh. The rash resolved within two weeks but 3 months later she developed verbal memory impairment, migratory arthritis of the knees, ankles and tibias. Fibromyalgia, tachycardias and a left sided Bell's palsy ensued. Constitutional symptoms of fatigue, malaise and severe depression caused her to undergo psychiatric care for 1-1/2 years before she was definitively diagnosed with chronic Borrelia burgdorferi infection. She was treated with ceftriaxone, 2 g intravenously every 12 hours for 14 days. Four months after apparent improvement she developed photophobia, headaches, pronounced memory loss, depression, dysesthesias and a painful, swollen left knee joint. Repeat ELISA, Western blot and DNA-PCR were all positive for B. burgdorferi. Spinal tap showed pleocytosis with positive antibody and PCR tests for neuroborreliosis. Over the next year the patient received prolonged ceftriaxone, 2 g per day intravenously for 3 months, and 3 individual short courses of oral ciprofloxacin, minocycline, and azithromycin. Symptoms failed to resolve. Two months after her last regimen of antibiotics a new annular erythematous eruption, suggestive of erythema migrans, reoccurred on the right thigh and developed under her left axilla. Doxycycline was instituted and the rash subsided. The patient refused further
antibiotic therapy because of associated intractable diarrhea and has made tentative plans to undergo "malartherapy" in China.

Physical examination: weight=60 Kg; height=160 cm; BP=130/70; HR=86 & reg; resp=18; T=37.3°C. Physical exam revealed a swollen and tender left knee. A thin, atrophic hypopigmented area of skin over the right thigh, typical of acrodermatitis chronica atrophicans was present. Neurologic exam showed some verbal memory deficit. There were bilateral, lower distal extremity paresthesias.

Laboratory studies: EKG demonstrated a first-degree atrioventricular block (PR internal >0.2 sec), some widening of the QRS complex and Wenckebach periodicity. There were no dropped beats. Left knee arthroscopy showed synovial hypertherphy with early erosive arthritis. Synovial fluid analysis revealed a WBC of 50,000 cells/ml with 70 % neutrophils and a positive DNA-PCR for Borrelia burgdorferi. Biopsy sections of synovial tissue showed chronic nonspecific synovitis. Warthin-Starry and silver staining histology revealed spirochetal organisms consistent with Borrelia burgdorferi. Lumbar puncture spinal fluid analysis showed pleocytosis, elevated gamma globulin and positive PCR for B. burgdorferi. Spinal fluid cultured for 2 months in Barbour-Stoenner-Kelly medium was reported positive for B. burgdorferi. Serum electrolytes, kidney, liver function and hematologic studies were all within normal limits. The patient underwent a stress EKG, attaining a maximum heart rate of 165 with no evidence of arrhythmia or S-T segment depression.

Clinical assessment and treatment evaluation: Lyme disease is a zoonosis caused by a slow growing pathogenic spirochete, Borrelia burgdorferi. In various mammalian species, including man, these organisms are known to invade heart, kidneys bladder, spleen and brain. Borrelia spirochetes are very resistant to treatment with antibiotics, especially if there is evidence of central nervous system or joint involvement. Viable B. burgdorferi have been isolated from antibiotic treated monolayers of fibroblasts. Borrelia spirochetes are known to be facultative intracellular pathogens in fibroblasts by laser scanning confocal microscopy. Central nervous system tissue, joints, front chamber of the eye and intracellular location can provide the Lyme spirochete with a protective environment against antibiotic therapy and Borrelia burgdorferi have been reliably cultured from patients with chronic disease, even from those previously aggressively treated. This patient has confirmed chronic CNS and joint Lyme disease in spite of extensive antibiotic therapy.
The Lyme spirochete is irreversibly inactivated by heating at 40°C for 3 hours, 41°C for 2 hours or 41.5°C for 1 hour. Susceptibility of all strains of Borrelia burgdorferi to penicillin and ceftriaxone is increased up to 16-fold by elevation of temperature from 36°C to 38°C. At 40°C Borrelia burgdorferi increases expression of at least 12 heat shock proteins (HSP), most of which are strongly immunogenic. The patient had no history of thermoregulatory problems. She was informed that her body temperature would be raised between 40 to 41°C for a period of 3 hours, the actual level and time under hyperthermia would depend on her monitored clinical parameters.

Pretreatment protocol: the evening prior treatment the patient was instructed not to eat and dress in cotton undergarments. Approximately 4 hours prior to treatment 2 mg alprazolam was administered by mouth. The patient dressed herself into a dry cold water immersion suit (Stearns, previously described) with headgear. Monitoring sensors, including EKG display, IV fluids and Foley catheter were attached and the suit was zipped closed. The patient opted for oxygen supplementation. The modified face mask was connected to the TEEM 100 metabolic Analysis System for V02 measurements. Data was recorded as previously described.

Treatment procedure: baseline recordings of 10 minutes showed a V02 of 220 cc/min., 3.7 cc O2/kg/min. The patient was infused with 1mg/kg DNP over a 2 minute period. V02 increased and stabilized at 250 cc/min, 5.3 cc/kg/min. A second dose of 2.0mg/kg was infused over a 2 minute period and the V02 peaked at 400 cc/min, 8.8 cc O2/kg/min. An additional dose of 1.0 mg/kg DNP was given 30 minutes after the second dose. The V02 increased and reached a stable plateau at 600 cc/min, 10.8 cc/kg/min. Rectal temperature continued to climb until a range of 40.2 to 40.6°C was reached at 70 minutes after the initial dose. A fall in V02 was noted at 90 minutes, a dopamine drip at 2-3 mcg/kg/min was initiated. V02 increased back to 680-710 cc/min. The temperature remained stable between 40.1°C and 40.6°C throughout the 3 hour plateau treatment period. The patient periodically requested the V02 monitoring be removed during the hyperthermia treatment period. She was accommodated with removal of the mask on two occasions for periods not exceeding 10 minutes. The patient experienced no problems during the procedure but was noticeably fatigued by hour 3. The treatment was terminated 4 hours and 10 minutes after the initial dose of DNP. Twenty five minutes after the patient was removed from the neoprene survival suit, the rectal core temperature dropped to 38.5°C. Normothermia was achieved approximately 60 minutes after cessation of therapy and removal from the survival suit. Approximately 6.5 to 7 hours after treatment the patient
experienced chills, an increase in oral temperature to 38.7 degrees centigrade and malaise. IV fluids and the dopamine drip at 2mcg/kg/min were restarted and the patient was closely observed. Her symptoms subsided over 3 hours and by the next day she felt active and hungry. It was surmised she may have experienced a delayed Jarisch-Herxheimer reaction. The patients monitored treatment flow chart is Figure 18.

Treatment outcome: at two months follow-up the patient stated her arthralgias, myalgias, malaise, fatigue and memory deficits have disappeared. Lower extremity dysesthesias were no longer present. EKG showed resolution of her first degree A-V block. The patient was informed of her past positive cerebrospinal fluid positive culture for the Lyme disease spirochete. It was suggested a repeat spinal tap be performed for B. burgdorferi by PCR and culture. If positive, the patient agreed she would be re-treated with both DNP induced hyperthermia and intravenous ceftriaxone for maximum synergism. Repeat spinal fluid analysis was normal, i.e., no elevated protein, no detectable Borrelia DNA by PCR and no pleocytosis. Three months later, spinal fluid culture on Barbour-Stoenner-Kelly II medium was reported negative.

Example 4

METHOD OF USING DNP WITH VASOPRESSORS AND CHEMOTHERAPY TO TREAT NEOPLASIA, PERITONEAL CARCINOMATOSIS

History: A 55 year old female presented with a distended abdomen due to ascites. Laparotomy revealed peritoneal dissemination of a malignancy with histological findings of an undifferentiated adenocarcinoma, origin unknown.

Physical examination: weight = 55 kg; height = 154 cm; BP = 140/90; HR = 88 & reg; Resp =22; T=37.6°C The patient was a well developed and well nourished Muslim female with a healing midline laparotomy scar. Ballotable ascites was detected in the abdomen. There was no lymphadenopathy.

Laboratory studies: laboratory examination of the ascitic fluid showed high levels of amylase. She had a hemoglobin of 9.2. High levels of amylase and tumor markers, including CA15-3, CA 125 and CA72-4 were present in the serum. Blood chemistry, liver and kidney function tests were within normal limits. Chest X-ray and EKG was normal. MRI and ultrasound of the
abdomen showed normal pancreas, liver and atrophic ovaries, there were widespread nodular lesions consistent with peritoneal carcinomatosis.

Clinical assessment and treatment evaluation: the patient had an inoperable malignancy of unknown origin. Chemotherapy in such cases is only of marginal survival benefit. Hyperthermia, combined with chemotherapy has been shown to be synergistic with increased tumor response and survival benefit. Tumor antigen markers are known to be increased by the heat shock response and may further enhance immunologic surveillance. The patient had no history of thermoregulatory problems but refused to be placed in wet suit or survival suit because of a "phobia of enclosed tight garments".

It was elected to treat the patient with hyperthermochemotherapy. Treatment consisted of DNP, and combination chemotherapy with carboplatin, mitomycin, and doxifluridine. An α-1 adrenergic receptor agonist was used to minimize peripheral vascular dilation and heat loss.

Pretreatment protocol: the patient was transfused with three units of packed red blood cells. A Foley catheter was inserted on each day of treatment. She was covered in a water soaked blanket containing a polyethylene lining. A shower cap with towels was used to prevent heat loss from the head. Intravenous lines were placed into both arms with 19 gauge intracaths. EKG, heart rate, rectal thermistor, and VO₂ monitors were attached. Oxygen supplemented facemask and equipment was attached and data monitored as previously described under Example 1.

Treatment protocol: the patient was given chemotherapy by mouth. The total doses of carboplatin, and mitomycin were 450 mg and 24 mg IV respectively on day 1 and last day of week 6. Doxifluridine, 600 mg, was orally administered every day for 5 days and repeated the last 5 days of week 6. On the day of DNP infusion, baseline recordings were established for 10 minutes. Mephenteramine sulfate, 30 mg, was given by intramuscular injection. Ten minutes later her heart rate increased to 96 and her VO₂ increased from 250 to 320 cc/min. VO₂, heart rate and blood pressure stabilized after 20 minutes and she was given an initial dose of 1mg/kg DNP. Additional 0.5 mg/kg infusions of DNP were administered in 3 successive infusions spaced 20 minutes apart. The patients VO₂ stabilized between 780-820cc/min and her core temperature increased to a maximum of 41.4°C. After a plateau temperature of 41.5°C± 0.5°C was reached, her level of VO₂ and temperature was maintained for a period of 2 hours and 30
minutes with an additional infusion of 0.5 mg/kg DNP given 50 minutes after the last dose. The DNP treatment protocol was repeated every fourth day for a period of 6 weeks. A representative monitored flow chart is shown in Figure 19.

Treatment outcome: By the combined treatments outlined above, ascites resolved by the end of the sixth week. Serum levels of amylase and all tumor markers decreased after the third week of treatment and were normal at week 6. Repeat magnetic resonance imaging and echo re-examination of the abdomen showed complete resolution of peritoneal metastasis. Nine and a half months after treatment, the patient is alive without any evidence of tumor reoccurrence.

Example 5

USE OF DNP WITH THERMOSENSITIVE LIPOSOMES

To overcome the toxicity to normal tissues of many anticancer agents such as doxorubicin and anti-infectious drugs such as amphotericin B, liposomal formulations have been developed. Liposomal doxorubicin is known to have reduced cardiotoxicity and increased antineoplastic efficacy. Thermosensitive liposomes can further enhance tumor targeting and decrease toxicity by release of their water soluble drug contents in response to tumor hyperthermia. Various synthetic and natural lipids such as dipalmitoyl phosphatidyl choline and distearoyl phosphatidyl choline or egg phosphatidyl choline and cholesterol can be combined in different molar ratios with ethanol, or other agents that have a biphasic effect on gel-to-liquid phase transition of phosphatidyl choline bilayers, to produce liposomes that melt (undergo gel-to-liquid crystalline phase transitions) at a predetermined hyperthermic temperature.

Thermosensitive liposomes were prepared from phosphatidyl choline (PC) and cholesterol (Ch) using the ethanol method of Tamura et al. A combination of PC:Ch in a 8:1 molar ratio in the presence of 6% (v/v) ethanol resulted in formation of liposomes having a transition temperature between 40.2 and 40.8°C. The anticancer drug dacarbazine [5-(3,3'-dimethyl-1-triazino) imidazole-4-carboxamide] was encapsulated in these heat-sensitive liposomes at a concentration of 3 mg/ml. The in vivo efficacy of the thermosensitive, liposome encapsulated dacarbazine was tested on Swiss albino mice transplanted with a dimethyl benzo-dithionaphptene derived ascites fibrosarcoma subjected to DNP induced hyperthermia.
Male, 10-12-week-old, Swiss albino mice were injected with 3x10^6 viable fibrosarcoma cells into the peritoneum. After 15 days the animals were divided into various treatment and control groups receiving intraperitoneal injections of free dacarbazine, DNP alone, DNP + empty liposomes and DNP + liposome encapsulated dacarbazine. DNP induced hyperthermia was recorded with neonatal rectal and 22 ga. hypodermic YSI probes. Temperatures were recorded 30 minutes after a 20 mg/kg intraperitoneal dose of DNP. DNP was administered every day for a total of 5 doses. In all cases the hypodermic, intraperitoneal temperatures were 1°C higher than the rectal.

As shown in Figure 20, survival curves of animals treated with DNP alone and DNP + drug containing liposomes were significantly improved in comparison to controls. DNP-hyperthermia treated animals remained alive at day 100 whereas sham treated animals all died by 60.

Example 6

USE OF DNP TO INDUCE AUTOLOGOUS HEAT SHOCK PROTEINS AS A FORM OF THERMAL PRECONDITIONING PRIOR TO ARTERIAL BALLOON CATHETERIZATION OR ISCHEMIC SURGICAL INJURY

DNP would be given orally at doses to increase the VO2 from 1.5 to 5 times above normal per day for a period of 2-6 days or, as an infusion at doses that would increase VO2 and core body temperatures no greater than 39°C for periods of 5 to 6 hours or, intravenous doses of DNP alone, with vasopressors, or other short acting metabolic stimulators, that would increase VO2 to equivalent core temperatures of 40-41°C for periods of 15-30 minutes. Within 8-48 hours after cessation of DNP, the patient would have maximum heat shock protein production. Such DNP induced stress would improve clinical outcome by induction of cellular heat shock protein synthesis with protection of the patient's, organs, tissues and cells from subsequent ischemic surgical or traumatic procedures.

This method of DNP induced preconditioning could be used to decrease intimal thickening and restenosis after angioplasty, improve ischemia/reperfusion injury in organ and tissue transplantation, and improve surgical outcome of procedures that require temporary or prolonged occlusion of arterial blood flow. Examples of such DNP induced autologous thermotolerance used as a form of preconditioning are depicted in Figure 21, which shows limitation of proliferative arterial catheter balloon injury in Sprague-Dawley rats pretreated with DNP induced
hyperthermia; Figure 22 shows the protective effect of DNP pretreatment before hepatic ischemic injury caused by Pringle’s maneuver; and, Figure 23 depicts improved musculocutaneous flap skin survival after induction of heat shock proteins by DNP.

Example 7

METHOD OF USING DNP TO ENHANCE PROTON EMISSION TOMOGRAPHY (PET) IN THE DIAGNOSIS OF MALIGNANCY AND/OR MALIGNANT TRANSFORMATION (GLIOMA)

History: A 24 year old white male with neurofibromatosis presented with a six month history of left sided loss of body sensation, emotional changes, sensory seizures, inattention to conversations and sensations of jamais vu.

Physical examination: weight=65 kg; height=175 cm; BP=135/80; HR=86 & reg; Resp =18; T=37.9°C. The patient was a well developed well nourished white male with left upper and lower extremity sensory loss, postural instability and loss of tactile discrimination. There was a frank left handed astereognosis. Eye examination was normal, without papilledema.

Laboratory studies: Complete hemogram, blood chemistry and endocrine examination were normal. EEG was within normal limits. MRI with gadolinium enhancement showed a decreased signal in the right temporoparietal region with no evidence of contrast enhancement. PET examination with [18F]fluoro-2-deoxy-D-glucose(FDG) revealed a homogeneous hypometabolic area (metabolic Grade 1) consistent with a Low grade glioma in the right temporoparietal region. There were no zones of high FDG uptake. Differentiation of displaced noninvasive gray matter from the tumor was not discernible on PET imaging.

Clinical assessment and diagnostic evaluation: although Low grade gliomas generally present histological features of benign tumor, it is known that the presence of zones of high FDG uptake by PET scan in such gliomas is associated with a higher percentage of malignant transformation. PET-FDG with evidence of tumor hypermetabolism is believed to be an early biochemical marker of cellular malignant transformation and is of prognostic value in High grade gliomas. Biochemically, high glucose (uptake of FDG) utilization in the presence of oxygen, known as aerobic glycolysis, is believed to be the result of a hyperactive hexokinase attached to tumor mitochondria. Increased FDG uptake therefore, represents increased hexokinase activity and is

SUBSTITUTE SHEET (RULE 26)
associated with increased aggressiveness in gliomas, menigiomas and other neoplasms. Since DNP uncouples oxidative phosphorylation, any shortfall in mitochondrial ATP production must come from increased glycolysis. As a result, FDG uptake will be proportionately increased in DNP treated malignant cells over those that are normal in contralateral brain white and gray matter. Since no abnormal FDG uptake was detected in the tumor by standard PET methodology and the PET scan was unable to clearly delineate the borders of the tumor, it was elected to give the patient a low dose of DNP to enhance FDG uptake and repeat the PET scan. Hypermetabolic components of the tumor would thus permit a more focused PET-guided stereotactic biopsy.

Pretreatment protocol: three days prior to DNP dosing and repeat PET-FDG scan, the patient’s dosage of phenytoin was increased from 100-mg three times daily to 200-mg three times a day. The same positron emission tomogram, a CTI-Siemens 933/08-12 which provides a 6.75-mm adjacent slices and in-plane spatial resolution (full-width at half maximum) of ~5mm, was to be used. The highest level of non to DNP stimulated FDG uptake in the tumor area was to be compared and qualitatively graded by two radiologists. Independently, each investigator was to visually evaluate the positron emission tomogram and use the following metabolic grading scale: I, FDG uptake less than contralateral white matter; II, uptake between the levels in contralateral white and gray matter; III, FDG uptake equal to or greater than in contralateral gray matter.

Diagnostic – treatment protocol: the patient was given a 300mg capsule of DNP (approximately 4mg/kg body weight) three hours prior to undergoing a PET-FDG scan. Forty minutes prior to the emission scan he was intravenously injected with a bolus of FDG according to standard methodology. Immediately prior to the 20-minute emission scan the patients VO₂ uptake was 40% above that at baseline. The patients DNP/VO₂ flow chart is Figure 24.

Diagnostic outcome: DNP enhanced PET-FDG scan revealed two areas of hypermetabolism. One of the areas surpassed the limits of the lesion on CT images and consequently only one of the targets (graded as a III on FDG uptake) was selected in the “abnormal PET-normal CT” area.

The plane that best displayed the abnormal FDG hypermetabolic uptake area was selected and a pixel located in the center of the zone was interactively pointed at on visual inspection. The coordinates of that DNP induced hypermetabolic pixel were then calculated and set as a target for biopsy. A PET-guided stereotactic biopsy was performed under the procedure described by
Levivier et al., i.e., the target from the PET image was projected onto the corresponding stereotactic computed tomographic (CT) slice to control the reliability and precision of target selection and the trajectory. Serial stereotactic biopsies were performed along the trajectory by the method described by Kelly et al.

On pathologic examination, including analysis of nuclear polymorphism and cell density, 2 foci of anaplasia consistent with glioblastoma (Grade III astrocytoma) were noted.

Treatment outcome: based on the DNP enhanced PET-FDG scan diagnostics outline above, this patient was found to have a malignant transformation in his otherwise Low grade glioma. This diagnostic treatment protocol procedure of detecting foci of hypermetabolism caused him to undergo systematic radiation therapy with chemotherapy (dibromodulcitol-procarbazine-carmustine) early in the course of his malignant process. One year after diagnosis and therapy the patient again underwent PET scanning. DNP enhancement (repeated as outlined under “Diagnostic” above) revealed a single hypermetabolic component (metabolic Grade II) in the tumor area. Repeat PET-guided biopsy revealed the area to be a zone of radionecrosis. The remaining viable tumor, even with DNP enhancement, continued to be a metabolic Grade I. The patient remains alive one and a half years after his diagnosis, albeit with left-sided hemiparesis.

Example 8

METHOD OF USING DNP TO ENHANCE DETECTION OF MALIGNANT TUMORS BY HIGH RESOLUTION DIGITAL INFRARED IMAGING (BREAST CARCINOMA)

History: a 34 year old white female with existing fibrocystic disease of the breast underwent yearly mammography and was found to have an equivocal opacity in the right breast, medial to the areola. Two past breast biopsies were negative for malignancy and consistent with fibroadenomatous disease of the breast. The patient was opposed to another breast biopsy (would be third), unless there was a definitive indication of a lesion over that of her known fibrocystic disease of the breasts.

Physical examination: WT = 60kg; HT = 164cm; BP = 120/72; HR = 88 & reg; R = 18/min; T = 37.7C. The patient was a normal appearing white female with scattered to diffuse nodularities in both breasts. A palpable 3 X 2cm, non-tender, lump was located 3cm medial to the right areola.
There was absence of nipple discharge, retraction, skin dimpling, rash or discoloration of either breast. There were no palpable axillary lymphadenopathy.

Laboratory studies: chest x-ray, EKG, blood chemistry, and hemogram examination was normal. Mammography, Doppler ultrasound, MRI, and scintinamography failed to indicate or eliminate a possible occult carcinoma in this young patient with dense, fibroadenomatous breast disease. A diffuse, non-cystic, opacity on the right breast was the only definitive finding from these breast studies.

Clinical assessment and diagnostic evaluation: this patient has had two previous open breast biopsies without evidence of malignancy. Early detection of breast carcinoma is of crucial importance to survival. False negative results of mammography (and other complimentary studies) range between 5-30%. The ability of infrared imaging technology to detect changes related to increased metabolism (tumor) and angiogenesis has greatly improved from that of 30 years ago. High resolution digital computerized infrared equipment can now detect focal increases in tumor temperature from as little as 0.05°C, and increases in focal breast temperatures may be as high as 1-2°C in malignant tumors versus normal, contralateral breast sites.

Since it is known that infrared imaging has at least a 19% rate of false positives and 17% of false negatives, and equivocal mammography and abnormal infrared imaging is not uncommon in young women with dense breast tissue and diffuse fibrocystic disease, the use of DNP to enhance tumor metabolism (infrared imaging) over that of normal tissue, could be of substantial diagnostic benefit. Specifically, DNP would greatly enhance tumor metabolism (infrared imaging), in comparison to non-DNP enhanced infrared imaging and would greatly increase tumor detection when there is either insufficient production or detection of metabolic heat or vascular changes. Further, the heat differential between DNP enhanced and non-DNP infrared tumor imaging may also decrease the false positive rate seen with this procedure, especially in benign conditions such as fibrocystic disease of the breast. Since non-DNP infrared imaging is capable of detecting as great as 1-3°C changes in focal temperature between normal and malignant tissue, DNP enhancement would increase the temperature difference several fold and enhance both the sensitivity and precision of currently available infrared imaging technology. The patient agreed to have both of her breasts examined non-invasively with infrared imaging,
before and after intravenous DNP administration to ascertain if there was increased infrared signaling from the worrisome, palpable lump in her right breast.

Prediagnostic protocol: the patient was disrobed to the waist and sat with her hands interlocked over her head for a five minute equilibration period in a draft free, thermally controlled room - kept between 18°C and 20°C. She did not take any oral medication, alcohol, coffee, and did not smoke, exercise or use deodorant three hours prior to testing. A baseline of 4 images consisting of an anterior, undersurface and 2 lateral views of each breast were generated by an integrated infrared imaging station consisting of a scanning mirror optical system containing a mercury-cadmium-telluride detector (Bales Scientific, CA). The infrared system had a spatial resolution of 600 optical lines, a central computerized software processor providing multi-tasking capabilities and a high-resolution color monitor capable of displaying 1024 X 768 resolution points with 110 colors or shades of gray per image. Images were stored on retrievable laser discs.

Diagnostic treatment protocol: after the above baseline studies were performed, the patient was given an initial intravenous dose of 1mg/kg DNP and observed for a period of 20 minutes. An additional 2mg/kg of DNP was then administered and 30 minutes thereafter, she was taken to the thermally controlled room for repeat DNP-enhanced infrared imaging. Immediately prior to transferring the patient to the thermally controlled room, the patient's VO₂ was incrementally increased to 50% above her VO₂ baseline, see Figure 25. Repeat infrared images were then obtained under the exact protocol used for obtaining baseline studies.

Diagnostic – treatment outcome: baseline (non-DNP enhanced) infrared imaging revealed insignificant vascular asymmetry and no significant temperature changes when the results were reviewed and compared to the rest of the ipsilateral or contralateral breast sites.

DNP enhanced infrared imaging resulted in a bilateral global breast temperature increase of approximately 0.5°C. An abnormal, 2.5°C increase in temperature was noted in the palpable, right breast lesion discovered by clinical exam. Since no non-cancer causes for such a dramatic temperature increase could be identified, i.e. abscess, trauma, or recent surgery, this 5 fold increase in heat production (above the DNP baseline increase of 0.5°C) was highly suspect to be caused by an early malignancy.
The patient was admitted to the hospital and under general anesthesia underwent an open breast biopsy. Frozen section (and later permanent tissue mounts) revealed a well-differentiated intraductal carcinoma. Progesterone and estrogen receptors, as determined by immunocytochemical methods, were negative. A simple, right mastectomy with axillary lymph node dissection was performed. A total of twelve lymph nodes were identified: there was no evidence of tumor. The patient refused chemotherapy and radiotherapy. She was placed on long-term oral tamoxifen (10mg twice a day).

Example 9

THE USE OF DINITROPHENOL WITH ARTIFICIAL ELECTRON RECEPTORS (OR OTHER FREE RADICAL FORMING AGENTS) IN THE TREATMENT OF HORMONE AND CHEMOTHERAPY RESISTANT MALIGNANCY (PROSTATE CANCER).

History: a 68 year old Mexican male, developed a gradual increase in low back pain, right hip pain and several episodes of hematuria over a 10 month period. He was referred to a urologist and diagnostic work-up revealed a carcinoma of the prostate with the extension of the tumor into the bladder. Bony metastasis were present to the right pelvis, fourth and fifth lumbar vertebra, right femur, left humerus, right sixth and seventh ribs and right scapula. He refused any form of surgery but underwent radiation therapy to the pelvis and symptomatic bony lesions. Treatment was initiated with megestrol acetate (640mg/day), prednisone (20mg/day) and leuprolide (7.5mg/month). After three months of therapy the patient continued to have progression of his disease manifested by increasing bone pain, rising prostatic specific antigen levels (PSA) and increasing serum acid phosphatase.

Physical examination: WT = 72kg; HT = 175cm; BP = 140/86; R = 22; T = 37.6 C; HR = 88 & reg; Exam revealed mild emaciation with some scrotal and +1 pitting bilateral lower extremity edema. There were scattered bilateral, basilar rales on examination of the chest.

Laboratory studies: EKG demonstrated a right partial bundle branch block. Chest x-ray showed mild chronic obstructive pulmonary disease with minimal fibrosis. There was some patchy, interstitial edema in both lower lung fields. There were no pulmonary metastasis. Complete blood count showed a mild anemia with a hemoglobin of 10.5 and a hematocrit of 34%. Liver function tests were normal. White blood cell count, differential and platelet count, was within normal limits. PSA level was 58ng/ml. Serum acid phosphatase was 2 X above normal. Blood
electrolytes including calcium were within normal limits. The acid phosphatase, AST, ALT and bilirubin levels were normal. Radionucleotide bone scan revealed multiple metastasis in the axial skeleton and ribs. Review of past prostatic biopsy slides showed a high grade adenocarcinoma of the prostate with a Gleason Grade of 8. Pulmonary function studies showed moderate airflow obstruction with mild hypoxemia and hypercarbia. Stress EKG was not performed because of his severe exercise intolerance.

Clinical assessment and treatment evaluation: the patient has a metastatic, hormone-refractory prostate carcinoma with clinical progression documented by increasing bone pain and rising serial PSA values. Under the TNM classification of the American Joint Cancer Committee for prostate cancer (T = degree of primary tumor extension; N = regional lymph node involvement; and, M = presence of distant metastasis), he has the highest stage (T4 N3 M1). Histologically, the tumor is aggressive by the Gleason Grading System. Since death due to prostatic carcinoma is almost invariably a result of failure to control metastatic disease, and since prostatic cancers are well-known to be sensitive to heat stress, the present DNP therapy was undertaken as a last resort effort to stop tumor progression and/or improve the patients quality of life.

In view of the patients age, pulmonary problems and poor performance status (Karnofsky Score of 6) it was decided to treat the patient with moderate doses of DNP and a free radical cycling agent, methylene blue (MB), to induce synergistic tumor killing. The effect of methylene blue on cellular reduction- oxidation status (redox) is well known. Methylene blue readily traverses cell membranes and acts as an electron acceptor from the major coenzymes. Unlike other oxidizing drugs, it cycles futilely, transferring electrons from endogenous substrates to oxygen. Depending on the redox status of a cell, MB can act as either an intracellular electron acceptor or donor. MB directly catalyzes the reaction of intracellular reductants, NADPH, NADH and GSH (reduced glutathione) with oxygen causing the production of hydrogen peroxide, superoxide anions, and the formation of the potent cytotoxic oxidant species, peroxynitrite. In DNP partially uncoupled mitochondria, MB further stimulates respiration due to its dual action of providing reducing equivalents necessary for beta-oxidation of fats and electron donating/shuttling capacity, with respect to the mitochondrial respiratory chain. It is an effective drug, at doses of 1-3mg/kg, in treating nitrate-induced methemoglobinemia. MB is also used as an antidote given as a 100mg IV bolus for encephalopathy associated with alkylating chemotherapy.
Since uncoupling, heat and MB increase the flux of cellular free radicals and malignant cells possess a high bioreductive capacity, the synergistic effects of DNP with MB would allow for maximum tumor killing with minimum to moderate levels of induced total body hyperthermia. Additional free radical cycling agents that can be used in lieu of MB include, but are not limited to: phenazine methosulfate, xenobiotics such as quinones (e.g., menadione, semiquinone, naphthoquinone, duroquinone, indigo carmine), nitrocompounds (e.g., metronidazole, niridazole, nitrofurazone, flunitrazepam), eminium ions (e.g., methyl viologen, benzyl viologen, etc.), and others. In this patient, DNP-MB therapy was to be administered so as not to exceed the baseline VO$_2$ level by 50-75%.

Pretreatment protocol: the patient was transfused with 2 units of packed red blood cells 48 hours prior to undergoing treatment. Intravenous fluids (Lactated Ringer’s solution) were administered at a rate of 100cc/hour. The patient was dressed in comfortable cotton clothing and placed in an air-conditioned room. Equipment for monitoring heart rate and rhythm, temperature and oxygen consumption was utilized as outlined in Example 1. An oral breathing tube was used to conduct TEEM VO$_2$ measurements. Oxygen supplementation and “crash cart” was available at bedside.

Treatment protocol: baseline VO$_2$ measurements for 8 minutes established an average VO$_2$ of 250cc/minute. DNP, at a dose of 2mg/kg, was infused intravenously over a 2 minute period. Repeat VO$_2$ at 20 minutes was stabilized at 340-360cc/minute. An additional 1mg/kg DNP infusion was administered, and 15 minutes thereafter the VO$_2$ increased and stabilized at 420cc/minute. Ten minutes thereafter, an infusion of methylene blue, 2mg/kg (dissolved in a 0.4% pyrogen-free isotonic saline solution-35ml) was administered over 20 minutes. Repeat VO$_2$ measurement at 20 minute intervals showed it to rise to and stabilize at 450-500cc/minute.

By hour 3, VO$_2$ declined to the 360-380cc/minute range. An additional 1mg/kg dose of DNP was infused over a 2 minute period. Repeat VO$_2$ measurements 20 minutes after this infusion showed an increase in VO$_2$ back to the 450-500cc/minute. Rectal probe temperature increased to a maximum of 39°C over baseline. Blood pressure and cardiac rates remained within normal limits. The patient withstood the procedure without any adverse effects and therapy was terminated 6 hours after the initial DNP dose. The protocol was repeated every other day for a total of 15 treatments (30 days). Therapy was discontinued for 2 weeks and the cycle was again repeated for an additional 30 days, treatment being administered every other day.
Treatment outcome: there was no evidence of general toxicity at any time during treatment. The patient noted a decrease in his low back, hip and other areas of bone pain on the 6th day following therapy. By 2 weeks, the patient was off all narcotic (morphine) analgesics and had a markedly increased appetite. On day 8, repeat PSA levels were increased by approximately 120% to 125ng/ml. Acid phosphatase remained unchanged. All other blood chemistries, including CBC, showed no significant alterations.

At 6 weeks after treatment, repeat PSA values showed a significant decline to 30ng/ml with a concomitant fall in serum acid phosphatase levels. At the final stage, 10 weeks after initiation of treatment, a prostatic biopsy was performed. Histologic examination revealed 95% of the tumor to be necrotic with only scattered or scarred acini containing an occasional malignant cell. There was a significant increase in stromal cells above that seen in his initial biopsy. One of the most striking changes noted by the pathologist was the formation of cyst-like structures within the epithelial cells. The patient was seen three months after initiation of therapy, at which time he had gained 8.2kg of weight, remained pain free and stated that he felt “normal”. Figure 26 shows monitored treatment parameters. Figure 27 shows biochemical, biopsy and clinical responses.

Oral DNP therapy (250mg twice a day, daily for 5 days and recycled after no medication for 2 days) was initiated after his IV therapy and continued up to 4 months. A repeat prostate biopsy at the end of month 4 was obtained. Pathologic examination revealed disintegration of remaining tumor acini along with the formation of with many epithelial cysts. Occasional residual tumor cells were fractured and disrupted with markedly reduced cytoplasm. There was extensive fibrosis with an apparent increase in the number of stromal cells. Cytoplasm volume was significantly diminished in both the residual tumor and normal cells. Overall, there were very few intact acini or viable acinar cells.

Example 10
METHOD OF USING DINITROPHENOL WITH BIOLOGIC RESPONSE MODIFIERS (IN THE TREATMENT OF HEPATITIS C INFECTION)

History: a 32 year old Investment Banker was evaluated for chronic Hepatitis C infection. She gave a past history of intermittent jaundice, dark urine, mild anorexia, nausea and vomiting. This episode occurred 10 years ago, approximately 3 months after a transfusion (3 units of packed red blood cells) for a cesarean section. She was currently asymptomatic, but on routine
health insurance exam she was found to have elevations in her ALT and AST (alanine and aspartate aminotransferase) levels: 140IU/L and 90IU/L, respectively. She drank 5-8 glasses of wine per week. Additional laboratory tests identified anti-HCV antibodies with an HCV-RNA level of 5 x 10^6/ml. The patient refused to undergo liver biopsy but agreed to treatment with interferon alpha-2b (3 million units injected subcutaneously 3 times per week) and ribavirin (500mg orally- twice a day). After 12 weeks of treatment she developed lethargy, severe headaches, fever, nausea and depression. Anemia was detected with a hemoglobin concentration of 9.2g/deciliter. As a result, her dosage of interferon was reduced to 1.5 million units 3 times a week and the dose of ribavirin was reduced to a total of 600 mg/daily. After 6 months of treatment her ALT and AST levels became normal and HCV-RNA became undetectable.

An additional six months of therapy however, failed to sustain her clinical improvement and she was found to have a relapse. Serum HCV-RNA levels rose to 5.2 million copies/ml and liver enzymes increased to 2.5-3 times that of the normal range. She was unable to tolerate any additional ribavirin because of severe anemia. She persistently refused to undergo a percutaneous liver biopsy.

Physical examination: WT = 48kg; HT = 150cm; BP = 128/82; HR = 76 & reg; R = 18; T = 37.5°C. Physical examination failed to reveal any signs of chronic liver disease. She was noted to have several scattered areas of scalp alopecia which she attributed to her anti-hepatitis C therapy.

Laboratory studies: EKG and chest x-ray were normal. CBC revealed a mild anemia with a hemoglobin of 10.2 and a hematocrit of 34%. WBC, differential and platelet count were within normal limits. Alkaline phosphatase was within normal limits. Serum AST and ALT were elevated to 2.5-3 times that of the upper normal limit. Serum HCV-RNA levels were found to be at 5.8 million copies/ml. The infecting hepatitis C strain was of genotype 1b. Antimitochondrial antibody serology was negative (titer less than 1:20). There were no other blood chemistry, hormone, or urine laboratory abnormalities.

Clinical assessment and treatment evaluation: the patient has a chronic Hepatitis C infection with relapse after combination ribavirin and interferon alpha-2b treatment. This is not uncommon in that the rate of relapse after an end-of-treatment response to interferon-ribavirin therapy may exceed 50%. She was unable to tolerate additional ribavirin therapy because of a related anemia.
Further, interferon dose escalation in non-responders to initial interferon therapy has only proved successful in a small number of cases. Despite her refusal to undergo any form of liver biopsy she agreed to undergo a combination of DNP and interferon therapy for a period of 12 weeks.

The liver is known to be one of the “hottest” organs in the human body. Liver temperatures exceeding 44°C have been documented in humans undergoing strenuous exercise. The hepatitis C virus is an RNA encoded sphere containing several polyproteins comprising a capsid, 2 envelope proteins, and at least 6 enzymatic proteins with varied functions. Hepatitis C virus is known to be heat sensitive and is inactivated by standard blood banking heating techniques. Case reports of hepatitis C inactivation with the use of extracorporeal hyperthermia are known. It has been reported that HIV positive patients treated with extracorporeal hyperthermia, many of which were also positive for hepatitis C, the hepatitis C virus was cleared (as determined by serum viral PCR-RNA analysis).

Based on the this patients failure to respond to conventional treatment, anecdotal and case report studies showing beneficial results with whole body hyperthermia, the patient underwent a combination of DNP and interferon therapy. She was informed that she would undergo daily treatments with intravenous DNP for five days per week and receive interferon alpha at a dose of 1.5 million units subcutaneously every two days. This treatment protocol would continue until her hepatitis C-RNA blood viremia was no longer detectable.

Treatement protocol: each evening prior to treatment the patient was instructed not to eat after 7pm and dress in cotton clothes. Approximately 6 hours prior to intravenous DNP administration she was to be given 1.5 million units of subcutaneous interferon-alpha every 3rd day. Repeat blood work, including CBC and platelet count, AST, ALT, and hepatitis C-RNA levels would be initially obtained at 48 hours and weekly thereafter. No efforts were to be made to prevent body heat loss. A single intravenous line was placed with a 21-gauge interacath. Heart rate, rectal thermistor, and VO2 monitoring was conducted during therapy as outlined.

Treatment procedure: the patient presented herself for outpatient treatment and was given a subcutaneous dose of 1.5 million units of interferon-alpha. Approximately 6 hours thereafter, at 1pm, a baseline VO2 recording of 5 minutes was 160cc/min. She was infused with 1mg/kg DNP over a 2 minute period. At 20 minutes, her VO2 increased and stabilized at approximately 210cc/min. A second dose of 1mg/kg DNP was infused and the VO2 peaked 20 minutes later at
250cc/min. An additional dose of 2.0mg/kg DNP was given 30 minutes following the second dose. Repeat VO2 showed a rise and stabilization 20 minutes thereafter at 360cc/min. The patient's rectal temperature increased and never exceeded 1.3°C above her normal baseline. Two hours after her last dose of DNP, her VO2 declined to 280cc/min. An additional 2mg/kg dose of DNP was administered. The patients VO2 increased and stabilized 20 minutes thereafter to a level of 420cc/min. She was noted to sweat profusely. Throughout treatment the patient was permitted to drink fluids ad libitum. She was notably fatigued at hour 5 of therapy. Monitored parameters and flow chart are shown in Fig. 23. The 5 day treatment protocol was repeated after a 2 day "DNP rest period". This regimen was repeated times 3. Subcutaneous interferon-alpha was administered for a total of 10 weeks. Figure 28 shows the patients DNP/interferon treatment flow chart.

Treatment outcome: by the treatment regimen outlined above, hepatitis C-RNA viral load decreased by approximately 2 logs after 48 hours. Over the next 5 days the viral load further decreased by an additional log. HCV-RNA became undetectable and the HCV viral genome remained cleared from the bloodstream at week 2 and thereafter. Alanine transaminase (ALT) levels increased 7 fold at 48 hours and remained elevated until week 3, at which time they returned to levels slightly below that which existed prior to therapy. CBC, bilirubin, and blood urea nitrogen (BUN) remained within normal limits. Alkaline phosphatase levels increased 2 fold at 48 hours but returned to pretreatment levels at day 7.

The patients HCV viral genome remained cleared from her bloodstream 18 months after therapy and there was normalization of her ALT.

Example 11

METHOD OF USING DINITROPHENOL INDUCED INTRACELLULAR HYPERTHERMIA TO INCREASE IMMUNOGENICITY OF HUMAN TUMORS

DNP would be given as an intravenous solution, or as an oral preparation, so as to increase oxygen consumption 2.5-5 times above normal for a period of 2-3 hours. Such treatment would be administered every other day for a period of 5-10 days. At 8-24 hours after the last day of treatment, the patient would be administered standard chemotherapy or specific monoclonal antibody immunotherapy directed against known mutated or inappropriately expressed...
oncogenic proteins (e.g., ras, p53, HER/neu, etc.), or combination anti-oncogenic immunotherapy with chemotherapy or radiation.

Heat shock proteins (HSPs) or stress-induced proteins are constitutively expressed in all living cells and are among the most abundant proteins found. However, many members of the HSP family can further be expressed by cellular stress-causing conditions such as heat, drugs, glucose deprivation, etc. Of importance to the present method is that the expression of HSPs in tumors is associated with a heightened immune and/or cytotoxic T-lymphocyte response. In particular, it is known that members of the HSP70 family (HSPs are generally classified by their molecular weights e.g., HSP90 kdaltons, HSP27 kdaltons, HSP70 kdaltons, etc.) are expressed on cell surfaces. Due to the ability of DNP to induce intracellular hyperthermia, the enhanced expression of human HSPs in DNP treated tumors could greatly increase their immunogenicity.

This method could be used to broaden the antigen-specific repertoire of many poorly immunogenic tumors by increasing the expression of HSP-peptide immunogenic determinants on their cell surfaces. Such consequences would heighten any endogenous specific anti-tumor immune response. Moreover, DNP-intracellular heat-inducible immunogenic targets could further increase the efficacy of exogenously synthesized and administered monoclonal antibodies. By example, patients with HER-2/neu overexpressing metastatic breast cancer (25% of breast cancer patients) would be treated by the DNP method outlined above. This treatment would then be followed by a standard loading dose and weekly infusions of anti-HER-2/neu monoclonal antibodies. Clinical benefits would be evaluated by overall response rates and duration of response.

Example 12
SYNTHESIS AND USE OF NOVEL CONJUGATES AND DERIVATIVES OF 2,4-DINITROPHENOL

Formation of novel nitrophenol compounds is of importance in that their alkyl, alkene, fatty acid, aromatic and other derivatives may significantly enhance their biologic activity and/or improve the therapeutic index. Many reactions of the benzene ring of phenols through halogenation, sulfonation, and nitration are known. Numerous procedures for C-alkylation of phenols through reduction of benzyl alcohol, aldehydes, benzonitriles and Mannich bases are published.
Alkylations or other "R" group additions have also been performed on various phenolic substrates using Stille or Negishi coupling reactions. An example of converting a nitrophenol compound to the desired alkylated (or other "R" group analog) by a 2 step procedure utilizing the Stille coupling reaction is illustrated in Figure 30. As shown in step 1, DNP is first iodinated with Barluenga's reagent (IPy2 BF4) to yield 2,4-dinitro-3,5-diiodophenol. In step 2, the nitroiodophenol is then converted to the alkylated derivative (in the instant example an ethylated derivative) via a co-catalytic, palladium-copper Stille reaction.

Compound 3 shown in Figure 30 is an ethylated derivative of DNP and is designed to increase uncoupling activity by adding lipophytic alkyl substituents to the benzene ring. Such analogs with augmented activity may be particularly useful in the treatment of bulky tumors and malignancies which possess a high fat content, e.g. liposarcoma, glioblastoma, etc.

A representative approach (Step 2) to the palladium-copper, co-catalytic ethylation of a nitroiodophenol is illustrated by the conversion of 2,4-dinitro-3,5-diiodophenol to 2,4-dinitro-3,5-diethylphenol. Nitroiodophenol (500mg, 934μmol) is added to a pressurized reaction containing N-ethylpyrrolidinone (1.5ml). Pd2dba3CHCL3 (27mg, 26μmol) and triphenylphosphine (50mg, 191μmol) is added to the stirring solution and slowly heated to approximately 50°C for 10 minutes. Copper iodide (17mg, 91μmol) is added to the stirring solution. The mixture is again heated to 50°C for 10 minutes. The solution is cooled to 32°C and tetraethyl tin (285μL, 2.05mmol) is added to the stirring solution. The reaction tube is sealed and heated with continuous stirring at 65°C for 12-16 hours. Aqueous workup and ethyl acetate extraction with drying by magnesium sulfate (MgSO4 ) and concentration yields the end product.

Example 13
SYNTHESIS OF AN EXPANDED COMBINATORIAL LIBRARY OF PUTATIVE UNCOUPLING AGENTS CAPABLE OF INDUCING INTRACELLULAR HYPERTERMIA.

The spectrum of potential classic uncoupling agents that can induce intracellular hyperthermia can be greatly expanded through a designed convergent synthetic approach. An almost limitless variety of uncouplers can be synthesized through a "combinatorialized" scheme to produce an expanded "library" of uncoupling agents with related structures. The scheme specifically
presented herein exemplifies the synthesis of 21 potential uncoupling agents, but can be expanded to 1,000 to 100,000 putative uncoupling agents.

Five classes of uncouplers are prepared via the convergent route shown in Figure 31. The synthetic scheme depicted in Figure 31 is designed as a combinatorial approach to allow access to a library of structurally related putative uncouplers for biological evaluation. While the given examples noted in Figure 31 will allow formation of at least 21 novel uncouplers, a simple variation in this synthetic scheme will allow the library of uncouplers to be expanded to include from 1,000 to 100,000 novel uncoupling agents. After discussing the general synthetic approach in Figure 31, the simple synthetic variations designed to expand the library of uncouplers will be described. Such variations will be apparent to those skilled in the art of synthetic organic chemistry and pharmaceutical development.

Starting from benzaldehyde (Figure 31, Compound 1), diiodination at the 3- and 5- positions using Barluenga’s reagent (IPy2BF4) affords Compound 2 which is alkylated using a cocatalytic, palladium-copper Stille reaction to produce a 3,5-disubstituted Compound 3. This 2 step approach is known for producing a variety of methylated phenols. Use of tetramethyltin then produces the dimethyl derivatives [Compound 3, where R = Me(methyl)]; tetrabutyltin produces the dibutyl derivatives [Compound 3, where R = Bu(butyl)]; and, tetrphenylium produces the diphenyl derivatives [Compound 3, where R = Ph(phenyl)]. A Baeyer-Villiger oxidation of Compound 3, with meta-chlorobenzoic peracid (mCPBA) followed by alkaline hydrolysis [KOH(potassium hydroxide)] of the resulting formate affords phenols, Compound 4. The homogeneous 2,4-dinitro-or 2,4-dicyano-derivatives are initially accessed from an intermediate Compound 4. Nitrosation of Compound 4 with nitrofluoromethylsulfonate salt (NO2CF3SO3) provides the 3,5-disubstituted-2,4-dinitrophenols shown in Compound 5. Three different uncoupling agents are produced via this synthetic route. Diiodination of Compound 4 at the 2- and 4- positions produces Compound 6 which is treated with copper(I)cyanide (CuCN) to give the 2,6-dicyanate derivative, Compound 7. Three additional uncouplers are synthesized by this route. The heterogeneous nitro-, cyano-uncouplers are also accessed from intermediate Compound 3. The 2-cyano-, 4-nitro-uncouplers are targeted as the steric effects of the cyano group at the 2-position is less than the corresponding 2-nitro-derivatives. Mono-iodination of Compound 3 through the thallium intermediate affords the selective 2-iodo-derivative, Compound 8. Conversion of Compound 8 to phenol, Compound 9, is accomplished as before through the Baeyer-Villiger oxidation and hydrolysis of the resulting formate. Selective 4-
Nitration to produce Compound 10 is readily accomplished with nitrotrifluoromethylsulfonate salt followed by cyration to afford 2-cyano-4-nitro-uncouplers, Compound 11. Three additional uncouplers are produced by this route.

Additional uncouplers, such as the 2,4,6-tricyano compounds, can also be produced through the same convergent synthesis. Exhaustive iodination of Compound 4 affords 2,4,6-triiodinated Compound 12 which is then directly converted to tricyano-uncouplers, Compound 13, through copper catalyzed exchange. Three more uncouplers are produced by this modification. A 2,4-dicyano-uncoupler carrying three variable substituents at the 3-, 5- and 6-positions is also readily produced through this convergent approach. Initial selective monobromination of the phenol Compound 4 at the ortho-position affords Compound 14 which is diiodinated at the 2,4-positions to produce the 2,4-diiodo-, 6-bromo-Compound 15 derivatives. Selective cyano exchange at the more reactive aryl iodide positions affords the dicyano Compound 16 derivatives. A final co-catalytic, palladium-copper Stille reaction results in the formation of the 3,5,6-trisubstituted, 2,4-dicyano-uncouplers. Use of the same tin reagents previously described allows the introduction of either methyl, ethyl, propyl, butyl, etc., or phenyl at the 6-position. In conjunction with the 3 different substituents at the 3- and 5-positions, 9 additional uncouplers are afforded by this additional expansive route.

The synthesis of 21 novel uncouplers depicted by the convergent approach in Figure 31 can be further modified. To those skilled in the art, a simple variation in this exemplary synthetic approach will allow a greatly expanded library of potential uncouplers to be synthesized. The expanded library can be produced by introduction of an array of alkyl and aryl substituents at the 3-, 5-, and/or 6-positions while maintaining the 2,4-dinitro-, 2,4-dicyano, 2-cyano-4-nitro- and/or the 2,4,6-tricyano-phenol substrate. This simple synthetic variation is accomplished by using a variety of well known palladium, zinc, or copper-mediated reactions at the stage of alkyl or aryl group incorporation, i.e., Figure 31, Compound 2 to 3 and Compound 16 to 17 conversions. This synthesis is a variation on the Stille reaction, the Heck reaction, the Negishi coupling, Suzuki couplings, Smealshack reactions and cuprate reactions. Such a variation can introduce a nearly of unlimited array of potential substituents onto the phenol core of the uncoupler. This combinatorial approach can even be further expanded by variable halogenation (either bromination or iodination) at the 3- and 5- positions to allow 2 different substituents to be introduced at these 2 positions in the ensuing metal-mediated halogen exchange reactions. This

SUBSTITUTE SHEET (RULE 26)
“combinatorial library” approach will allow a broad range of potential uncouplers to be synthesized and evaluated for potential biological activity, including safety and effectiveness.

Activity of the many diverse conjugates and derivatives of 2,4-dinitrophenol (and other uncoupling agents) may be tested by known in vitro methods for oxygen consumption, e.g., tissue or cellular suspensions with Clark type oxygen sensors. Toxicity, mutagenicity and LD50 studies in animals would be performed under recognized protocols prior to use of any such novel compounds in human subjects. Upon establishing toxicity and safety criteria, the various novel conjugates and derivatives can be administered under dose escalation trials as outlined previously for the clinical use of dinitrophenol.

It will be apparent to those skilled in the art that numerous modifications and variations can be made to the processes and compositions of this invention. Thus, it is intended that the present invention cover the modifications and variations of this invention provided they come within the scope of the appended claims and their equivalents.
REFERENCES


54.) Lee, M.H. et al. (1996) "HIV-1 Load is Decreased in Chronic Infected ACH-2 Cell Line by Successive In Vitro Hyperthermia Treatment" XI International Conference On AIDS, Vancouver, Canada


SUBSTITUTE SHEET (RULE 26)


SUBSTITUTE SHEET (RULE 26)


SUBSTITUTE SHEET (RULE 26)


CLAIMS:
What is claimed is:

1. A method for inducing intracellular hyperthermia comprising the step of administering an amount of a mitochondrial uncoupling agent sufficient to induce intracellular hyperthermia.

2. The method of claim 1, wherein the mitochondrial uncoupling agent is 2,4 dinitrophenol.

3. The method of claim 1, wherein the mitochondrial uncoupling agent is selected from the group consisting of: classic uncouplers, including 2,4 dinitrophenol, clofazimine, albendazole, cambendazole, oxibendazole, triclabendazole (TCZ), 6-chloro-5-[2,3-dichlorophenoxyl]-2-methylthio-benzimidazole and their sulfoxide and sulfone metabolites, thiobendazole, rafoxanide, bithionol, niclosamide, eutypine, various lichen acids (hydroxybenzoic acids) such as (+)-usnic acid, vulpinic acid and atranorin, 2', 5-dichloro-3-t-butyl-4'-nitrosalicylanilide (S-13), 3, 4', 5-trichlorosalicylanilide (DCC), platanetin, 2- trifluoromethyl-4, 5, 6, 7-tetrachlorobenzimidazole (TTFB), 1799, AU-1421, 3,4,5,6,9,10-hexahydro-14,16-dihydroxy-3-methyl-1H-2-benzoaxacyclotetradecin-1,7(8H)-dione (zeeralenone), N,N-1-bis-(4-trifluoromethylphenyl)-urea, resorcyclic acid lactones and their derivatives, 3,5-di-t-butyl-hydroxybenzylidenemononitrile(SF6847), 2,2',bis (hexafluoroacetylonyl) acetone, triphenyl boron, carbonylcyanide 4-trifluoromethoxyphenylhydrazone (FCCP), tributylamine (TBA), carbonyl cyanide 3-chlorophenylhydrazone (CICCP), 1, 3, 6, 8-tetranitrocarbazole, tetrachlorobenzotriazole, 4-iso-octyl-2,6-dinitrophenol(Octyl-DNP), 4-hydroxy-3,5-diido-benzonitrile, mitoguazone (methylglyoxal bisguanylylhydrazone), pentachlorophenol (PCP), 5-chloro-2-mercaptopbenozothiazole (BZT-SH), tribromocimidazole (TBI), N-(3-trifluoromethylphenyl)-anthranilic acid (Flufenamic acid), 4-nitrophenol, 4, 6-dinitroresol, 4-isobutyl-2,6-dinitrophenol, 2-azido-4-nitrophenol, 5-nitro-benzotriazole, 5-chloro-4-nitrobenzotriazole, tetrachlorobenzotriazole, methyl-o-phenylhydrazone, N-phenylantranilic acid, N-(3-nitrophenyl)anthranilic acid, N-(2,3-dimethylphenyl) anthranilic acid, mefenamic acid, diflunisal, flufenamic acid, N-(3-chlorophenyl) anthranilic acid, carbonyl cyanide 4-trifluoromethoxyphenylhydrazone (FCCP), SR-4233 (Tirapazamine), atovaquone, carbonyl cyanide 4-(6'-methyl-2'-benzothiazyl)-phenylhydrazone(BT-CCP), ellipticine, olivacine, ellipticinium, isoellipticine and related isomers, methyl-0-phenylhydrazonocyanacetacider,methyl-0-(3-chlorophenylhydrazino) cyanoacetatic acid, 2-(3'-chlorophenylhydrazono)-3-oxobutyronitrile, thiosalicylic acid, 2-(2',4-dinitrophenylhydrazono)-.
3-oxo-4,4-dimethylvaleronitrile, relanium, melipramine, and other diverse chemical entities including unsaturated fatty acids (up to C_{14} optimum), sulfloramid and its metabolite perfluorooctane sulfonamide (DESFA), perfluoroctanoate, clofibrate, Wy-14, 643, ciprofibrate, and fluoroalcohols; ionophorous antibiotic uncouplers, including gramicidin, nigericin, tyrothricin, tyrocidin, valinomycin, alamethicins, harzianin HA V, saturnisporin SA IV, zervamicins, magainin, cecropins, melittin, hypecins, suzukacillins, monensins, trichotoxins, antiamoebins, crystal violet, cyanine dyes, cadmium ion, trichosporin-B and their derivatives; and other heterogeneous coupling compounds, including desaspidin, ionized calcium (Ca^{++}), uncoupling proteins such as UCPI-1, UCP-2, UCP-3, PUMP (Plant Uncoupling Mitochondrial Protein), histones, polylysines, A206668-a protein, and compound K23187.

4. The method of claim 1, wherein the mitochondrial uncoupling agent is a conjugate comprising 2,4 dinitrophenol.

5. The method of claim 1, further wherein the induced intracellular hyperthermia is used in the diagnosis or treatment of infections, malignancies or other medical conditions.

6. The method of claim 5, wherein the induced intracellular hyperthermia is used in the diagnosis or treatment of infections, malignancies or other medical conditions selected from the group consisting of cancer, and infections or infestations.

7. The method of claim 5, wherein the induced intracellular hyperthermia is used in the diagnosis or treatment of cancer.

8. The method of claim 5, wherein an animal is administered the mitochondrial uncoupling agent and a separate medication is administered, wherein the second medication increases the overall metabolic rate of the animal, the metabolic rate of a specific target tissue in the animal, or an increase in free radical flux.

9. The method of claim 8, wherein the second medication is selected from the group consisting of glucagon, arbutamine, dobutamine, vasopressin, glutamine, proline, octanoate, methylene blue (tetramethylthionine), ubiquinone, menadione, hematoporphyrin, polyunsaturated fatty acids including linoleic (double bonds at carbons 9 and 12), alpha-linolenic (double bonds at carbons 9, 12, and 15), gamma-linolenic (double bonds at carbons 6, 9, and 12),
100
arachidonic (double bonds at carbons 5, 8, 11, and 14), eicosapentaenoic (double bonds at 5, 8, 11, 14, and 17), docosahexenoic (double bonds at carbons 4, 7, 10, 13, 16, and 19), cis-parinaric (double bonds at 9, 11, 13, and 15) and, monounsaturated fatty acids including oleic (double bond at carbon 9), erucic (double bond at carbon 13), phenazine methosulfate, 2,6-dichlorophenolindophenol, coenzyme Q1, CoQ2 and their analogs duroquinone and decylosibiquinone.

10. The method of claim 5, wherein the induced intracellular hyperthermia involve the induction of heat shock proteins.

11. The method of claim 5, a second therapeutic agent, or therapy, is administered.

12. The method of claim 11, wherein the second, therapeutic agent or therapy, is selected from the group consisting of: anti-fungal agents, including Amphotericin B, Griseofulvin, Fluconazole (Diflucan), Itraconazole, 5-fluoro-cytosine (Fluctocytosine, 5-FC), Ketotaconazole and Miconazole; anti-bacterial agents, including beta lactam rings (penicillins), macrocyclic lactone rings (macrolides), polycyclic derivatives of napthacene-carboxamide (tetracyclines), amino sugars in glycosidic linkages (aminoglycosides), peptides (bacitracin, gramicidin, polymixins, etc.), nitrobenzene derivatives of dichloroacetic acid, large ring compounds with conjugated double bond systems (polyenes), various sulfa drugs including those derived from sulfanilamide (sulfonamides, 5-nitro-2-furianyl compounds (nitrofurans), quinolone carboxylic acids (nalidixic acid), fluorinated quinolones (ciprofloxan, enoxacin, ofloxacin, etc.), nitroimidazoles (metroindazole), peptide antibiotics (such as bacitracin, bleomycin, cactinomycin, capreomycin, colistin, dactinomycin, gramacidin A, enduracitin, amphotycin, gramicidin J, mikamycins, polymyxins, stendomycin, actinomycin; aminoglycosides represented by streptomyacin, neomycin, paromycin, gentamycin ribostamycin, tobramycin, amikacin; lividomycin beta lactams represented by benzylpenicillin, methicillin, oxacillin, hetacillin, piperacillin, amoxicillin and carbenacillin; lincosaminides represented by clindamycin, lincomycin, celesticetin, desalaceticin; chloramphenicol; macrolides represented by erythromycins, lankamycin, leucomycin, picromycin), nucleosides (such as 5-azacytidine, puromycin, septacidin and amicetin; phenazines represented by myxin, lomofungin, iodin), oligosaccharides (including curamycin and everninomycin; sulfonamides represented by sulfathiazole, sulfadiazine, sulfanilimide, sulfapyrazine) polyenes (including amphotericins, candidcidin and nystatin, polyethers tetracyclines (including doxycyclines, minocyclines, methacyclines, methacyclines.
chlordetracyclines, oxytetracyclines, demeclocyclines), nitrofurans (including nitrofurazone, furazolidone, nitrofurantoin, furium, nitrovin and nitroxime), and quinolone carboxylic acids (including nalidixic acid, piromidic acid, pipemidic acid and oxolinic acid); antiviral agents including interferons α, β and γ, amantadine, rimantadine, arildone, ribavirin, acyclovir, abacavir, vidarabine (ARA-A) 9-1,3-dihydroxy-2-propoxy methylguanine (DHPG), ganciclovir, enviroxime, foscarnet, ampligen, podophyllotoxin, 2,3-dideoxytidine (ddC), iododeoxyuridine (IDU), trifluorothymidine (TFT), dideoxyinosine (ddi), d4T, 3TC, zidovudine, efavirenz, protease inhibitors such as indinavir, saquinavir, ritonavir, nelfinavir, amprenavir, and specific antiviral antibodies; anti-cancer drugs, including cell cycle-specific agents (including structural analogs or antimetabolites of methotrexate, mercaptopurine, fluorouracil, cytarabine, thioguanine, azacitidinе), bleomycin peptide antibiotics, such as podophyllin alkaloids including etoposide (VP-16) and teniposide (VM-26), various plant alkaloids such as vincristine, vinblastine, and paclitaxel, anti-neoplastic cell cycle-nonspecific agents such as various alkylating compounds such as busulfan, cyclophosphamide, mechlorethamine, melphalan, altretamine, ifosfamide, cisplatin, dacarbazine, procarbazine, lomustine, carmustine, lomustine, semustine, chlorambucil, thiopeta and carboptatin; various hormones, hormone agonists and biologic response modifying agents, including flutamide, prednisone, ethinyl estradiol, diethylstilbestrol, hydroxyprogesterone caproate, meoxyprogesterone, megestrolacetate, testosterone, fluoxymesterone and thyroid hormones such as di-,tri- and tetraiodothyroidine, the aromatase inhibitor, amino glutethimide, the peptide hormone inhibitor octreotide and gonadotropin-releasing hormone agonists such as goserilin acetate and leuprolide, biologic response modifiers such as various cytokines, interferon alpha-2a, interferon alpha-2b, interferon-gamma, interferon-beta, interleukin-1, interleukin-2, interleukin-4, interleukin-10, monoclonal antibodies (anti-HER-2/neu humanized antibody), tumor necrosis factor, granulocyte-macrophage colony-stimulating factor, macrophage-colony-stimulating factor, various prostaglandins, phenylacetates, retinoic acids, leukotrienes, thromboxanes and other fatty acid derivatives; and radiation therapy.

13. The method of claim 1, wherein the mitochondrial uncoupling agent is an analog of 2,4 dinitrophenol.

14. The method of claim 1, wherein the mitochondrial uncoupling agent is a derivative of 2,4 dinitrophenol.
15. A method for inducing intracellular free radicals comprising the step of administering an amount of a mitochondrial uncoupling agent sufficient to induce intracellular free radicals.

16. The method of claim 15, wherein the mitochondrial uncoupling agent is 2,4-dinitrophenol.

17. The method of claim 15, wherein the mitochondrial uncoupling agent is selected from the group consisting of: classic uncouplers, including 2,4-dinitrophenol, clofazimine, albendazole, cambendazole, oxibendazole, triclabendazole (TCZ), 6-chloro-5-[2,3-dichlorophenoxy]-2-methylthio-benzimidazole and their sulfoxide and sulfone metabolites, thiobendazole, raboxanide, bithionol, niclosamide, eutypine, various lichen acids (hydroxybenzoic acids) such as (+)usnic acid, vulpinic acid and atranorin, 2′, 5-dichloro-3-t-butyl-4′-nitrosalicylanilide (S-13), 3′, 4′, 5-trichlorosalicylanilide (DCC), platanetin, 2′-trifluoromethyl-4, 5, 6, 7′-tetrachlorobenzimidazole (TTFB), 1799, AU-1421, 3,4,5,6,9,10-hexahydro-14,16-dihydroxy-3-methyl-1H-2-benzoxacyclotetradecin-1,7(8H)-dione (zeaalenone), N,N′-bis-(4-trifluoromethylphenyl)-urea, resorcylic acid lactones and their derivatives, 3,5-di-t-butyl-hydroxybenzylidenemalononitrile(SF6847), 2,2′-bis(hexafluoroacetyl) acetone, triphenyl boron, carbonylcyanide 4-trifluoromethoxyphenylhydrazone (FCCP), tributylamine (TBA), carbonyl cyanide 3-chlorophenylhydrazone (CICCP), 1, 3, 6, 8-tetranitrocarbazole, tetrachlorobenzotriazole, 4-isooctyl-2,6-dinitrophenol(Octyl-DNP), 4-hydroxyl-3,5-didobenzoazitore, mitoguazone (methylglyoxal bisguanylylhydrazine), pentachlorophenol (PCP), 5-chloro-2-mercatobenzothiazole (BZT-SH), tribromoisimidazale (TBI), N-(3-trifluoromethylphenyl)-anthranilic acid (Flufenamic acid), 4-nitrophenol, 4, 6-dinitroresol, 4-isobutyl-2,6-dinitrophenol, 2-azido-4-nitrophenol, 5-nitrobenzotriazole, 5-chloro-4-nitrobenzotriazole, tetrachlorobenzotriazole, methyl-o-phenylhydrazone, N-phenylantranilic acid, N-(3-nitrophenyl)anthranilic acid, N-(2,3-dimethylphenyl) anthranilic acid, mefenamic acid, diflunisal, flufenamix acid, N-(3-chlorophenyl) anthranilic acid, carbonyl cyanide 4-trifluoromethoxyphenylhydrazone (FCCP), SR-4233 (Tirapazamine), atovaquone, carbonyl cyanide 4-(6′-methyl-2′-benzothiazyl)-phenylhydrazone(BT-CCP), ellipticine, olivacine, ellipticineum, isoellipticine and related isomers, methyl-0-phenylhydrazonocyanacetic acid, methyl-0-(3-chlorophenylhydrazono) cyanacetic acid, 2-(3′-chlorophenylhydrazono)-3-oxobutyonitrile, thiosalicylic acid, 2-(2′,4-dinitrophenylhydrazono)-3-oxo-4,4-demethylvaleronitrile, relanium, melipramine, and other diverse chemical entities.
including unsaturated fatty acids (up to C₁₄ optimum), sulflaramid and its metabolite perfluoroctane sulfonamide (DESFA), perfluoroccanoate, clofibrate, Wy-14, 643, ciprofibrate, and fluoroalcohols; ionophorous antibiotic uncouplers, including gramicidin, nigericin, tyrothricin, tyrocidin, valinomycin, alamethicins, harzianin HA V, saturnisporin SA IV, zervamicins, magainin, cecropins, melittin, hylpecins, suzukacillins, monensins, trichotoxins, antiamoebins, crystal violet, cyanine dyes, cadmium ion, trichosporin-B and their derivatives; and other heterogeneous uncoupling compounds, including desaspidin, ionized calcium (Ca⁺⁺), uncoupling proteins such as UCP1-1, UCP-2, UCP-3, PUMP (Plant Uncoupling Mitochondrial Protein), histones, polylysines, A206668-a protein, and compound K23187.

18. The method of claim 15, wherein the mitochondrial uncoupling agent is a conjugate comprising 2,4 dinitrophenol.

19. The method of claim 15, wherein the mitochondrial uncoupling agent is a derivative of 2,4 dinitrophenol.

20. The method of claim 15, wherein the mitochondrial uncoupling agent is a analog of 2,4 dinitrophenol.

21. The method of claim 15, further wherein the induced intracellular free radicals are used in the diagnosis or treatment of infections, malignancies or other medical conditions.

22. The method of claim 13, wherein the induced intracellular free radicals are used in the diagnosis or treatment of infections, malignancies or other medical conditions selected from the group consisting of cancer, and bacterial, parasitic, fungal, and viral infections or infestations.

23. The method of claim 21, wherein an animal is administered the mitochondrial uncoupling agent and a separate medication is administered, wherein the second medication increases the overall metabolic rate of the animal, the metabolic rate of a specific target tissue in the animal, or an increase in free radical flux.

24. The method of claim 23, wherein the second medication is selected from the group consisting of glucagon, arbutamine, dobutamine, vasopressin, glutamine, proline, octanoate, methylene blue (tetramethylthionine), ubiquinone, menadione, hematoporphyrin.
polyunsaturated fatty acids including linoleic (double bonds at carbons 9 and 12), alpha-linolenic (double bonds at carbons 9, 12, and 15), gamma-linolenic (double bonds at carbons 6, 9, and 12), arachidonic (double bonds at carbons 5, 8, 11, and 14), eicosapentaenoic (double bonds at 5, 8, 11, 14, and 17), docosahexenoic (double bonds at carbons 4, 7, 10, 13, 16, and 19), cis-parinaric (double bonds at 9, 11, 13, and 15) and, monounsaturated fatty acids including oleic (double bond at carbon 9), erucic (double bond at carbon 13), phenazine methosulfate, 2,6-dichlorophenolindophenol, coenzyme Q1, CoQ2 and their analogs duroquinone and decylubiquinone.

25. The method of claim 21 wherein the intracellular free radicals are used in the diagnosis or treatment of Lyme disease.

26. The method of claim 21, wherein the induced intracellular free radicals involve the induction of heat shock proteins.

27. The method of claim 15, a second, therapeutic agent or therapy is administered.

28. The method of claim 27, wherein the second, therapeutic agent, or therapy, is selected from the group consisting of: anti-fungal agents, including Amphotericin B, Griseofulvin, Fluconazole (Diflucan), Intracnazole, 5 fluoro- cytosine (Fluctocytosine, 5-FC), Ketatoconazole and Miconazole; anti-bacterial agents, including beta lactam rings (penicillins), macrocyclic lactone rings (macrolides), polycyclic derivatives of naphacencarboxamide (tetracyclines), amino sugars in glycosidic linkages (aminoglycosides), peptides (bacitracin, gramicidin, polymixins, etc.), nitrobenzene derivatives of dichloroacetic acid, large ring compounds with conjugated double bond systems (polyenes), various sulfa drugs including those derived from sulfanilamide (sulfonamides, 5-nitro-2-furianyl compounds (nitrofurans), quinolone carboxylic acids (nalidixic acid), fluorinated quinolones (ciprofloxan, enoxacin, ofloxacin, etc.), nitroimidazoles (metroindazole), peptide antibiotics (such as bacitracin, bleomycin, cacticomycin, capreomycin, colistin, dactinomycin, gramicidin A, enduracitin, amphotomycin, gramicidin J, mikamycin, polymixins, stendomycin, actinomycin; aminoglycosides represented by streptomycin, neomycin, paromycin, gentamycin ribostamycin, tobramycin, amikacin; lvidomycin beta lactams represented by benzylpenicillin, methicillin, oxacillin, hetacillin, piperacillin, amoxicillin and carbenacillin; lincomaminides represented by clindamycin, lincomycin, celleriacetin, deslaceticin; chloramphenicol; macrolides represented by erythromycins,
lankamycin, leucomycin, picromycin), nucleosides (such as 5-azacytidine, puromycin, septacidin and amicetin; phenazines represented by myxin, lomofungin, iodin), oligosaccharides (including curamycin and everninomycin; sulfonamides represented by sulfathiazole, sulfadiazine, sulfanilimide, sulfapyrazine) polyenes (including amphotericins, candidicin and nystatin, polyethers tetracyclines (including doxycyclines, minocyclines, methacyclines, chlortetracyclines, oxytetracyclines, demeclocyclines), nitrofurans (including nitrofurazone, furazolidone, nitrofurantoin, furium, nitrovin and nifuroxime), and quinolone carboxylic acids (including nalidixic acid, piromidic acid, pipemidic acid and oxolinic acid); antiviral agents including interferons α, β and γ, amantadine, rimantadine, arbidone, ribavirin, acyclovir, abacavir, vidarabine (ARA-A) 9-1,3-dihydroxy-2-propoxy methylguanine (DHPG), ganciclovir, enviroxime, foscamet, ampligen, podophyllotoxin, 2,3-dideoxytidine (ddC), iododeoxyuridine (IDU), trifluorothymidine (TFT), dideoxinosine (ddi), d4T, 3TC, zidovudine, efavirenz, protease inhibitors such as indinavir, saquinavir, ritonavir, nelfinavir, amprenavir, and specific antiviral antibodies; anti-cancer drugs, including cell cycle-specific agents (including structural analogs or antimetabolites of methotrexate, mercaptupuorine, fluorouracil, cytarabine, thioguanine, azacitidine), bleomycin peptide antibiotics, such as podophyllin alkaloids including etoposide (VP-16) and teniposide (VM-26), various plant alkaloids such as vincristine, vinblastine, and paclitaxel, anti-neoplastic cell cycle-nonspecific agents such as various alkylating compounds such as busulfan, cyclophosphamide, mechloroethamine, melphalan, altretamine, ifosfamide, cisplatin, dacarbazine, procarbazine, lomustine, carmustine, lomustine, semustine, chlorambucil, thiopeta and carboplatin; various hormones, hormone agonists and biologic response modifying agents, including flutamide, prednisone, ethinyl estradiol, diethylstilbestrol, hydroxyprogesterone caproate, medroxyprogesterone, megestrolacetate, testosterone, fluoxymesterone and thyroid hormones such as di-,tri- and tetraiodothyroidine, the aromatase inhibitor, amino glutethimide, the peptide hormone inhibitor octreotide and gonadotropin-releasing hormone agonists such as goserilin acetate and leuprolide, biologic response modifiers such as various cytokines, interferon alpha-2a, interferon alpha-2b, interferon-gamma, interferon-beta, interleukin-1, interleukin-2, interleukin-4, interleukin-10, monoclonal antibodies (anti-HER-2/neu humanized antibody), tumor necrosis factor, granulocyte-macrophage colony-stimulating factor, macrophage-colony-stimulating factor, various prostaglandins, phenylacetates, retinoic acids, leukotrienes, thromboxanes and other fatty acid derivatives; and radiation therapy.

30. The method of claim 29, wherein the mitochondrial uncoupling agent is 2,4 dinitrophenol.

31. The method of claim 29, wherein the mitochondrial uncoupling agent is a conjugate comprising 2,4 dinitrophenol.

32. The method of claim 29, wherein the disease is selected from the group consisting of cancer, and infections or infestations of bacterial, parasitic, fungal, and viral pathogens.

33. The method of claim 29, wherein the induced intracellular hyperthermia is used in the treatment of cancer.

34. The method of claim 29, wherein an animal is administered the mitochondrial uncoupling agent and a separate medication is administered, wherein the second medication increases the overall metabolic rate of the animal, the metabolic rate of a specific target tissue in the animal, or an increase in free radial flux.

35. The method of claim 34, wherein the second medication is selected from the group consisting of glucagon, arbutamine, dobutamine, vasopressin, glutamine, proline, octanoate, methylene blue (tetramethylthionine), ubiquinone, menadione, hematoporphyrin, polyunsaturated fatty acids including linoleic (double bonds at carbons 9 and 12), alpha-linolenic (double bonds at carbons 9, 12, and 15), gamma-linolenic (double bonds at carbons 6, 9, and 12), arachidonic (double bonds at carbons 5, 8, 11, and 14), eicosapentaenoic (double bonds at 5, 8, 11, 14, and 17), docosahexenoic (double bonds at carbons 4, 7, 10, 13, 16, and 19), cis-parinaric (double bonds at 9, 11, 13, and 15) and, monounsaturated fatty acids including oleic (double bond at carbon 9), erucic (double bond at carbon 13), phenazine methosulfate, 2,6-dichlorophenolindophenol, coenzyme Q1, CoQ2 and their analogs duroquinone and decylubiquinone.

36. The method of claim 29, wherein the induced intracellular hyperthermia used involves
the induction of heat shock proteins.

37. A method for diagnosing disease in an animal by chemically inducing intracellular hyperthermia comprising the step of administering an amount of a mitochondrial uncoupling agent sufficient to induce intracellular hyperthermia.

38. The method of claim 37, wherein the mitochondrial uncoupling agent is 2,4 dinitrophenol.

39. The method of claim 37, wherein the mitochondrial uncoupling agent is a conjugate comprising 2,4 dinitrophenol.

40. The method of claim 37, wherein the disease is selected from the group consisting of cancer, and infections or infestations of bacterial, parasitic, fungal, and viral pathogens.

41. The method of claim 37, wherein the induced intracellular hyperthermia is used in the diagnosis or treatment of cancer.

42. The method of claim 37, wherein an animal is administered the mitochondrial uncoupling agent and a separate medication is administered, wherein the second medication increases the overall metabolic rate of the animal, the metabolic rate of a specific target tissue in the animal, or an increase in free radical flux.

43. The method of claim 42, wherein the second medication is selected from the group consisting of glucagon, arbutamine, dobutamine, vasopressin, glutamine, proline, octanoate, methylene blue (tetramethylthionine), ubiquinone, menadione, hematoporphyrin, polyunsaturated fatty acids including linoleic (double bonds at carbons 9 and 12), alpha-linolenic (double bonds at carbons 9, 12, and 15), gamma-linolenic (double bonds at carbons 6, 9, and 12), arachidonic (double bonds at carbons 5, 8, 11, and 14), eicosapentaenoic (double bonds at 5, 8, 11, 14, and 17), docosahexenoic (double bonds at carbons 4, 7, 10, 13, 16, and 19), cis-parinaric (double bonds at 9, 11, 13, and 15) and, monounsaturated fatty acids including oleic (double bond at carbon 9), erucic (double bond at carbon 13), phenazine methosulfate, 2,6-dichlorophenolindophenol, coenzyme Q1, CoQ2 and their analogs duroquinone and decylubiquinone.
44. The method of claim 37, wherein the induced intracellular hyperthermia involves the induction of heat shock proteins.

45. The method of claim 37, wherein the mitochondrial uncoupling agent is selected from the group consisting of: classic uncouplers, including 2,4 dinitrophenol, clofazimine, albendazole, cambendazole, oxibendazole, triclabendazole (TCZ), 6-chloro-5-[2,3-dichlorophenoxyl]-2-methylthio-benzimidazole and their sulfone and sulfone metabolites, thiobendazole, rafinoxanide, bithionol, niclosamide, eutypine, various lichen acids (hydroxybenzoic acids) such as (+)-usnic acid, vulpinic acid and atranorin, 2', 5-dichloro-2-t-butyl-4'-nitrosalicylanilide (S-13), 3', 4', 5-trichlorosalicylanilide (DCC), platanetin, 2-trifluoromethyl-4, 5, 6, 7-tetrachlorobenzimidazole (TTFB), 1799, AU-1421, 3,4,5,6,9,10-hexahydro-14,16-dihydroxy-3-methyl-1H-2-benzoxacyclotetradecin-1,7(SH)-dione (zearalenone), N,N^1-bis-(4-trifluoromethylphenyl)-urea, resorcylic acid lactones and their derivatives, 3,5-di-t-butyl-hydroxybenzylidenemalononitrile(SF6847), 2,2',bis (hexafluoroacetonyl) acetone, triphenyl boron, carbonylcyanide 4-trifluoromethoxyphenylhydrazone (FCCP), tributylamine (TBA), carbonyl cyanide 3-chlorophenylhydrazone (CICCP), 1, 3, 6, 8-tetranitrocarbazole, tetrachlorobenzotriazole, 4-isooctyl-2,6-dinitrophenol(Octyl-DNP), 4-hydroxy-3,5-didobenzonitrile, mitoguazone (methylglyoxal bisguanylylhydrazone), pentachlorophenol (PCP), 5-chloro-2-mercatobenzothiazole (BZT-SH), tribromoimidazole (TBI), N-(3-trifluoromethylphenyl)-anthranilic acid (Flufenamic acid), 4-nitrophenol, 4, 6-dinitroresol, 4-isobutyl-2,6-dinitrophenol, 2-azido-4-nitrophenol, 5-nitrobenzotriazole, 5-chloro-4-nitrobenzotriazole, tetrachlorobenzotriazole, methyl-o-phenylhydrazone, N-phenylanthranilic acid, N-(3-nitrophenyl)anthranilic acid, N-(2,3-dimethylphenyl) anthranilic acid, mefenamic acid, diflunisal, flufenamix acid, N-(3-chlorophenyl) anthranilic acid, carbonyl cyanide 4-trifluoromethoxyphenylhydrazone (FCCP), SR-4233 (Tirapazamine), atovaquone, carbonyl cyanide 4-(6'-methyl-2'-benzothiazyl)-phenylhydrazone(BT-CCP), ellipticine, olivacin, ellipticinium, isoeillipticine and related isoemers, methyl-0-phenylhydrazonocyaanoaceticacid,methyl-0-(3-chlorophenylhydrazono) cyanoacetic acid, 2-(3'-chlorophenylhydrazono)-3-oxobutyronitrile, thiosalicylic acid, 2-(2',4-dinitrophenylhydrazono)-3-oxo-4,4-demethylvaleronitrile, relaimium, melipramine, and other diverse chemical entities including unsaturated fatty acids (up to C14 optimum), sulfamid and its metabolite perfluorooctane sulfonamide (DESFA), perfluoroctanoate, clofibrate, Wy-14, 643, ciprofibrate,
and fluoroalcohols; ionophorous antibiotic uncouplers, including gramicidin, nigericin, tyrothricin, tyrocidin, valinomycin, alamethicins, harzianin HA V, saturnisporin SA IV, zervamicins, magainin, cecropins, melittin, hylecins, suzukacillins, monensins, trichotoxins, antiamoebins, crystal violet, cyanine dyes, cadmium ion, trichosporin-B and their derivatives; and other heterogeneous uncoupling compounds, including desapnid, ionized calcium (Ca\(^{++}\)), uncoupling proteins such as UCPI-1, UCP-2, UCP-3, PUMP (Plant Uncoupling Mitochondrial Protein), histones, polylysines, A206668-a protein, and compound K23187.

46. The method of claim 37, wherein a second therapeutic agent or therapy is administered.

47. The method of claim 46, wherein the second therapeutic agent or therapy is selected from the group consisting of: anti-fungal agents, including Amphotericin B, Griseofulvin, Fluconazole (Diffucan), Intracanazole, 5 fluoro-cytosine (Fluctocytosine, 5-FC), Ketatoconazole and Miconazole; anti-bacterial agents, including beta lactam rings (penicillins), macrocyclic lactone rings (macrolides), polycyclic derivatives of napthacencarboxamide (tetracyclines), amino sugars in glycosidic linkages (aminoglycosides), peptides (bacitracin, gramicidin, polymixins, etc.), nitrobenzene derivatives of dichloroacetic acid, large ring compounds with conjugated double bond systems (polyenes), various sulfa drugs including those derived from sulfanilamide (sulfonamides, 5-nitro-2-furianyl compounds (nitrofurans), quinolone carboxylic acids (nalidixic acid), fluorinated quinilones (ciprofloxan, enoxacin, ofloxacin, etc.), nitroimidazoles (metroindazole), peptide antibiotics (such as bacitracin, bleomycin, cactinomycinc, capreomycin, colistin, dactinomycin, gramicacin A, enduracidin, amphotomycin, gramicidin J, mikamycins, polymyxins, stendomycin, actinomycin), aminoglycosides represented by streptomycin, neomycin, paromycin, gentamycin ribostamycin, tobramycin, amikacin; lividomycin beta lactams represented by benzylpenicillin, methicillin, oxacillin, hetacillin, piperacillin, amoxicillin and carbencillin; lincomaminides represented by clindamycin, lincomycin, celesticetin, desalicatein; chloramphenicol; macrolides represented by erythromycins, lankamycin, leucomycin, picromycin), nucleosides (such as 5-azacytidine, puromycin, septacinidin and amicetin; phenazines represented by myxin, lomofungin, iodin), oligosaccharides (including curamyccin and everinomycin; sulfonamides represented by sulfathiazoze, sulfadiazine, sulfanilimide, sulfapyrazine) polyenes (including amphotericins, candidicin and nystatin, polyethers tetracyclines (including doxycyclines, minocyclines, methacyclines, chlorotetracyclines, oxytetracyclines, demeclocyclines), nitrofurans (including nitrofurazone, furazolidone, nitrofurantoin, furium, nitrovin and nifuroxime), and quinolone carboxylic acids
(including nalidixic acid, piromidic acid, pipemidic acid and oxolinic acid); antiviral agents including interferons α, β and γ, amantadine, rimantadine, arildone, ribavirin, acyclovir, abacavir, vidarabine (ARA-A) 9-1,3-dihydroxy-2-propoxy methylguanine (DHPG), ganciclovir, enviroxime, foscarnet, ampligen, podophyllotoxin, 2,3-dideoxytidine (ddC), iododeoxyuridine (IDU), trifluorothymidine (TFT), dideoxyinosine (ddI), d4T, 3TC, zidovudine, efavirenz, protease inhibitors such as indinavir, saquinavir, ritonavir, nelfinavir, amprenavir, and specific antiviral antibodies; anti-cancer drugs, including cell cycle-specific agents (including structural analogs or antimetabolites of methotrexate, mercaptopurine, fluorouracil, cytarabine, thioguanine, azacitidine), bleomycin peptide antibiotics, such as podophyllin alkaloids including etoposide (VP-16) and teniposide (VM-26), various plant alkaloids such as vincristine, vinblastine, and paclitaxel, anti-neoplastic cell cycle-nonspecific agents such as various alkylating compounds such as busulfan, cyclophosphamide, mechlorethamine, melphalan, altretamine, ifosfamide, cisplatin, dacarbazine, procarbazine, lomustine, carmustine, lomustine, semustine, chlorambucil, thiopeta and carboplatin; various hormones, hormone agonists and biologic response modifying agents, including flutamide, prednisone, ethinyl estradiol, diethylstilbestrol, hydroxyprogesterone caproate, medroxyprogesterone, megestrolacetate, testosterone, fluoroxymesterone and thyroid hormones such as di-,tri- and tetraiodothyroidine, the aromatase inhibitor, amino glutethimide, the peptide hormone inhibitor octreotide and gonadotropin-releasing hormone agonists such as goserelin acetate and leuprolide, biologic response modifiers such as various cytokines, interferon alpha-2a, interferon alpha-2b, interferon-gamma, interferon-beta, interleukin-1, interleukin-2, interleukin-4, interleukin-10, monoclonal antibodies (anti-HER-2/neu humanized antibody), tumor necrosis factor, granulocyte-macrophage colony-stimulating factor, macrophage-colony-stimulating factor, various prostaglandins, phenylacetates, retinoic acids, leukotrienes, thromboxanes and other fatty acid derivatives; and radiation therapy.


49. The method of claim 48, wherein the mitochondrial uncoupling agent is 2,4 dinitrophenol.
50. The method of claim 48, wherein the mitochondrial uncoupling agent is selected from
the group consisting of: classic uncouplers, including 2,4 dinitrophenol, clofazimine,
albendazole, cambendazole, oxibendazole, triclabendazole (TCZ), 6-chloro-5-[2,3-
dichlorophenoxy]-2-methylthio-benzimidazole and their sulfoxide and sulfone metabolites,
thiobendazole, rafoxanide, bithionol, niclosamide, eutypine, various lichen acids
(hydroxybenzoic acids) such as (+)usnic acid, vulpinic acid and atranorin, 2’, 5-dichloro-3-t-
butyl-4’-nitrosalicylanilide (S-13), 3, 4’, 5-trichlorosalicylanilide (DCC), platanin, 2-
trifluoromethyl-4, 5, 6, 7- tetrachlorobenzimidazole (TTFB), 1799, AU-1421, 3,4,5,6,9,10-
hexahydro-1,16-dihydoxy-3-methyl-1H-2-benzoazacyclotetradecin-1,7(8H)-dione
(zearalenone), N,N1-bis-(4-trifluoromethylphenyl)-urea, resorcyclic acid lactones and their
derivatives, 3,5-di-t-butyl-hydroxybenzylidenemalononitrile(SF6847), 2,2’,bis
(hexafluoroacetonyl) acetone, triphenyl boron, carbonylcyanide 4-
trifluoromethoxyphenylhydrazone (FCCP), tributylamine (TBA), carbonyl cyanide 3-
chlorophenylhydrazone (CICCP), 1, 3, 6, 8-tetranitrocarbazole, tetrachlorobenzotriazole, 4-isoo-
ctyl-2,6-dinitrophenol(Octyl-DNP), 4-hydroxy-3,5-didobenzonitrile, mitoguazone
(methylglyoxal bisguanilhydrazone), pentachlorphenol (PCP), 5-chloro-2-
mercatobenzothiazole (BZT-SH), tribromoimidazol (TBI), N-(3-trifluoromethylphenyl)-
anthranilic acid (Flufenamic acid), 4-nitrophenol, 4, 6-dinitroresol, 4-isobuty1-2,6-
dinitrophenol, 2-azido-4-nitrophenol, 5-nitrobenzotriazole, 5-chloro-4-nitrobenzotriazole,
tetrachlorobenzotriazole, methyl-o-phenylhydrazone, N-phenylantranilic acid, N-(3-
nitrophenyl)anthranilic acid, N-(2,3-dimethylphenyl) anthranilic acid, mefenamic acid,
diflunisal, flufenamic acid, N-(3-chlorophenyl) anthranilic acid, carbonyl cyanide 4-
trifluoromethoxyphenylhydrazone (FCCP), SR-4233 (Tirapazamine), atovaquone, carbonyl
cyanide 4-(6’-methyl-2’-benzothiazyl)-phenylhydrazone(BT-CCP), ellipticine, olivacine,
ellipticine, isoeclipticine and related isomers, methyl-0-
phenylhydrazonocyanoceticacid,methyl-0-(3-chlorophenylhydrazono) cyanoacetic acid, 2-(3’-
chlorophenylhydrazono)-3-oxobutyronitrile, thiosalicylic acid, 2-(2’,4-dinitrophenylhydrazono)-
3-oxo-4,4-demethylvaleronitrile, relanium, melipramine, and other diverse chemical entities
including unsaturated fatty acids (up to C14 optimum), sulfalamid and its metabolite
perfluoroocetane sulfonamide (DESA), perfluoroctanoate, clofibrate, Wy-14, 643, ciprofibrate,
and fluorooctahols; ionophorous antibiotic uncouplers, including gramicidin, nigericin,
tyrothricin, tyrocidin, valinomycin, alamethicins, harzianin HA V, saturnisporin SA IV,
zervamicins, magainin, eceopins, melitin, hypeleins, suzukacillins, monensins, trichotoxins,
antiamoebins, crystal violet, cyanine dyes, cadmium ion, trichosporin-B and their derivatives;
and other heterogeneous uncoupling compounds, including desaspidin, ionized calcium (Ca$^{++}$), uncoupling proteins such as UCPI-1, UCP-2, UCP-3, PUMP (Plant Uncoupling Mitochondrial Protein), histones, polylysines, A206668-a protein, and compound K23187.

51. The method of claim 48, wherein the mitochondrial uncoupling agent is a conjugate comprising 2,4 dinitrophenol.

52. The method of claim 48, further wherein the induced heat shock proteins condition the animal for a specific condition.

53. The method of claim 52, wherein the specific condition is surgery.

54. The methods of claims 1, 15, 29, 48 and 51, wherein the uncoupling agent is produced using combinatorial technology.
Glucose

ATP → Glucose 6-phosphate → ADP

ATP → Fructose 6-phosphate → ADP

Fructose 1,6-phosphate → Dihydroxyacetone phosphate

2 (Glyceraldehyde 3-phosphate) → 4H

2 (1,3-Diphosphoglyceric acid)

2ADP → 2 (3-Phosphoglyceric acid) → +2ATP

2 (2-Phosphoglyceric acid)

2 (2-Phosphoenolpyruvic acid)

2ADP → 2 (Pyruvic acid) → 2ATP

NET REACTION PER MOLECULE OF GLUCOSE:
Glucose + 2ADP + 2PO₄⁻⁻ → 2 Pyruvic acid + 2ATP + 4H + HEAT

FIG. 1
\[
\text{CH}_3-C-COOH + \text{CoA-SH} \rightarrow \text{CH}_3-C-S-\text{CoA} + \text{CO}_2 + 2\text{H}^+ \\
\text{Pyrubic Acid} \quad \text{(Coenzyme A)} \quad \text{(acetyl CoA)}
\]
Flow of Electrons During Oxidative Phosphorylation

- NADH to Complex I (NADH-ubiquinone oxidoreductase)
- NAD+ to Complex II (Succinate-ubiquinone oxidoreductase)
- Succinate to fumarate
- CoQ
- Complex III (Ubiquinol-cytochrome c oxidoreductase)
- Cyt c
- Complex IV (Cytochrome c oxidase)
- $\frac{1}{2} \text{O}_2 + 2\text{H}^+$ to H2O + Heat

FIG. 3
(1) NADH$^+ + \frac{1}{2}O_2 + H^+ \rightarrow H_2O + NAD^+$ (oxidation)

(2) ADP$^+ + HPO_4^{2-} + 2H^+ \rightarrow ATP^{4-} + H_2O$ (phosphorylation)

(3) Substrate $\text{NAD}^+$ accepts $2e^-$ and $2H^+$ to form deHase

4. Coupled by electro-chemical membrane gradient

FIG. 4
FIG. 5
\[
\begin{align*}
0^-_2 + 0^-_2 + 2H^+ & \xrightarrow{\text{MnSOD}} H_2O_2 + O_2 \\
Fe^{+2} + H_2O_2 & \xrightarrow{} Fe^{+3} + OH^- + OH^- \\
OH^- + H_2O_2 & \xrightarrow{} H_2O + O_2^- + H^+ \\
O_2^- + H_2O_2 & \xrightarrow{} O_2 + OH^- + OH^- \\
Fe^{+2} + OH^- & \xrightarrow{} Fe^{+3} + OH^- 
\end{align*}
\]

FIG. 7a
FIG. 9
FIG. 11
<table>
<thead>
<tr>
<th>Tissue</th>
<th>Mass (kg)*</th>
<th>Blood Flow (L/min)*</th>
<th>Metabolic Rate (W)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Liver</td>
<td>2.6</td>
<td>1.5</td>
<td>18</td>
</tr>
<tr>
<td>Brain</td>
<td>1.4</td>
<td>0.75</td>
<td>17</td>
</tr>
<tr>
<td>Skeletal Muscle</td>
<td>31.0</td>
<td>1.2 to 24</td>
<td>17 to 350</td>
</tr>
<tr>
<td>Heart Muscle</td>
<td>0.3</td>
<td>0.25 to 31</td>
<td>10 to 31</td>
</tr>
<tr>
<td>Kidney</td>
<td>0.3</td>
<td>1.25</td>
<td>6</td>
</tr>
<tr>
<td>Skin</td>
<td>3.6</td>
<td>0.4 to 2.8</td>
<td>4 to 30</td>
</tr>
</tbody>
</table>

* Mean values under physiologic conditions.

FIG. 12
<table>
<thead>
<tr>
<th>TIME</th>
<th>MEDICATION/PROCEDURE</th>
<th>VO2 (ml/min)</th>
<th>HEAT (Kcal/hr)</th>
<th>TEMP (°C)</th>
<th>HR (BPM)</th>
<th>VCO2 (ml/min)</th>
<th>VE (L/min)</th>
<th>NOTES</th>
</tr>
</thead>
<tbody>
<tr>
<td>-5 to 0</td>
<td>Body Wet Suit</td>
<td>240</td>
<td>70.2</td>
<td>37.1</td>
<td>88</td>
<td>210</td>
<td>7.1</td>
<td>Base mean over 5 minutes</td>
</tr>
<tr>
<td>0 to 2</td>
<td>*DNP-1mg/kg/IV</td>
<td>260</td>
<td>75.8</td>
<td>37.4</td>
<td>86</td>
<td>300</td>
<td>7.6</td>
<td>DNP infused over 2 minutes</td>
</tr>
<tr>
<td>10</td>
<td>DNP-2mg/kg/IV</td>
<td>340</td>
<td>99.1</td>
<td>37.2</td>
<td>86</td>
<td>398</td>
<td>8.8</td>
<td>All vital signs normal</td>
</tr>
<tr>
<td>20</td>
<td>DNP-2mg/kg/IV</td>
<td>600</td>
<td>175</td>
<td>37.3</td>
<td>82</td>
<td>490</td>
<td>16.9</td>
<td>DNP infused over 2 minutes</td>
</tr>
<tr>
<td>40</td>
<td>DNP-2mg/kg/IV</td>
<td>710</td>
<td>207</td>
<td>39.1</td>
<td>94</td>
<td>690</td>
<td>18</td>
<td>DNP infused over 2 minutes</td>
</tr>
<tr>
<td>60</td>
<td>780</td>
<td>227</td>
<td>39.8</td>
<td>90</td>
<td>710</td>
<td>16.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>90</td>
<td>120</td>
<td>221</td>
<td>40.2</td>
<td>92</td>
<td>680</td>
<td>17.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>150</td>
<td>Body Wet Suit Removed</td>
<td>700</td>
<td>204.2</td>
<td>40.3</td>
<td>98</td>
<td>680</td>
<td>18.1</td>
<td></td>
</tr>
<tr>
<td>160</td>
<td>680</td>
<td>198</td>
<td>40.1</td>
<td>105</td>
<td>670</td>
<td>16.9</td>
<td>Evaporative heat loss initiated</td>
<td></td>
</tr>
<tr>
<td>240</td>
<td>600</td>
<td>175</td>
<td>39.2</td>
<td>98</td>
<td>590</td>
<td>14.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>300</td>
<td>500</td>
<td>145</td>
<td>38.4</td>
<td>96</td>
<td>490</td>
<td>14</td>
<td></td>
<td></td>
</tr>
<tr>
<td>360</td>
<td>Final Reading</td>
<td>340</td>
<td>99.1</td>
<td>37.6</td>
<td>88</td>
<td>300</td>
<td>11.4</td>
<td>Vital signs stable</td>
</tr>
</tbody>
</table>

*DNP=2,4-dinitrophenol
*VO2=oxygen consumption
*Heat=VO2 x 4.862 Kcal
*Temp = degrees centigrade
*HR = heart rate (beats/min)
*VCO2=carbon dioxide produced
*VE=expired air volume (liters/min)

NOTE: 1 liter of oxygen consumed yields 4.862 kilocalories of heat at standard conditions
<table>
<thead>
<tr>
<th>TIME (min)</th>
<th>MEDICATION/PROCEDURE</th>
<th>VO2 (ml/min)</th>
<th>HEAT (Kcal/hr)</th>
<th>TEMP (°C)</th>
<th>HR (BPM)</th>
<th>VCO2 (ml/min)</th>
<th>VE (L/min)</th>
<th>NOTES</th>
</tr>
</thead>
<tbody>
<tr>
<td>-60</td>
<td>diazepam, 10mg/PO</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-15</td>
<td>IV fluids, D5W/5NS+7meq K+</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(-10 to 0)</td>
<td>baseline readings</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0 to 3</td>
<td>DNP, 1mg/kg/IV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>410</td>
<td>119</td>
<td>37.3</td>
<td>76</td>
<td>380</td>
<td>12.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>DNP, 3mg/kg/IV</td>
<td>123</td>
<td>37</td>
<td>82</td>
<td>330</td>
<td>11.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>40</td>
<td>620</td>
<td>180</td>
<td>37.2</td>
<td>84</td>
<td>680</td>
<td>17.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>40 to 42</td>
<td>Glucagon, 0.5mg/kg/ivdrip/hr</td>
<td>760</td>
<td>221</td>
<td>37.5</td>
<td>85</td>
<td>750</td>
<td>18.2</td>
<td></td>
</tr>
<tr>
<td>50</td>
<td>800</td>
<td>236</td>
<td>37.8</td>
<td>90</td>
<td>790</td>
<td>18.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>60 to 70</td>
<td>Glucagon, 1.0mg/kg/ivdrip/hr</td>
<td>810</td>
<td>250</td>
<td>36</td>
<td>94</td>
<td>840</td>
<td>21</td>
<td></td>
</tr>
<tr>
<td>75 to 80</td>
<td>Glucagon 2.0mg/kg/ivdrip/hr</td>
<td>860</td>
<td>260</td>
<td>38.5</td>
<td>100</td>
<td>890</td>
<td>21.7</td>
<td></td>
</tr>
<tr>
<td>90</td>
<td>910</td>
<td>265</td>
<td>39.1</td>
<td>110</td>
<td>920</td>
<td>26.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>100</td>
<td>880</td>
<td>256</td>
<td>39.6</td>
<td>112</td>
<td>970</td>
<td>26.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>110</td>
<td>960</td>
<td>279</td>
<td>39.9</td>
<td>110</td>
<td>940</td>
<td>24.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>120</td>
<td>880</td>
<td>256</td>
<td>40.1</td>
<td>112</td>
<td>980</td>
<td>25.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>130</td>
<td>900</td>
<td>262</td>
<td>40.3</td>
<td>115</td>
<td>850</td>
<td>26.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>140</td>
<td>890</td>
<td>260</td>
<td>40.1</td>
<td>112</td>
<td>1,050</td>
<td>27.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>150</td>
<td>880</td>
<td>256</td>
<td>40.2</td>
<td>100</td>
<td>950</td>
<td>25.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>160</td>
<td>Glucagon discontinued</td>
<td>830</td>
<td>242</td>
<td>40.1</td>
<td>110</td>
<td>900</td>
<td>26.7</td>
<td></td>
</tr>
<tr>
<td>170</td>
<td>IVs discontinued, monitors removed</td>
<td>810</td>
<td>236</td>
<td>39.5</td>
<td>100</td>
<td>880</td>
<td>24.5</td>
<td></td>
</tr>
<tr>
<td>420</td>
<td>Oral tube for VO2</td>
<td>360</td>
<td>105</td>
<td>37.2</td>
<td>88</td>
<td>400</td>
<td>8.1</td>
<td></td>
</tr>
</tbody>
</table>

FIG. 15
<table>
<thead>
<tr>
<th>TIME (min)</th>
<th>MEDICATION/PROCEDURE</th>
<th>VO2 (ml/min)</th>
<th>HEAT (Kcal/hr)</th>
<th>TEMP (°C)</th>
<th>HR (BPM)</th>
<th>VCO2 (ml/min)</th>
<th>VE (L/min)</th>
<th>NOTES</th>
</tr>
</thead>
<tbody>
<tr>
<td>(-5 to 0)</td>
<td>Baseline</td>
<td>300</td>
<td>87.5</td>
<td>38.1</td>
<td>85</td>
<td>275</td>
<td>5.9</td>
<td></td>
</tr>
<tr>
<td>0 to 2</td>
<td>DNP, 2mg/kg/IV</td>
<td>320</td>
<td>99</td>
<td>38.2</td>
<td>86</td>
<td>290</td>
<td>6.2</td>
<td>DNP infused over a 2 min period</td>
</tr>
<tr>
<td>20</td>
<td></td>
<td>340</td>
<td>99.1</td>
<td>38.1</td>
<td>88</td>
<td>300</td>
<td>8.1</td>
<td></td>
</tr>
<tr>
<td>30</td>
<td></td>
<td>380</td>
<td>110</td>
<td>38.6</td>
<td>92</td>
<td>350</td>
<td>9.6</td>
<td></td>
</tr>
<tr>
<td>40 to 42</td>
<td>DNP, 2mg/kg/IV</td>
<td>340</td>
<td>99</td>
<td>38.8</td>
<td>90</td>
<td>360</td>
<td>10</td>
<td>DNP infused over a 2 min period</td>
</tr>
<tr>
<td>60</td>
<td></td>
<td>610</td>
<td>178</td>
<td>39.4</td>
<td>90</td>
<td>390</td>
<td>11.4</td>
<td>BP: falls to 110/50</td>
</tr>
<tr>
<td>90</td>
<td></td>
<td>630</td>
<td>183</td>
<td>39.5</td>
<td>92</td>
<td>630</td>
<td>21</td>
<td>BP: 105/60</td>
</tr>
<tr>
<td>92</td>
<td>Levophed, 1ugm/min/lvdrp</td>
<td>650</td>
<td>189.5</td>
<td>39.5</td>
<td>92</td>
<td>630</td>
<td>21</td>
<td>BP: 100/60</td>
</tr>
<tr>
<td>96</td>
<td></td>
<td>790</td>
<td>230</td>
<td>39.8</td>
<td>102</td>
<td>770</td>
<td>17.4</td>
<td>BP: 110/60</td>
</tr>
<tr>
<td>100</td>
<td></td>
<td>850</td>
<td>247</td>
<td>40.1</td>
<td>115</td>
<td>830</td>
<td>16.7</td>
<td>BP: 130/80</td>
</tr>
<tr>
<td>115</td>
<td>Levophed decreased to 0.5ugm/min</td>
<td>1,000</td>
<td>291</td>
<td>41.5</td>
<td>110</td>
<td>1,200</td>
<td>25.8</td>
<td>Stable BP @ 130/80</td>
</tr>
<tr>
<td>125</td>
<td></td>
<td>980</td>
<td>285</td>
<td>41.6</td>
<td>108</td>
<td>1,040</td>
<td>26.6</td>
<td>Rt. Lower extremity uncovered</td>
</tr>
<tr>
<td>126</td>
<td></td>
<td>880</td>
<td>256</td>
<td>41.1</td>
<td>110</td>
<td>990</td>
<td>27.2</td>
<td></td>
</tr>
<tr>
<td>180</td>
<td></td>
<td>950</td>
<td>279</td>
<td>41.5</td>
<td>112</td>
<td>1,000</td>
<td>29.8</td>
<td></td>
</tr>
<tr>
<td>220</td>
<td></td>
<td>1,000</td>
<td>291</td>
<td>41.3</td>
<td>110</td>
<td>1,100</td>
<td>28.3</td>
<td></td>
</tr>
<tr>
<td>230</td>
<td></td>
<td>800</td>
<td>233</td>
<td>41.1</td>
<td>105</td>
<td>920</td>
<td>27.8</td>
<td>VO2 falling</td>
</tr>
<tr>
<td>240</td>
<td></td>
<td>760</td>
<td>221</td>
<td>41.3</td>
<td>108</td>
<td>830</td>
<td>21.1</td>
<td>VO2 continues to fall</td>
</tr>
<tr>
<td>242 to 244</td>
<td>DNP, 1mg/kg/IV</td>
<td>890</td>
<td>260</td>
<td>41.4</td>
<td>110</td>
<td>980</td>
<td>24.8</td>
<td>DNP infused over a 2 min period</td>
</tr>
<tr>
<td>280</td>
<td></td>
<td>1,080</td>
<td>315</td>
<td>41.6</td>
<td>115</td>
<td>1,280</td>
<td>28.6</td>
<td>Both lower extremities uncovered</td>
</tr>
<tr>
<td>300</td>
<td></td>
<td>1,000</td>
<td>291</td>
<td>41.3</td>
<td>110</td>
<td>1,190</td>
<td>29.5</td>
<td></td>
</tr>
<tr>
<td>320</td>
<td>Levophed stopped</td>
<td>1,100</td>
<td>320</td>
<td>41.1</td>
<td>108</td>
<td>1,240</td>
<td>31.1</td>
<td></td>
</tr>
<tr>
<td>360</td>
<td></td>
<td>950</td>
<td>277</td>
<td>40.9</td>
<td>98</td>
<td>1,040</td>
<td>29.2</td>
<td>cold water dry suit</td>
</tr>
<tr>
<td>390</td>
<td></td>
<td>910</td>
<td>265</td>
<td>39.2</td>
<td>94</td>
<td>990</td>
<td>28.5</td>
<td></td>
</tr>
<tr>
<td>420</td>
<td>Monitors removed</td>
<td>830</td>
<td>242</td>
<td>38.6</td>
<td>92</td>
<td>920</td>
<td>16.8</td>
<td></td>
</tr>
<tr>
<td>450</td>
<td>oral breathing tube</td>
<td>420</td>
<td>123</td>
<td>37.8</td>
<td>88</td>
<td>510</td>
<td>10.2</td>
<td></td>
</tr>
<tr>
<td>480</td>
<td></td>
<td>340</td>
<td>99.1</td>
<td>37.5</td>
<td>90</td>
<td>440</td>
<td>8.9</td>
<td>Vital signs within normal limits</td>
</tr>
</tbody>
</table>

FIG. 17
<table>
<thead>
<tr>
<th>TIME (min)</th>
<th>MEDICATION/PROCEDURE</th>
<th>VO2 (ml/min)</th>
<th>HEAT (Kcal/hr)</th>
<th>TEMP (°C)</th>
<th>HR (BPM)</th>
<th>VCO2 (ml/min)</th>
<th>VE (L/min)</th>
<th>NOTES</th>
</tr>
</thead>
<tbody>
<tr>
<td>(-240)</td>
<td>alprazolam, 2mg/PO</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>to calm anxiety dressed</td>
</tr>
<tr>
<td>(-20)</td>
<td>dressed in dry water immersion suit</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>dressed</td>
</tr>
<tr>
<td>(-15)</td>
<td>IV fluids, D5W1/2NS+7mec K+</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Monitors &amp; Foley attached</td>
</tr>
<tr>
<td>(-10 to 0)</td>
<td>Baseline Readings</td>
<td>220</td>
<td>64.2</td>
<td>37.3</td>
<td>86</td>
<td>190</td>
<td>5.2</td>
<td></td>
</tr>
<tr>
<td>0 to 2</td>
<td>DNP, 1mg/kg/IV</td>
<td>230</td>
<td>67</td>
<td>37.3</td>
<td>90</td>
<td>200</td>
<td>5.5</td>
<td>DNP infused over a 2min period</td>
</tr>
<tr>
<td>20</td>
<td></td>
<td>250</td>
<td>72.9</td>
<td>37.2</td>
<td>88</td>
<td>230</td>
<td>6.3</td>
<td></td>
</tr>
<tr>
<td>20 to 22</td>
<td>DNP, 2mg/kg/IV</td>
<td>250</td>
<td>72.9</td>
<td>37.8</td>
<td>86</td>
<td>220</td>
<td>6.3</td>
<td>DNP infused over a 2min period</td>
</tr>
<tr>
<td>30</td>
<td>DNP, 1mg/kg/IV</td>
<td>310</td>
<td>90.4</td>
<td>38.4</td>
<td>86</td>
<td>290</td>
<td>10.4</td>
<td></td>
</tr>
<tr>
<td>50</td>
<td></td>
<td>380</td>
<td>110</td>
<td>38.9</td>
<td>90</td>
<td>350</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>50 to 54</td>
<td>DNP, 1.0mg/kg/IV</td>
<td>400</td>
<td>116</td>
<td>39.5</td>
<td>90</td>
<td>350</td>
<td>14</td>
<td>DNP infused over a 2min period</td>
</tr>
<tr>
<td>70</td>
<td></td>
<td>600</td>
<td>175</td>
<td>40.2</td>
<td>110</td>
<td>550</td>
<td>18</td>
<td>Patient became briefly agitated</td>
</tr>
<tr>
<td>80</td>
<td></td>
<td>570</td>
<td>166</td>
<td>40.8</td>
<td>96</td>
<td>550</td>
<td>18</td>
<td></td>
</tr>
<tr>
<td>90</td>
<td></td>
<td>500</td>
<td>145</td>
<td>40.1</td>
<td>100</td>
<td>510</td>
<td>15</td>
<td></td>
</tr>
<tr>
<td>95 to 98</td>
<td>Dopamine Drip/3mcg/kg/min</td>
<td>520</td>
<td>151.6</td>
<td>40.2</td>
<td>115</td>
<td>500</td>
<td>15.8</td>
<td>20 sec readings show fall in VO2</td>
</tr>
<tr>
<td>100</td>
<td></td>
<td>630</td>
<td>183</td>
<td>40.3</td>
<td>115</td>
<td>610</td>
<td>18</td>
<td></td>
</tr>
<tr>
<td>110</td>
<td></td>
<td>680</td>
<td>198.2</td>
<td>40.2</td>
<td>110</td>
<td>690</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>150</td>
<td></td>
<td>710</td>
<td>207</td>
<td>40.5</td>
<td>110</td>
<td>700</td>
<td>21</td>
<td></td>
</tr>
<tr>
<td>180</td>
<td></td>
<td>680</td>
<td>198.2</td>
<td>40.6</td>
<td>115</td>
<td>690</td>
<td>19</td>
<td>Dopamine discontinued</td>
</tr>
<tr>
<td>250</td>
<td></td>
<td>650</td>
<td>189</td>
<td>40.1</td>
<td>110</td>
<td>660</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td>255</td>
<td>Insulating Suit open</td>
<td>600</td>
<td>175</td>
<td>39.6</td>
<td>112</td>
<td>610</td>
<td>22</td>
<td>patient complains of fatigue</td>
</tr>
<tr>
<td>280</td>
<td></td>
<td>430</td>
<td>125</td>
<td>39.1</td>
<td>115</td>
<td>410</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>320</td>
<td></td>
<td>340</td>
<td>99.1</td>
<td>37.8</td>
<td>92</td>
<td>330</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>400</td>
<td>chills &amp; rigors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>401 to 405</td>
<td>IV fluids, dopamine 2mcg/kg/min</td>
<td>380</td>
<td>110</td>
<td>38.7</td>
<td>100</td>
<td>270</td>
<td>15</td>
<td>IV fluids &amp; observation</td>
</tr>
<tr>
<td>500 to 610</td>
<td>Symptoms subsided</td>
<td>250</td>
<td>72.8</td>
<td>37.8</td>
<td>90</td>
<td>230</td>
<td>7</td>
<td>Jarisch-Herxheimer?</td>
</tr>
</tbody>
</table>

**FIG. 18**
<table>
<thead>
<tr>
<th>TIME (min)</th>
<th>MEDICATION/PROCEDURE</th>
<th>VO2 (ml/min)</th>
<th>HEAT (Kcal/hr)</th>
<th>TEMP (°C)</th>
<th>HR (BPM)</th>
<th>VCO2 (ml/min)</th>
<th>VE (L/min)</th>
<th>NOTES</th>
</tr>
</thead>
<tbody>
<tr>
<td>(-50 to -40)</td>
<td>covered in water soaked blanket</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(-40 to -30)</td>
<td>polyethylene wrap around blanket</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(-30 to -10)</td>
<td>Carboplatin-45mg/mitomycin-24mg (total dose given by IV infusion)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(-10 to 0)</td>
<td>mephenetamine sulfate/30mg/IM</td>
<td>230</td>
<td>67</td>
<td>37.6</td>
<td>90</td>
<td>200</td>
<td>5.9</td>
<td>Mean values over 10 min period</td>
</tr>
<tr>
<td>0 to 1</td>
<td></td>
<td>250</td>
<td>72.9</td>
<td>37.7</td>
<td>85</td>
<td>220</td>
<td>6.3</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td>320</td>
<td>93.3</td>
<td>37.9</td>
<td>96</td>
<td>290</td>
<td>5.9</td>
<td>BP Increased to 140/88</td>
</tr>
<tr>
<td>15</td>
<td></td>
<td>340</td>
<td>99.1</td>
<td>38.1</td>
<td>98</td>
<td>300</td>
<td>7.5</td>
<td>BP stable at 140/90</td>
</tr>
<tr>
<td>20 to 22</td>
<td>DNP, 1.0mg/kg/IV</td>
<td>380</td>
<td>110</td>
<td>38.2</td>
<td>100</td>
<td>350</td>
<td>6.6</td>
<td>DNP infused over a 2 min period</td>
</tr>
<tr>
<td>23</td>
<td></td>
<td>450</td>
<td>131.2</td>
<td>38.2</td>
<td>105</td>
<td>440</td>
<td>9.8</td>
<td></td>
</tr>
<tr>
<td>28</td>
<td></td>
<td>400</td>
<td>116.6</td>
<td>38.8</td>
<td>105</td>
<td>510</td>
<td>12.9</td>
<td></td>
</tr>
<tr>
<td>30</td>
<td></td>
<td>430</td>
<td>125.4</td>
<td>39</td>
<td>110</td>
<td>500</td>
<td>13.2</td>
<td></td>
</tr>
<tr>
<td>40 to 42</td>
<td>DNP, 0.5mg/kg/IV</td>
<td>480</td>
<td>139.9</td>
<td>39.4</td>
<td>110</td>
<td>580</td>
<td>15.8</td>
<td>DNP infused over a 2 min period</td>
</tr>
<tr>
<td>50</td>
<td></td>
<td>520</td>
<td>151.6</td>
<td>39.9</td>
<td>115</td>
<td>540</td>
<td>16.2</td>
<td></td>
</tr>
<tr>
<td>60</td>
<td></td>
<td>640</td>
<td>186.6</td>
<td>40.3</td>
<td>112</td>
<td>660</td>
<td>18.4</td>
<td>DNP infused over a 2 min period</td>
</tr>
<tr>
<td>70</td>
<td></td>
<td>660</td>
<td>192.4</td>
<td>40.8</td>
<td>115</td>
<td>720</td>
<td>21.3</td>
<td></td>
</tr>
<tr>
<td>80</td>
<td></td>
<td>780</td>
<td>227.4</td>
<td>40.9</td>
<td>110</td>
<td>880</td>
<td>19.3</td>
<td>DNP infused over a 2 min period</td>
</tr>
<tr>
<td>90</td>
<td></td>
<td>800</td>
<td>233</td>
<td>41.2</td>
<td>120</td>
<td>850</td>
<td>18.7</td>
<td></td>
</tr>
<tr>
<td>100</td>
<td></td>
<td>820</td>
<td>239</td>
<td>41.4</td>
<td>125</td>
<td>810</td>
<td>20.6</td>
<td></td>
</tr>
<tr>
<td>120</td>
<td></td>
<td>790</td>
<td>230.4</td>
<td>41.5</td>
<td>115</td>
<td>740</td>
<td>15.5</td>
<td></td>
</tr>
<tr>
<td>130</td>
<td></td>
<td>800</td>
<td>233</td>
<td>41.4</td>
<td>110</td>
<td>850</td>
<td>14.9</td>
<td></td>
</tr>
<tr>
<td>131 to 133</td>
<td>DNP, 0.5mg/kg/IV</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DNP infused over a 2 min period</td>
</tr>
<tr>
<td>150</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>160</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>170</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>180</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>200</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>210</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>240</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>260</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**FIG. 19**
FIG. 20
<table>
<thead>
<tr>
<th>TIME (min)</th>
<th>MEDICATION/PROCEDURE</th>
<th>VO2 (ml/min)</th>
<th>HEAT (Kcal/hr)</th>
<th>TEMP (°C)</th>
<th>HR (BPM)</th>
<th>VCO2 (ml/min)</th>
<th>VE (L/min)</th>
<th>NOTES</th>
</tr>
</thead>
<tbody>
<tr>
<td>(-10 TO 0)</td>
<td>Baseline Readings</td>
<td>230</td>
<td>67</td>
<td>37.5</td>
<td>86</td>
<td>210</td>
<td>4.9</td>
<td>Increased for 3 days</td>
</tr>
<tr>
<td>0</td>
<td>DNP, 300mg/PO</td>
<td>220</td>
<td>64</td>
<td>37.5</td>
<td>84</td>
<td>200</td>
<td>5.1</td>
<td>DNP by mouth with H2O</td>
</tr>
<tr>
<td>20</td>
<td></td>
<td>230</td>
<td>67</td>
<td>37.4</td>
<td>88</td>
<td>210</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>60</td>
<td></td>
<td>250</td>
<td>73</td>
<td>37.3</td>
<td>88</td>
<td>220</td>
<td>5.5</td>
<td></td>
</tr>
<tr>
<td>120</td>
<td>FDG/Bolus/IV</td>
<td>300</td>
<td>87</td>
<td>37.5</td>
<td>82</td>
<td>280</td>
<td>6.3</td>
<td></td>
</tr>
<tr>
<td>140</td>
<td>PET Scan initiated</td>
<td>320</td>
<td>93</td>
<td>37.5</td>
<td>86</td>
<td>300</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>210</td>
<td>PET Scan completed</td>
<td>340</td>
<td>99</td>
<td>37.5</td>
<td>86</td>
<td>310</td>
<td>10</td>
<td>No complaints</td>
</tr>
<tr>
<td>480</td>
<td></td>
<td>260</td>
<td>76</td>
<td>37.4</td>
<td>84</td>
<td>250</td>
<td>7</td>
<td>No complaints</td>
</tr>
</tbody>
</table>

**FIG. 24**
<table>
<thead>
<tr>
<th>TIME</th>
<th>MEDICATION/PROCEDURE</th>
<th>VO2</th>
<th>HEAT</th>
<th>TEMP</th>
<th>HR</th>
<th>VCO2</th>
<th>VE</th>
<th>NOTES</th>
</tr>
</thead>
<tbody>
<tr>
<td>(-10 to 0)</td>
<td>Baseline</td>
<td>180</td>
<td>52</td>
<td>37.7</td>
<td>88</td>
<td>160</td>
<td>4.8</td>
<td></td>
</tr>
<tr>
<td>1 to 2</td>
<td>DNP/1mg/kg/IV</td>
<td>180</td>
<td>52</td>
<td>37.6</td>
<td>86</td>
<td>165</td>
<td>4.6</td>
<td>DNP infused over 2 min</td>
</tr>
<tr>
<td>22 to 24</td>
<td>DNP/2mg/kg/IV</td>
<td>210</td>
<td>61</td>
<td>37.7</td>
<td>86</td>
<td>190</td>
<td>4.8</td>
<td>No complaints</td>
</tr>
<tr>
<td>60</td>
<td>Thermal imaging</td>
<td>300</td>
<td>93</td>
<td>37.2</td>
<td>84</td>
<td>300</td>
<td>5.8</td>
<td>In isothermally controlled room</td>
</tr>
</tbody>
</table>

**FIG. 25**
<table>
<thead>
<tr>
<th>TIME (min)</th>
<th>MEDICATION/PROCEDURE</th>
<th>VO2 (ml/min)</th>
<th>HEAT (Kcal/hr)</th>
<th>TEMP (°C)</th>
<th>HR (BPM)</th>
<th>VCO2 (ml/min)</th>
<th>VE (L/min)</th>
<th>NOTES</th>
</tr>
</thead>
<tbody>
<tr>
<td>-240</td>
<td>2 units packed RBCs</td>
<td>250</td>
<td>73</td>
<td>37.6</td>
<td>88</td>
<td>220</td>
<td>6.4</td>
<td>48 hours prior to treatment</td>
</tr>
<tr>
<td>-8 to 0</td>
<td>Lactated Ringers/IV</td>
<td>260</td>
<td>75.8</td>
<td>37.8</td>
<td>88</td>
<td>230</td>
<td>6.3</td>
<td>100cc/hour</td>
</tr>
<tr>
<td>0 to 2</td>
<td>DNP, 1mg/kg/IV</td>
<td>340</td>
<td>90</td>
<td>37.9</td>
<td>90</td>
<td>330</td>
<td>12</td>
<td>DNP infused over a 2min period</td>
</tr>
<tr>
<td>20</td>
<td></td>
<td>360</td>
<td>105</td>
<td>37.9</td>
<td>90</td>
<td>320</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>45 to 47</td>
<td>DNP, 1mg/kg/IV</td>
<td>340</td>
<td>99</td>
<td>37.9</td>
<td>94</td>
<td>340</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>60</td>
<td>Methylene blue, 2mg/kg/IV</td>
<td>420</td>
<td>122</td>
<td>38</td>
<td>92</td>
<td>400</td>
<td>14</td>
<td>administered in 35ml-20min infusion</td>
</tr>
<tr>
<td>70</td>
<td></td>
<td>430</td>
<td>125</td>
<td>37.9</td>
<td>96</td>
<td>410</td>
<td>15</td>
<td>Patient feels &quot;warm&quot;</td>
</tr>
<tr>
<td>80</td>
<td></td>
<td>500</td>
<td>145</td>
<td>36</td>
<td>96</td>
<td>490</td>
<td>16</td>
<td></td>
</tr>
<tr>
<td>90</td>
<td></td>
<td>480</td>
<td>140</td>
<td>38.1</td>
<td>94</td>
<td>460</td>
<td>18</td>
<td></td>
</tr>
<tr>
<td>110</td>
<td></td>
<td>430</td>
<td>125</td>
<td>38.2</td>
<td>92</td>
<td>410</td>
<td>16</td>
<td></td>
</tr>
<tr>
<td>130</td>
<td></td>
<td>390</td>
<td>114</td>
<td>38.3</td>
<td>96</td>
<td>380</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>150</td>
<td></td>
<td>380</td>
<td>110</td>
<td>38.3</td>
<td>96</td>
<td>360</td>
<td>15</td>
<td></td>
</tr>
<tr>
<td>200</td>
<td></td>
<td>360</td>
<td>105</td>
<td>38.3</td>
<td>92</td>
<td>340</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>200 to 202</td>
<td>DNP, 1mg/kg/IV</td>
<td>370</td>
<td>106</td>
<td>38.2</td>
<td>92</td>
<td>350</td>
<td>15</td>
<td>DNP infused over a 2min period</td>
</tr>
<tr>
<td>222</td>
<td></td>
<td>450</td>
<td>131</td>
<td>38.4</td>
<td>92</td>
<td>430</td>
<td>16</td>
<td>no complaints</td>
</tr>
<tr>
<td>240</td>
<td></td>
<td>490</td>
<td>143</td>
<td>38.5</td>
<td>94</td>
<td>470</td>
<td>15.7</td>
<td></td>
</tr>
<tr>
<td>300</td>
<td></td>
<td>520</td>
<td>151</td>
<td>38.8</td>
<td>96</td>
<td>490</td>
<td>16</td>
<td></td>
</tr>
<tr>
<td>360</td>
<td>Treatment terminated</td>
<td>470</td>
<td>137</td>
<td>38.9</td>
<td>96</td>
<td>450</td>
<td>15.8</td>
<td></td>
</tr>
<tr>
<td>540</td>
<td></td>
<td>380</td>
<td>110</td>
<td>38.4</td>
<td>92</td>
<td>350</td>
<td>14</td>
<td>no complaints</td>
</tr>
</tbody>
</table>

FIG. 26
<table>
<thead>
<tr>
<th>Treatment Period</th>
<th>Serum PSA Level (ng/mL)</th>
<th>Acid Phosphatase (U/L)</th>
<th>Clinical Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>58</td>
<td>1.2</td>
<td>Bone pain, lack of appetite, Karnofsky score of 6.</td>
</tr>
<tr>
<td>Day 6</td>
<td>68</td>
<td>1.6</td>
<td>Increased appetite, decrease in bone pain.</td>
</tr>
<tr>
<td>Day 8</td>
<td>125</td>
<td>1.6</td>
<td>Off all pain meds. Marked increase in appetite.</td>
</tr>
<tr>
<td>Day 14</td>
<td>88</td>
<td>1.4</td>
<td>Karnofsky score of 7. Remains pain free.</td>
</tr>
<tr>
<td>6 weeks</td>
<td>30</td>
<td>1</td>
<td>Karnofsky score 8. Pain free.</td>
</tr>
<tr>
<td>10 weeks</td>
<td>18</td>
<td>0.6</td>
<td>Gained 8.2 kg of weight. Pain free.</td>
</tr>
<tr>
<td>12 weeks</td>
<td>12</td>
<td>0.6</td>
<td>Total of 8.3 kg of weight gain. Pain free.</td>
</tr>
<tr>
<td>4 months</td>
<td>6.5</td>
<td>0.65</td>
<td>Karnofsky score of 9.</td>
</tr>
</tbody>
</table>

*PSA = Prostatic Specific Antigen

*Biopsy – Significant comments by pathologist.

*Treatment period – DNP given IV every other day x 30, repeated after 2 weeks for additional 30 days; then 250 mg orally 2 times daily for 5 days and, recycled after no DNP for 2 days for a total period of 4 months.
<table>
<thead>
<tr>
<th>TIME (min)</th>
<th>MEDICATION/PROCEDURE</th>
<th>VO2 (ml/min)</th>
<th>HEAT (Kcal/hr)</th>
<th>TEMP (°C)</th>
<th>HR (BPM)</th>
<th>VCO2 (ml/min)</th>
<th>VE (L/min)</th>
<th>NOTES</th>
</tr>
</thead>
<tbody>
<tr>
<td>(-360)</td>
<td>Interferon alpha/1.5 million units/SQ</td>
<td>160</td>
<td>47</td>
<td>37.5</td>
<td>76</td>
<td>140</td>
<td>3.5</td>
<td></td>
</tr>
<tr>
<td>(-5 to 0)</td>
<td>Baseline readings</td>
<td>150</td>
<td>44</td>
<td>37.5</td>
<td>76</td>
<td>140</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>0 to 2</td>
<td>DNP, 1mg/kg/IV</td>
<td>210</td>
<td>61</td>
<td>37.7</td>
<td>80</td>
<td>190</td>
<td>4.2</td>
<td></td>
</tr>
<tr>
<td>20 to 22</td>
<td>DNP, 1mg/kg/IV</td>
<td>250</td>
<td>73</td>
<td>38</td>
<td>84</td>
<td>220</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>50 to 52</td>
<td>DNP, 2mg/kg/IV</td>
<td>360</td>
<td>105</td>
<td>38.3</td>
<td>86</td>
<td>330</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>70</td>
<td>DNP, 2mg/kg/IV</td>
<td>280</td>
<td>82</td>
<td>38.8</td>
<td>88</td>
<td>260</td>
<td>8.5</td>
<td></td>
</tr>
<tr>
<td>170 to 172</td>
<td>DNP, 2mg/kg/IV</td>
<td>420</td>
<td>122</td>
<td>38.8</td>
<td>88</td>
<td>400</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>190</td>
<td>Treatment terminated</td>
<td>400</td>
<td>116</td>
<td>38.7</td>
<td>86</td>
<td>370</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>240</td>
<td>Treatment terminated</td>
<td>380</td>
<td>110</td>
<td>38.7</td>
<td>90</td>
<td>360</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>300</td>
<td>Treatment terminated</td>
<td>340</td>
<td>99</td>
<td>38.5</td>
<td>90</td>
<td>330</td>
<td>13</td>
<td></td>
</tr>
</tbody>
</table>

*NOTES: DNP infused over 2min period, sweating profusely, very thirsty, marked fatigue, no complaints other than severe fatigue.*
<table>
<thead>
<tr>
<th>Treatment Period</th>
<th>HCV-RNA* (copies/ml)</th>
<th>AST* (IU/L)</th>
<th>ALT* (IU/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>$5.8 \times 10^6$</td>
<td>78</td>
<td>85</td>
</tr>
<tr>
<td>48 hours</td>
<td>$4.6 \times 10^4$</td>
<td>400</td>
<td>610</td>
</tr>
<tr>
<td>14 days</td>
<td>non-detectable</td>
<td>380</td>
<td>570</td>
</tr>
<tr>
<td>21 days</td>
<td>non-detectable</td>
<td>100</td>
<td>78</td>
</tr>
<tr>
<td>18 months</td>
<td>non-detectable</td>
<td>45</td>
<td>34</td>
</tr>
</tbody>
</table>

*HCV-RNA – Roche polymerase chain reaction methodology

*AST – aspartate aminotransferase

*ALT – alanine aminotransferase

**FIG. 29**
STARTING: 2,4-dinitrophenol

2,4-dinitro-3,5-diodophenol

Fig. 30
## INTERNATIONAL SEARCH REPORT

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) :A61K 31/06  
US CL :514/728  
According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
U.S. : 514/728

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

**CHEMICAL ABSTRACTS**

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>US 5,005,588 A (RUBIN) 09 April 1991, see columns 7 and 8.</td>
<td>1-14</td>
</tr>
<tr>
<td>A</td>
<td>US 5,622,686 A (GORDON et al) 22 April 1997, see entire document.</td>
<td>1-54</td>
</tr>
<tr>
<td>A</td>
<td>US 4,569,836 A (GORDON) 11 February 1986, see entire document.</td>
<td>1-54</td>
</tr>
</tbody>
</table>

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:  
  *A* document defining the general state of the art which is not considered to be of particular relevance  
  *B* earlier document published on or after the international filing date  
  *L* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason as specified  
  *Q* document referring to an oral disclosure, use, exhibition or other means  
  *P* document published prior to the international filing date but later than the priority date claimed  
  *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principal or theory underlying the invention  
  *X* document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone  
  *Y* document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is taken alone  
  *A* document member of the same patent family

Date of the actual completion of the international search  
09 NOVEMBER 1999

Date of mailing of the international search report  
09 DEC 1999

Name and mailing address of the ISA/US Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorizing officer  
JAMES H. REAMER

Telephone No. (703) 308-1235

Form PCT/ISA/210 (second sheet)(July 1992)